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Abstract
Following the identification o f a highly resistant protease containing a novel insertion 
(35QN), together with a series of additional gag mutations. We wished to explore the 
gtfg-protease interrelationships, and associated replication capacity 
deficit/compensation. A replication competent NL4-3 based HIV-1 vector system was 
developed allowing ligation o f full length gag  with or without protease derived from 
patient plasma virus. Drug susceptibility assays were undertaken using the MTT 
assay, and replication capacity assessed by a GHOST indicator cell line. Recombinant 
viruses containing the protease alone or protease with full length gag  demonstrated 
reduced susceptibility to Pis. The recombinants containing the gag  from the patient 
isolated virus were shown to have a much reduced replication capacity compared to 
wild-type, even when cloned with the cognate protease. However, the virus containing 
the patient virus derived gag  and protease, demonstrated a 2-fold increase in 
resistance to some o f the Pis tested. The production of high titred stocks was shown to 
require multiple reversions in gag. This occurred in both viruses containing this 
region derived from the original patient virus. The reversion pattern was shown to be 
dependant on whether or not the recombinant contained the highly resistant protease. 
The lack of reversions from the input genotype in the protease only virus isolate, 
suggest that this virus is not growth impaired, which was also confirmed by a growth 
comparison study.
The interaction of protease with the gag  demonstrates a co-dependence regarding the 
evolution under drug selection pressure. The removal of the pressure causes reversion 
of some, but not all o f the gag  mutations. The lack of reversion in the protease gene 
suggests that the virus mutates gag  to accommodate the protease. The reversion 
pattern in gag  was particularly evident in the p2 protein and or the p2/p7 cleavage 
site.
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Chapter 1 Introduction
1.1 AIDS Epidemic and Viral Etiology
AIDS (Acquired Immune Deficiency Syndrome) was first defined by the Centers for 
Disease Control and Prevention (CDC) in September 19 8 2 35 as a disease, at least 
moderately predictive of a defect in cell-mediated immunity, occurring in a person 
with no known cause for diminished resistance to that disease. Such diseases include 
Kaposi's sarcoma (KS), Pneumocystis carinii pneumonia (PCP), and other serious 
"opportunistic" infections predictive o f cellular immunodeficiency. The causative 
agent of AIDS was first isolated at the Institute Pasteur 14 and later at the National
1 77Cancer Institute . The virus had been known under two names, lymphadenopathy- 
associated virus (LAV) and Human T-cell Lymphotropic virus type 3 (HTLV-III). In 
May 1986, members of a subcommittee empowered by the International Committee 
on the Taxonomy of Viruses published an article suggesting a new name for the 
etiological agent of AIDS; Human Immunodeficiency Virus (HIV) 44. HIV belongs to 
the Lentiviridae family o f retroviruses. These viruses are able to infect a number of 
different animal species, including cats, sheep, horses, cattle and monkeys. Studies to 
determine the origins o f HIV focused on cross-species (zoonotic) infections with 
viruses closely related to Simian Immunodeficiency Virus (SIV). The cross species 
jump required for viruses to establish in either a simian or human host is not an 
uncommon phenomenon it has been seen with monkey smallpox, simian/human T cell
i
leukaemia virus and simian monkey virus
The viruses causing the HIV epidemic have been subdivided into HIV-1 and HIV-2. 
A strain of SIV isolated from a frozen sample taken from a captive member of the 
sub-group of chimpanzees known as Pan troglodytes troglodytes (P. t. troglodytes), 
indicated that P. t. troglodytes was the primary reservoir for HIV-1 and had been the
source of at least three independent introductions of SIVcpz into the human
102population . The primate reservoir o f HIV-2 has been clearly identified as the sooty 
mangabey (Cercocebus atys) l02,126,classified as an old world monkey. A strain of 
SIV, (SIVsm) that is genetically indistinguishable and closely related phylogenetically 
to HIV-2 was found in substantial numbers o f wild-living sooty mangabeys. The 
natural habitat of these primates coincides with the epicentre of the HIV-2 epidemic 
located in Western Africa. These monkeys and chimpanzees are commonly hunted for 
food, this close contact between the two species represents a ready source for
14
potential zoonotic transmissions of SIVsm and SIVcpz to humans. Using calculations 
based on a fixed mutation rate i.e. a constant rate of evolution, researchers estimated 
that the zoonotic transmission from chimpanzee to human responsible for the HIV-1 
epidemic, most likely occurred around the 1930’s, with a confidence interval o f ± 20 
years 126'163.
The number of people living with HIV continues to grow, in 2006 a total o f 39.5 
million people were living with HIV, which represents an increase o f 2.6 million 
compared to figures for 2004 32°. Approximately two thirds (63%) o f all adults and 
children infected with HIV worldwide live in sub-Saharan Africa. Figure 1.1 shows 
the global distribution of the HIV-1 epidemic.
15
Figure 1.1: Adults and children estimated to be living with HIV in 2006. Total: 39.5 (34.1 -4 7 .1 ) million. Global summary of the AIDS 
epidemic December 2006. Figures and diagram reproduced from the 2006 AIDS epidemic update. A joint United Nations Programme on 
HIV/AIDS (UNAIDS) and the World Health Organization (WHO) report 32°.
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1.1.2 HIV Diversity
The majority of HIV infections are derived from HIV-1. HIV-2 infections have been 
mainly located in countries such as the former Portuguese colony Guinea Bissau, 
where it was first isolated in a 29 year old African AIDS patient from an area 
bordering Senegal41. HIV-2 was originally referred to as lymphadenopathy associated 
virus type 2. Some cases o f HIV-2 have also been reported in India, and Brazil and 
some other countries which had past socio-economic links with Portugal. Portugal 
itself has the highest rate o f HIV-2 infection in Europe, HIV-2 accounts for around 
10-13% of total HIV infections 41,274.There are 3 distinct groups o f HIV-1, group M 
for ‘major’, so called as the vast majority of infections worldwide stem from this 
group, group O for ‘outlier’ and N for ‘new’ . The diversity afforded to HIV by its 
evolutionary flexibility has allowed the virus to establish different strains throughout 
the world. These ‘founder’ infections are established when a single strain of HIV 
populates a particular area. Over time the virus continues to infect several different 
hosts and establishes a population, subsequent sequence analysis o f these viruses 
shows a higher sequence similarity within that population, than compared to other 
HIV populations present within different geographical locations. Within group M 
there is a further level of classification referred to as subtypes or clades, which refer to 
the major clades found within HIV-1 group M viruses. These clades are designated A 
to K. The distribution of the clades is shown in Figure 1.2. Another clade or assembly 
of clades are the CRF’s Circular recombinant forms, which are essentially viruses 
composed o f genes derived from two or more different clades within group M that 
arise by recombination. Examination of clade distribution reveals that subtype C is 
predominant in Southern and eastern Africa, India, Nepal and China. A and A/G 
recombinants are mainly located in and around Central and West Africa 330. The 
predominant subtype in North America and Western Europe and Australia is subtype 
B 148. The basis for subtype classification is usually alignment o f sequences in the env 
gene, where differences of 20-50% can be seen and more recently classification based 
on protease and reverse transcriptase (RT) sequences which can show variation o f 10- 
12% at the nucleotide level or 5-6% at the amino acid level 148. The impact o f subtype 
on rates of transmission, disease progression and other clinical consequences are not 
clearly understood, but one area o f research aimed at determining the difference in 
response to antivirals seems to imply that subtype does not adversely affect response
17
to treatment and that mutational patterns that arise in subtype B also appear in non-B
148subtypes . Differences have been reported that suggest the divergent evolutionary 
paths taken by different HIV-1 clades may play a role in virus pathogenesis. Centlivre 
et al. reported that the subtype C virus is better adapted to replication in gut associated 
lymphoid tissue (GALT) . It is thought that the primary cellular targets for HIV are 
the activated cluster o f differentiation 4 (CD4+) T lymphocytes expressing the 
chemokine receptor for HIV entry chemokine (C-C motif) receptor 5 (CCR5). This 
population of T cells is thought to be in higher concentration in the GALT than in 
peripheral blood, spleen or lymph nodes. This could explain why the gut is the 
preferred target for viral replication and early CD4 T cell depletion. Increased 
activation of the subtype C virus promoter by the GALT cytokine microenvironment 
would favour it’s replication during primary infection and could have resulted in 
enhanced transmission rates. This in turn would afford a growth advantage to this 
subtype and may explain the observation that the subtype C virus dominates HIV-1 
epidemiology, accounting for 50% of infected individuals in the world 36.
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Figure 1.2: Geographical distribution of HIV-1 clades. Letters indicate the predominant HIV-1 clade circulating in selected countries. A/B, 
B/E, and B/F indicate co-circulation of two dominant clades; AE and AG indicate circulating recombinant forms.
Figure taken from UNAIDS/WHO 32°.
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Sequencing of virus isolates from the clade C subtype has revealed that they posses a 
uniquely truncated regulatory protein, Regulator o f expression o f viral proteins (Rev) 
and an enlarged viral protein u (Vpu) gene. Analysis of subtype D samples has shown 
that they contain a C-terminally truncated version of another regulatory protein, Tat
im Tin__
protein ’ ’ . The functions of these proteins will be discussed more extensively in
the Life cycle section 1.3. However, it could be said that variation in the two 
regulatory genes Tat and Rev and variation in Vpu, which affects viral infectivity, 
could have resulted due to virus-host adaptation and resulted in increased virus 
production and therefore transmissibility. Undoubtedly, the aim of a virus when it 
infects its host is to replicate and spread its progeny virus to nearby cells and 
ultimately to a new host and therefore continue the spread of the virus among the host 
species. The adaptation to host genetics is the initial evolutionary pressure placed on 
the virus when it first infects the host. The ability of HIV to adapt quickly to its host 
immune system and other environmental pressures that it may be exposed to is a 
consequence of several factors which are discussed in the next section.
1.1.2a Mechanisms for HIV sequence variation
An estimated 109 to 1010 virions are generated in each infected patient daily 140,333. As 
early as one week after the onset of clinical symptoms approximately, 105 to 107 HIV 
RNA copies/ml are present in the initial burst of viral replication associated with 
primary infection. However, this only represents 102 to 104 infectious units o f HIV 
134,263 r p ^ i s  recjuctjon jn actual replication competent virus compared to viral RNA 
measurements, represents a substantially impaired viral population which is primarily 
due to two unique steps within the Retroviridae Life cycle which contribute to the 
genetic diversity of HIV. The first is the process carried out by the enzyme RT 
(discussed further in Life cycle section 1.3). The RT of HIV is devoid o f any error 
repair mechanisms and hence it has a very high mutation rate (3 x 1 O'5 substitutions/
316site/ generation) , which is thought to generate every possible point mutation, every 
day in an infected person 45,204.The second process also occurs during genome 
duplication and involves two template jumps which are required to replicate the 
terminal repeat regions during proviral DNA synthesis. Retroviral RNA is a dimer, 
held together by sequences near the 5'ends o f both strands. This diploid RNA allows
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recombination to occur in virions that contain two RNAs encoding different genetic 
information. Genetic recombination is one of the mechanisms that facilitates the rapid 
diversification o f HIV populations, a single round of replication in T lymphocytes in 
vitro generating an average of nine recombination events per virus, and infection of
178macrophages led to approximately 30 crossover events . Recombination occurs 
when an individual becomes infected with another strain of HIV, this can be by co- 
infection, which is when two viruses infected within a timescale of each other, such 
that the immune response is directed simultaneously at both. Another possibility is 
re-infection, also termed super-infection, this occurs when an individual who has 
previously been exposed to an infection and has established an immune response to 
that infection then becomes infected by another strain 30°. Recombination can result in 
the generation of intra-subtypes, which are composed of viruses from within the same 
subtype or inter-subtypes which are generated when the RNAs of two subtypes of 
viruses are co-packaged into the same virion. Intra-subtype recombination occurs at a 
much higher frequency than inter-subtype recombination. A proposed mechanism for 
the lower recombination rates detected across subtypes was suggested by Chin et al.y 
where they investigated the barriers to HIV-1 inter-subtype recombination, between 
subtypes B and C. The data demonstrated that mismatched sequences in the 5’ 
untranslated region (5’UTR) which are involved in dimerisation initiation and 
packaging of viral RNA, altered the ability of HIV to form heterozygous virions, this 
in turn caused a reduction in the observed recombination rate 37.
It is thought that HIV recombinants contribute to 10^10% of the HIV infections in 
Africa and 10-30% of those in Asia. Many of the inter-subtype recombinants circulate 
with high prevalence in certain geographical regions, such as A/E recombinants in 
Thailand and B/C recombinants in parts of Southeast Asia and C hina37.
1.1.3 Course of Infection
HIV can be transmitted by exposure of the oral, rectal, or vaginal mucosa during 
sexual intercourse, which accounts for more than 90% of HIV infections worldwide
89 298’ . It can also be transmitted by inoculation with contaminated blood or blood
products, such as through the sharing of equipment during intravenous drug injection, 
through blood transfusion products and through perinatal transmission from mother to
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newborn infant. Approximately half the cases of primary infection remain 
asymptomatic whereas, the remainder of patients experience flu-like symptoms within 
a month of infection.
Clinically HIV-1 infection of typical progressors, who represent the majority o f HIV- 
infected individuals, can be divided into 3 phases, see Figure 1.3. During primary
o
infection, the initial phase, the virus load is extremely high (up to 10 HIV-1 RNA 
copies/ml of plasma) , this also coincides with a decline in the number o f CD4+ T 
lymphocytes. After the initial burst o f viremia, virus levels in the blood start to 
decline. This reduction is thought to be due to the development o f an immune 
response to HIV-1 infection through the activation of cytotoxic CD8+ T lymphocyte 
(CTL) response. The CTL response exerts its antiviral effect through several different 
means, including the production o f specific antiviral chemicals such as, interferon 
gamma, which inhibits viral replication.
The second phase of infection is also known as the long asymptomatic period; this 
phase is associated with a gradual loss of CD4+ cells which correlates with levels of 
viremia. During this long period of sustained replication that precedes the final stage, 
CD4+ T cells are constantly being infected, eliminated and regenerated. The 
elimination of cells can occur by infection related cell death and through immune 
destruction of infected or by-stander cells i.e. cells that are not infected but may have 
viral proteins attached, due to cell to cell contact of an infected cell. This phase is also 
known as clinical latency and generally can last eight to ten years in typical
242progressors
The final stage is known as clinical immunodeficiency or AIDS; this is preceded by a 
rapid decline in CD4+ cells and increase in viral load. Individuals who are at this 
stage o f HIV infection usually succumb to one of the many opportunistic infections 
associated with the late stage disease status.
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Figure 1.3: Phases of HIV-1 infection. Typical course of HIV infection. Patterns of 
CD4+ T-cell decline and virus load increase vary greatly from one patient to another, 
as do the actual values o f viral RNA load. Figure taken from Coffin et al. 46.
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1.2 HIV Replication and Structure
1.2.1 HIV-1 Virion structure
The lentiviruses like other retroviruses are enveloped viruses, the mature virions have 
a spherical morphology o f 1 lOnm in diameter 36°. The outer envelope is composed of 
a lipid bilayer with viral envelope glycoproteins. Since the envelope is mainly derived 
from the infected cell, and so some cellular components are also incorporated. The 
envelope surrounds an internal layer of matrix protein (MA), which is anchored to the 
internal surface o f the lipid bilayer by N-terminal myristoyl associated groups 89149. 
This matrix shell contains a dense cone-shaped nucleocapsid core in which the viral 
genomic RNA molecules, viral proteins and some cellular factors are packaged.
The genome of all retroviruses consists of three genes; Group specific Antigens 
(gag), Polymerase (Pol) and Envelope (env), these encode the structural proteins. The 
more complex retroviruses such as SIV and HIV encode additional proteins, Tat, Rev, 
Negative factor (Nef), Viral infectivity factor (Vif), Vpu and Viral protein r (Vpr) that 
have regulatory or accessory roles.
The genome size of HIV is approximately 9.2kb; it is present as two identical single 
stranded RNA molecules within the virion, but in persistently infected cells it exists as 
proviral double-stranded DNA . Figure 1.4 shows a linear representation of the 
HIV-1 genome. The polyprotein products o f the 3 main genes are processed into 
mature particle-associated proteins by either viral protease, as is the case with the 55- 
kDa Gag precursor Pr55Gag and the 160-kDa Gag-Pol precursor P rl60Gag Po1. Or by 
host cell proteases, as occurs with the 160-kDa env precursor. The additional proteins, 
Tat, Rev, Vpr, Vif, Vpu and N ef are primary translation products of messenger RNA 
(mRNA) splicing, although HIV protease also cleaves a single site in N e f66,89.
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Figure 1.4: Organization of the HIV-1 genome. The location of the long terminal repeats (LTRs) and the genes encoded by HIV-1 are 
indicated, gag, Pol and Env proteins are initially synthesized as polyprotein precursors. The Gag precursor is cleaved by the viral protease into 
the mature Gag proteins: matrix (MA), capsid (CA), nucleocapsid (NC) and p6. The GagPol precursor undergoes protease mediated processing 
to generate the Gag proteins and the Pol enzymes: protease, reverse transcriptase (RT) and integrase (IN). The Env glycoprotein precursor gpl60 
is cleaved by a cellular protease during transport to the cell surface to generate the mature surface glycoprotein gpl20 and the transmembrane 
glycoprotein gp41. The sizes of the genes and encoded proteins are not to scale. Figure taken from Freed (2004)%.
1.3 Life cycle
The HIV Life cycle can be divided into two phases, early and late, as depicted in 
Figure 1.5. The early stages o f replication involve binding, fusion, entry, reverse 
transcription and integration. The late phase of the Life cycle begins with the 
regulated expression o f the integrated proviral genome, leading to virus budding and 
finally maturation.
1.3.1 Early Phases 
1.3.1a HIV Entry
Fusion of HIV to CD4+ T cells requires interaction of viral gpl20, the surface subunit 
(SU) envelope glycoprotein and CD4 on the cellular plasma membrane; this triggers a 
conformational change in gpl20 which reveals the previously occluded coreceptor 
binding site. The binding of the cellular coreceptor induces another conformational 
change in the transmembrane region of viral glycoprotein, exposing the hydrophobic 
N-terminal portion o f gp41 known as the fusion peptide, which is inserted into the 
plasma membrane of the target cell. Specific heptad repeat regions within gp41 fold to 
form a stable six helix bundle structure which interacts with the plasma membrane 
leading to fusion and pore formation 39 47’199’345
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Figure 1.5: HIV-1 Life Cycle. General features of the HIV-1 replication cycle. The 
early phase (upper portion of the diagram) begins with CD4 recognition and involves 
events up to and including integration of the proviral DNA, and the late phase 
includes all events from transcription of the integrated DNA to virus budding and 
maturation. Figure fom Turner et al. 318.
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1.3.1b Target Cell Receptors
Entry into the target cell requires that the viral membrane must be fused with the 
plasma membrane of the cell. This process is facilitated by an interaction of the 
envelope protins of HIV, gpl60 with cellular receptors. Two host receptors are 
usually required for entry of HIV into the cell. The primary receptor CD4, is a type 1 
integral membrane glycoprotein l95, which is a 55-kDa member of the 
immunoglobulin (Ig) superfamily 57. CD4 is a ligand for Major Histocompatibility 
Complex (MHC) class II molecules and is expressed predominantly on the surface of 
T-helper cells. It is a receptor for IL-16, which is a cytokine with chemoattractant
39activity for CD4+ lymphocytes, monocytes and eosinophils
The second cellular receptor HIV interacts with was first identified in 1996 and is a 
member of the G protein-coupled receptor superfamily of seven-transmembrane 
domain proteins. By facilitating entry into cells, these receptors play a major role in 
determining viral tropism. HIV cellular tropism is described in terms of its ability to 
replicate in macrophages or T-cells lines. Viruses that are able to infect and establish 
infection in macrophages and peripheral blood mononuclear cells (PBMCs) are 
classified as M-tropic. These strains also fail to induce syncytia (giant multinucleated 
cells) and so are also termed non-syncytium inducing (NSI) strains. Viruses that are 
able to infect T-cells and PBMCs and also induce synctia (SI) are referred to as T- 
tropic. The a-chemokine receptor CXCR4 previously known as Fusin 87 was 
identified as the primary coreceptor required for infection by T-tropic isolates. The 
infection of macrophages and PBMCs required the presence o f CD4 and the (3- 
chemokine receptor CCR5 43. Dual tropic viruses are able to gain entry using either 
CCR5 or CXCR4. Early in infection, a homogenous population which utilises the 
CCR5 coreceptor dominates, studies have demonstrated that the transition from CCR5 
utilizing (R5) phenotype to a CXCR4 (X4) phenotype is associated with increased 
viral replication kinetics and progression to AIDS 39’208’316’323 The association of R5 
viruses with primary infection is also demonstrated by the resistance to infection o f 
individuals who possess two copies of a non-functional CCR5 allele, A CCR5. The 32 
bp deletion results in a premature stop codon and a truncated receptor protein; as a 
result no CCR5 is expressed on the surface. Homozygotes are strongly, but not
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absolutely protected against infection by HIV-1; heterozygosity does not protect 
against HIV-1 infection but is possibly associated with an improved prognosis in the 
form of prolonged onset of symptoms and overall survival periods 39.
Chemokine receptors form rod like structures on the cell membrane with a central 
pore surrounded by the 7 transmembrane regions, which contain four domains 
exposed on the surface and three extracellular loops. The sites involved in HIV entry 
for R5 viruses require interaction o f CCR5 with gpl20, this is thought first to involve 
an initial interaction between sulfated tyrosines in the CCR5 N-terminus and gpl20,
317followed by a second interaction with the second extracellular loop 
Chemokines are the natural ligands of the chemokine receptors and are 8 to 10-kDa 
proteins made up of 70-120 amino acid residues. They adopt a common folding 
pattern and show 20 to 70 percent homology in amino acid sequences with each other 
,86. The family of chemokines contains four subsets (CXC, CXXXC, CC and C), 
which are differentiated on the relative position of their cysteine residues. In the a - 
chemokines, the first two cysteine residues are separated by a single amino acid 
(CXC), whereas in the p-chemokines, the first two cysteine residues are adjacent to 
each other (CC) 220 .
The natural ligands for CCR5 are Regulated on Activation, Normal T cell Expressed 
and Secreted (RANTES), Macrophage Inflammatory Protein-la (M IP-la), and MIP- 
1(3. The homozygous ACCR5 allele is tolerated in individuals who express it due 
promiscuity of its ligands which are able to bind with other receptors. M IP-la  can 
bind to CCR1 and RANTES can bind CCR1 or CCR3, although M IP-lp binds only to 
CCR5 317. CXCR4 is the only receptor for stromal-derived factor 1 (SDF-1). SDF-1 
was originally isolated from a bone marrow stromal cell line and was found to 
support the proliferation of bone marrow B-cell progenitors in the presence of 
interleukin (IL)-7 220. The SDF-1/CXCR4 system plays an important role in the 
migration of progenitors during embryologic development; knock-out of either 
CXCR4 or SDF-1 is lethal in mouse embryos causing marked cardiac and cerebellar 
defects 3I7.
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1.3.1c Virus Receptors
The HIV envelope glycoproteins are synthesised as a single polypeptide precursor, 
gpl60, which undergoes cleavage in the Golgi apparatus. The processing of gpl60 is 
thought to involve one or more proteases from the subtilisin family of endoproteases 
which have shown the ability to correctly cleave HIV-1 gpl60 into biologically active
197 9 1 7gpl20 and gp41 ’ . HIV undergoes extensive glycosylation i.e. the addition o f N-
linked polysaccharide chains called glycans, also known as N-linked glycosylation. 
This occurs most abundantly on gpl20, where nearly half the molecular mass is
i - j n  'J f . n
attributable to N-linked glycans ’ . The role o f glycosylation in HIV infection is
thought to have two functions; firstly it is thought essential for correct folding and the 
overall conformation of gpl20. Secondly, as a mechanism to conceal antibody 
epitopes on gpl20; glycans illicit no immunogenic response as they are produced by 
the host cell. Immune evasion may also be achieved by repositioning the glycans so 
that they cause a structural change in the viral receptor and so affect the binding sites 
for neutralizing antibodies. The rearrangement effects of the glycans could 
conceivably compensate for localised amino acid changes caused by neutralizing 
antibody evasion 243. The amount of glycosylation has also been implicated in the 
compartmentalisation of viruses, those viruses originating from the semen were 
shown to contain less surface glycans 265.
During the HIV budding process, the gpl20-gp41 complexes, which are initially 
expressed at the surface of infected cells, are incorporated into the virus envelope and 
displayed on its surface as viral spikes. Both subunits of the viral envelope proteins 
are connected through non-covalent interactions 39,243. Wild-type HIV virions showed 
14 ± 7 Env spikes per virion, randomly distributed, while SIV has a much higher 
density of surface receptors with around 73 ± 25 spikes per virion which are also 
unevenly distributed. Each envelope spike is composed of three molecules of gpl20 
and gp41, formed as trimer. The transmembrane regions, or ‘stalks’, project from the 
‘head’, the gpl20 trimers, in a manner similar to the legs of a tripod ,360
The sequence of gpl20 can be divided into five conserved regions (C1-C5) and five 
variable regions (V1-V5), its structure has been determined through the use of 
truncated proteins that lacked VI/V2 and V3 regions 243. The interactions o f gpl20
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and coreceptors that are involved in tropism are located in V1/V2 and V3 loops in an 
area known as the bridging shee t39 243.
It has been suggested that the amount of receptors expressed on the surface of the 
virus influences the infectivity. Using SIV, Yuste et al. demonstrated that deletions in 
the cytoplasmic tail o f gp41 increased levels of Env incorporated into mature virions, 
however, only a modest increase in infectivity was demonstrated. Surface expression 
of env was increased from an initial range of 7 to 16 spikes for wild type SIV and 200 
to 417 for the gp41 truncated mutant. However, a comparable increase in infectivity 
was not observed, only an increase o f 2-3 fold in infection was detected 354. Such a 
mechanism of increasing infectivity, by expressing a truncated gp41 transmembrane 
protein has been seen in vivo in a virus isolated from a patient with primary 
symptomatic infection and experiencing rapid CD4 cell decline. This patients virus 
also contained an amino acid substitution that mutated a highly conserved tyrosine 
residue in env, which is also thought to increase surface expression of envelope 
glycoproteins. 100
1.3.Id Primary Infection
The primary target for HIV is the CD4+ T lymphocytes, although on establishing 
primary infection the virus is first thought to interact with dendritic cells (DC). DCs 
are antigen presenting cells that capture, transport and present antigens to CD4+ and 
CD8+ T lymphocytes. Although HIV can infect certain dendritic cells, such 
Langerhans cells (LCs) 294, DCs role in establishing primary infection is thought to be 
involved in the capture and transport of HIV-1 to the lymph nodes for viral
987propagation and dissemination . A subset of DC’s present in dermal and mucosal 
tissues express the C-type (i.e calcium dependent) lectin, DC-specific intercellular 
adhesion molecule 3 (ICAM-3)-grabbing non-integrin, (DC-SIGN). This is able to 
bind to ICAM-3 on resting T cells and it has been reported that DC-SIGN binds 
gpl20 with a higher affinity than CD4 121; however, the virus is unable to utilise DC- 
SIGN for entry. Instead it is thought to function as an attachment factor for HIV-1 by 
binding to the mannose residues on the heavily glycosylated gpl20 protein and 
facilitating DC-mediated viral transmission. I24 332.
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HIV infection through sexual contact is the major route o f transmission 354 with 
herterosexual intercourse accounting for more than 90% of all infections globally 55. 
Infections in women account for approximately half the infections worldwide and 
transmission from male to female has also been shown to be more effective than 
female to male 55>294. in females the initial barrier to the incoming virus is in the 
vaginal epithelium, the events that lead to entry and establishment of infection are not 
fully understood. Recent research has suggested that both activated and resting CD4+
139cells as well as LCs are the primary source of infection . LCs cells are situated in 
epidermis of the skin and in all mucous membranes including oral, vaginal and 
cervical epithelium. They do not express DC-SIGN, but are capable of supporting 
infection through CD4 and CCR5 mediated entry, CCR5 is expressed at low levels, 
present only on 24-49% of cells, with CXCR4 being undetectable 294. Novel in situ 
studies were carried out using an ‘ex vivo organ culture system’; where vaginal 
epithelial sheets were removed from donors, grown and used to monitor infection
1 TOwith fluorescently labelled HIV-1 virions . Using inhibitors to CCR5, monoclonal 
antibodies to CD4 and C-type lectin inhibitors, it was shown that entry into LCs was 
partially mediated by CD4 and CCR5. The role of DC-SIGN was only marginal and 
the majority of infection was through endocytic means in the LCs. The endocytosed 
virions in the LCs remain viable for up 5 days after infection 294 and were able to 
infect CD4+ T-cells through LC-T-cell conjugates. This mechanism of capture, 
internalisation and transport o f virus to CD4+ T-cell rich regions of the lymph nodes, 
an area primed for viral replication, has become known as the ‘Trojan Horse’ 
scenario, taken from Greek mythology 294. It was also shown that upon the first 
encounter with HIV-1, simultaneous entry occurred in both LCs and CD4+ T cells in 
the outer vaginal epithelium 139.
Receptor expression on the primary target cells for HIV has shown an equal 
distribution of both coreceptors, CCR5 and CXCR4. However, as mentioned earlier 
the coreceptor usage of HIV isolated during most asymptomatic infections has been 
CCR5. The preferential replication of the R5 virus early in infection could be 
explained by differential expression of the coreceptors on the most prolific virus 
producing cell i.e. the activated T-lymphocyte. Analysis of expression levels of 
chemokine receptors in HIV-1 infected and uninfected individuals revealed CCR5 
expression on CD4+ T cells is up-regulated and CXCR4 is down-regulated in HIV-
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infected individuals, compared with uninfected controls. The primary target for HIV, 
the activated T cells, predominantly express CCR5, lower expression of CXCR4 and 
higher expression of CCR5 on CD4+ T cells correlated with advancing disease 240. 
CXCR4 utilising viruses emerge during the late stages of disease and can be isolated 
from up to 50% of AIDS cases although infrequently from subtype C infected patients 
39. Other reasons for this disproportionate level of R5 could be chemokines and post 
entry events. CCR5 is thought to promote post entry steps, one possible mechanism is 
through the increased ability to mobilise calcium in monocyte-derived macrophages, 
which promotes the transport o f the capsid through the highly viscous cytoplasm 
157,301 -g ajSQ SUpp0rted by the observations of Schmidtmayerova et al. They
demonstrated that CXCR4 binding and entry was possible in macrophages, but that
replication was restricted at a post entry level, predominantly at the step o f nuclear
288importation of the pre-integration complex (PIC) . The prevention o f CXCR4 virus 
infection could also be affected by the cells along the mucosal membrane, which 
express high levels of SDF-1. CCR5 may also out compete CXCR4 as it binds soluble 
gpl20 with greater affinity 317. Although many research articles have demonstrated 
X4 infection of cells associated with initial infection can occur. These may be partly 
explained by the Hn vitro’ nature of the work which was carried out away from the 
chemokine rich environment of the mucosa. Data from one study which looked at the 
receptor usage o f patients with early stage disease showed that all the samples were 
either R5 (70-80%) or dual tropic, no X4 utilising viruses were found 317. It has also 
been reported that virus present in male semen is predominantly of R5 phenotype, 
even if the majority o f circulating virus from the individual was X4 265.
The binding of virus envelope with the cell has been shown to induce many 
chemotactic events. These may be solely related to virus entry such as, the ability o f 
HIV/SIV to recruit susceptible target cells to sites of active viral replication; this 
represents an important mechanism for viral dissemination. Chemotaxis may result in 
the aggregation o f receptors to facilitate fusion 157. As mentioned earlier the receptor 
density is relatively low and there appears to be no uniform arrangement on the viral
360membrane . Therefore, the receptors may not be bound to specific positions and 
may be free to coalesce to a specific site to facilitate fusion 111. This would seem to be 
an efficient means of compensating for either low density o f receptors or inefficient 
fusion due to immune evasion. Env engagement has also been shown to signal the
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recruitment of receptors and Gag on the membrane of effector cells during cell to cell 
direct transfer l47. This chemotaxis ‘priming’ of the host cell may also be used for 
entry and aggregate cellular proteins required for events further downstream in the 
replication cycle 95.
1.3.2 Virus Uncoating
Fusion allows the transference of the virus core and capsid containing two copies of 
the unspliced viral genome along with the enzymes protease, RT and integrase 
through the fusion pore Also packaged into the capsid is the nucleocapsid protein 
(NC) p7, which helps to stabilise the viral RNA and the accessory proteins Nef, V if 
and V p r89.
The initial step in uncoating is the dissociation o f the matrix coat from the lipid 
membrane; this is attached to the matrix through the N-terminal myristyl moeity. 
Dissociation is thought to be triggered by basic residues within the matrix proteins, 
which connect to the lipid membrane through electrostatic interactions. Myristylation 
and phosphorylation are crucial regulatory events for matrix function. The 
phosphorylation of specific tyrosine residues in matrix which are thought to interact 
directly with the lipid membrane, are thought to be required for successful 
dissociation 95 149. Uncoating is the process that occurs directly after entry into the 
cytoplasm, but before the completion of reverse transcription and nuclear en try81. The 
uncoating process is still not very clearly understood. Experimental determination of 
exactly what processes are required for successful uncoating have been hampered by 
the need to purify cores in the presence of detergent to remove the outer envelope 
region, this in turn causes instability of the purified cores. However, some studies 
have been able to determine the requirement for cellular factors to assist in uncoating. 
This was demonstrated using sucrose density gradients and ultracentrifugation to 
separate the intact virus cores, which were then exposed to the lysate from activated 
or unactivated CD4+ lymphocytes. Only cores that were incubated with the lysate 
from activated cells were able to complete the uncoating process and initiate reverse 
transcription 10. Many other cellular factors have been implicated in assisting, or are 
required, in order for uncoating and reverse transcription to occur. The ATPase heat 
shock protein 70 (Hsp70) is a constituent of the HIV-1 virion and is thought to play a 
key role in stabilisation of the core structure 221. It has also been implicated in nuclear
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localisation of the HIV-1 viral PIC to the nucleus in the absence o f HIV-1 Vpr 
protein. The Hsp70 protein family members perform a variety of functions that could 
implicate their role in early entry events of HIV-1. Proteins in this group facilitate 
assembly and disassembly of oligomeric protein complexes as well as their folding 
and intracellular transport 123.
The dissociation of the matrix complex exposes the viral capsid, bound to it are 
approximately 200 molecules o f the human cellular proline isomerase, cyclophilin A 
(C ypA ),318 although HIV-2 and SIV do not package CyPA 339. The incorporation of 
CypA occurs during assembly and is thought to be required to abrogate host 
restriction factors 96 and may also play a role in uncoating by helping to destabilise
1 IQthe mature capsid; acting as an uncoating factor . Structural studies have revealed 
that CypA binds in Gag to a loop structure within capsid, residues 85-99, it 
specifically interacts with Gly89 and Pro90 339. Mutation of either of these two 
residues or treatment with the immunosuppressive agent Cyclosporin A, abolishes the 
capsid-CypA interaction and confers a substantial loss of infectivity on the virus 132. 
The block to infection is post-entry and is thought to occur before completion of
O 1
uncoating The host restriction factor thought to be responsible for diminished 
replication in CypA deficient viruses is the human form of the a  spliced variant of the 
tripartite motif (TRIM) 5 gene. The mechanism by which TRIM5 exerts its host 
restriction effect is still unknown, it may disrupt either or both o f the highly ordered
O 1
events of uncoating or reverse transcription . The binding of CyPA may also obscure 
capsid residues or cause structural changes that prevent detection or binding by the 
restriction complex 302.
Another cellular defence mechanism that has been shown to be active against 
retroviruses is a member of a family of RNA-editing enzymes that deaminates 
cytosine residues in viral DNA. Apolipoprotein B mRNA-editing enzyme, catalytic 
polypeptide-like 3G (APOBEC3G), also known as CEM15, catalyses the replacement 
of cytosine by uracil in the minus strand DNA during reverse transcription. This leads 
to the replacement of the uracil with a thymidine and the possible degradation by host 
uracil-DNA glycosylases in the uracil-based excision pathway. The other possibility 
is G —>A hypermutation, this results from the uracils being replaced for thymidine in 
the minus-strand DNA, which is an adenosine in the complementary strand 96’308.
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However, HIV also packages a host a derived enzyme that removes uracil bases from 
DNA, called uracil DNA glycosylase hUNG-2; this may counteract the activity o f 
APOBEC3G 1%. Although the potential role for the uracil removal is unclear, one 
mechanism HIV has to counteract APOBEC3G is Vif. The mechanism V if employs 
to inhibit G—>A hypermutation is still unclear, it has been shown to bind to 
APOBEC3G and induce its degradation and may also prevent its incorporation into 
virions 96. The inhibition of APOBEC3G packaging into the virion by V if does not 
affect mRNA levels o f APOBEC3G, which suggests that V if effects protein 
expression, post-transcriptionally96’308.
Uncoating can be seen as a two stage process, firstly as described above the 
dissociation of matrix occurs, which is followed by a slower secondary stage of capsid 
protein disassembly75. The cone shaped capsid of HIV-1 is composed o f a polymer of
nc
approximately 1500 capsid proteins ; the association of capsid with the reverse 
transcription complex (RTC) is still not clearly understood. RTC’s which are 
complexes of viral proteins and cellular components, are reverse transcription 
competent and this activity has been shown regardless o f whether or not capsid was 
still bound. The capsid of HIV-1 has also been shown to contain pores that may allow 
for the diffusion o f nucleotides and so increase the possibility that active reverse 
transcription takes place in the cytoplasm 75’203.
HIV-1 like all other lentiviruses is able to infect non-dividing cells; this is achieved 
through its ability to transport the PIC to the nucleus. The PIC is a high molecular 
weight nucleoprotein complex, containing the viral proteins integrase, matrix, RT, NC 
and Vpr, it is thought to contain very little or possibly no capsid 75. The PIC differs 
from the RTC in that PICs are defined as integration-competent complexes, whereas 
RTCs are thought to contain incomplete components of reverse transcription 233. 
Nuclear targeting o f the PIC could be achieved by several methods, research has 
suggested that many if  not all o f the viral proteins present in the PIC contain nuclear 
localisation signals. The Vpr may facilitate nuclear localisation through invoking the 
cellular nuclear import machinery 318. The nuclear import signal may also come from 
an associated cellular protein, as mentioned earlier many cellular proteins are 
packaged with the virion during assembly. The cellular protein lens epithelium-
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derived growth factor/p75 (LEDGF/p75) is thought to target the PIC to the nucleus
75through its interaction with integrase
The core is thought to utilise the host cell cytoskeleton by travelling on the system of 
actin microfilaments network within the cell to aid transport to the nucleus through 
the highly viscous cytoplasm. 111196. This event is thought to be triggered by fusion 
which, it is proposed, may activate chemotatic signals also causing remodelling o f the 
actin cytoskeleton l47.
1.3.3 Reverse Transcription
HIV genome contains the highly conserved region that encodes for the viral enzymes, 
Protease, RT and IN 89. The production of the aforementioned proteins is the result of 
HIV protease cleavage of the Prl60Gag Po1, the major protein product is the Pr55Gag, 
which is expressed approximately 90%-95% of the time. The mechanism for 
production of the virally encoded enzymes is through a slippage or ribosomal 
frameshift during the translation of Pr55Gag 89. RT of HIV and all other retroviruses 
carry out both DNA polymerase and Ribonuclease H (RNase H) activities; the RNase 
H is nuclease specific to the RNA strand of an RNA-DNA hybrid 46.
1.3.3a Reverse Transcriptase Structure
Mature virions contain RT in the form of a heterodimer made up of two subunits, p66 
and p51. The p51 subunit is generated by protease cleavage of p66; therefore both 
subunits share identical sequences which are located at the N-terminal region. The 
p55 subunit lacks the RNase H domain and does not contribute to either o f the 
catalytic activities of RT. Although isolated RNase H is not active and requires the 
presence of p51 to restore activity, it is thought that residues located in the C-terminal 
region of p51 and p66 are important for RNase H cleavages ll3.
Crystal structures of p66 domain of RT initially bound to inhibitors and also unbound 
have revealed a structure that resembles a right hand, see Figure 1.6.
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Figure 1.6: S tructure of HIV-1 RT. Cartoon overview of the subdomains of HIV-1 
RT. The subdomains of the polymerase domain, which are named based on analogy to 
a human right hand, are colour coded. Both subunits are shown. Fingers (blue), palm 
(red), thumb (green), connection (yellow). The RNase H domain, which is part of the 
p66 subunit, is shown in light brown. Figure adapted from Coffin et al. 46.
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This has lead to the use of nomenclature based on that similarity; the subdomains 
have been named fingers, palm, thumb and the connection subdomain, which links the 
polymerase domain to the RNase H domain 46. The palm domain of p66 contains the 
polymerase active site, which forms a cleft, exposing the three catalytic aspartic acid 
residues 110, 185 and 186. The latter two aspartic acid residues are located in a 
conserved region which contains the motif YXDD. Mutagenesis of any of the 
catalytic residues results abolishment of polymerase activity. This m otif is conserved 
among numerous viral and cellular polymerases and believed to be essential for
1 1 o '111
polymerase function ’ . The p51 subunit has a more rigid structure and despite
having identical amino acid sequence does not form a polymerising cleft, the aspartic 
acid active site residues in the palm subdomain are buried underneath a more closed
318conformation adopted by the fingers subdomain
The structural analyses of RT with various templates bound have suggested that the 
overall structure is flexible. The proposed mechanism of action suggests the fingers 
close in around the primer-template and deoxyribonucleotide triphosphate (dNTP) 
prior to formation of the 3’—>5’ phosphodiester bond, this causes the lengthening o f 
the growing chain, resulting in a relaxation in the fingers subdomain. The release of 
the pyrophosphate allows the enzyme to advance to incorporate the next dNTP 89,318. 
The majority of residues in RT that are in contact with the template DNA are located 
in the p66 subdomain, with the palm and thumb subdomains clamping the DNA and 
3’- hydroxyl group (OH) of the primer in the correct conformation relative to residues
*5 1 O
in the active site . The primer-template chain extends for 18 bases from the active 
site of RT to that of RNase H 113.
1.3.3b Initiation of Reverse Transcription
Reverse transcription requires a primer with a free 3’-OH group to initiate extension; 
this is provided by the binding of host encoded cellular tRNAlys primer, the tRNA 
primer interacts with the thumb subdomain of RT. The 18 nucleotides located at the 
3’-terminal end of tRNAlys are complementary to a region located downstream from 
the 5’-end of the unspliced viral RNA, known as the primer binding site 113. There are 
three major types of tRNAlys isoacceptors, tRNAlys1,2 that differ from each other by 
only a single base pair in the anticodon stem and tRNAlys3, which has a much more 
diverse sequence with 14-16 changes. All three isoacceptors are packaged although in 
lentiviruses only tRNAlys3 serves as the tRNA primer 113158. The enzyme that
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aminoacylates tRNAlys to the charged active form is lysyl-tRNA synthetase, which is 
also packaged into the virion during assembly. The tRNAlys is associated with Gag- 
Pol during assembly, although the exact nature of the complex is not fully known. The 
lysyl-tRNA synthetase is thought to bind to Gag and several other interactions are 
required between Gag, Gag-Pol, viral RNA, tRNAlys and lysyl-tRNA synthetase l58. 
The annealing of the tRNAlys primer to the primer binding site does not appear to
. 779require Gag maturation
1.3.3c Overview of Reverse Transcription
Following initiation of reverse transcription, synthesis of minus-strand DNA proceeds 
eventually leading to the formation of a double-stranded pro vial DNA copy, prior to 
integration into the host genome. To accomplish this successfully, HIV-1 undergoes 
two template switches that occur by virtue of sequence homology. These occur within 
the primer binding site and the repeat regions located at both the 5 ’ and 3 ’ ends of the 
viral genome 46’89>n3. The majority of first strand transfers occur after the entire 5’- 
repeat region has been synthesised , these may be either inter-strand or intra-strand, 
both are thought to occur at similar frequency, while second strand transfer is thought 
to be solely intra-molecular i.e. a transfer from the 5’ repeat region of one viral RNA 
to the 3’ repeat region of the same RNA molecule ,13.
A brief description of the steps involved in reverse transcription is outlined below and 
in a diagram of the process is presented in Figure 1.7.
1. Reverse transcription is initiated with tRNAlys primer annealing to primer 
binding site in the viral RNA template. Minus-strand DNA synthesis is 
initiated from the 3 ’-OH of the tRNAlys primer and proceeds through terminal 
repeat region to the 5 ’ end of the genome.
2. Concomitant with DNA synthesis of the minus-strand, the RNA strand of the 
RNA/DNA hybrid is degraded by RNase H, this produces a short single 
stranded fragment called minus-strand strong stop DNA. The length o f this 
fragment is approximately 100-150 bases due to the location of the tRNAlys 
binding site. The sequence of this fragment is complementary to the repeat 
region located on 3’-end of the genome and this leads to the first translocation, 
termed first strand transfer.
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3. The formation of the RNA/DNA hybrid allows continuation o f minus-strand 
DNA to the primer binding site at the 5’ end; this is accompanied by RNase H 
degradation of the RNA strand of the RNA/DNA hybrid.
4. This degradation by RNase H proceeds up to a purine rich region termed the 
polypurine tract (PPT), this stretch of sequence is relatively resistant to RNase 
H degradation.
5. The synthesis of plus-strand DNA is initiated from the 3’ end of the PPT using 
the single-stranded minus DNA as a template. This generates plus-stranded 
strong stop DNA which includes sequence o f the primer binding site o f the 
tRNAlys that initially served as the template for minus-strand DNA synthesis.
6. RNase H removes the tRNAlys primer, exposing the sequences in the plus- 
stranded DNA primer binding site that are complementary to those in the 3’- 
end on minus-strand DNA, promoting the second strand transfer.
7. Plus and minus-strand synthesis continues until completion; with each strand 
able to use the other as a template.
Plus-strand DNA terminates at the end of the minus-strand or when RT encounters the 
central termination sequence (CTS). The CTS is essentially a centrally located PPT 
and results in the linear DNA molecule bearing in its centre a stable 99 nucleotide 
long, plus strand overlap referred to as the central DNA flap. This flap along with 
other viral proteins is incorporated into the PIC and is thought to facilitate its nuclear
233import
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Figure 1.7: Process of reverse transcription of the retroviral genome. (Black line) 
RNA; {light colour) minus-strand DNAs; {dark colour) plus-strand DNA. See text for 
a description of this process. Figure adapted from Coffin et al. 46.
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1.3.4 Integration
As previously mentioned the PIC is an integration competent complex, the migration 
of the PIC to the nucleus is thought to be achieved through viral components and also 
through the packaging of cellular components. Other cellular proteins are required to 
help with integration, as in vitro work on integration revealed that purified integrase 
was only able to partially complete the process 95’209. The high mobility group protein, 
HMG I(Y) has also been shown to be important for successful completion of 
integration and is thought to associate with the PIC during its journey to the nucleus 
233. Other cellular proteins include integrase interactor 1 (INI 1), which targets 
integration to transcrciptionally active regions of the host chromosome. Another host 
protein, barrier-to-autointegration (BAF) protein, prevents autointegration events that
80 9'K^may result in the production of aberrant forms of proviral DNA ’ . The PIC is
90^estimated to be 50nm in diameter , it contains a linear copy of proviral DNA from 
which two to three nucleotides are cleaved from the 3’ end by integrase, to form a 
pre-integration substrate 46.
The integrase enzyme of retroviruses allows the insertion the newly synthesised 
proviral DNA into the host genome, which then serves as a template for production of 
new virions for the lifetime of the infected cell. Full-length integrase is 288 amino 
acids long, it is a 32 kDa protein that has three domains: the central/catalytic core, the 
C-terminal, and the N-terminal domains. The catalytic core domain contains the 
highly conserved active site residues (Asp64, Aspl 16, and Glul52). Mutation of these 
residues generally leads to a loss of all the catalytic activity o f the enzyme and thus, 
the catalytic triad is thought to be an essential component of the integrase active site. 
The N-terminal domain (amino acids 1-50) is thought to be involved in protein 
multimerisation, it contains a zinc binding motif that stabilises protein folding. The C- 
terminal domain (amino acids 213-288) has a very high affinity for DNA and thus, is 
thought to play a role in binding to host DNA 172. Crystal structures indicate a dimeric 
model in which two monomers interact with each other, although it is not clear 
whether integrase works in vivo as a monomer, a dimer, or a tetramer l89 266.
This primary step in the integration process is called terminal cleavage, this event 
probably occurs in the cytosol and results the terminal addition of recessed 3’-OH 
groups to the viral DNA, providing the sites of attachment into the host chromosomal 
DNA. The second step is the staggered cleavage of the target cellular DNA, this
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occurs in the nucleus and is not based on target sequences, but primarily on the 
overall structure, with highly bent DNA sites being the preferred target for integration 
l72. The 3’ recessed ends of the viral DNA are joined to the 5’ cellular DNA by the 
integrase-viral DNA complex. Cellular repair complexes in conjunction with integrase 
and possibly RT repair the gaps completing the integration process. 46’89'209 318
1.3.5 Late Stages
1.3.5a Transcription, Translation and Export
Following integration of proviral DNA into the host chromosome, the provirus serves 
as a template for the synthesis of viral mRNAs. Transcription and splicing of HIV 
mRNA is a complex process, and is initiated in the U3 of the 5’ long terminal repeat 
(LTR). The viral regulatory proteins Tat, Rev and N ef are the first proteins to be 
produced early on in infection. Accumulation of Tat and Rev has a profound effect on
89transcription and both these proteins play an essential role in its regulation 
1.3.5b Long Terminal Repeats
Regulation of basal transcription levels is controlled by the interaction of cellular 
proteins with specific sequences within the HIV LTRs. Initial rounds o f transcription 
are carried out by cellular RNA polymerase II, the induction of the polymerase 
complex requires the binding of several cellular transcription factors, including 
transcription factor II D (TFII D) which binds to the TATA sequence upstream of the 
transcription start site 54. Other protein/DNA interactions with the HIV LTR such as, 
the binding of nuclear factor kappa B (NF-kB) and binding of Spl are also thought to 
contribute to basal transcription levels 95.
1.3.5c Tat
The initial transcriptional activity of the LTRs is very low; this increases dramatically 
when the transcriptional activator protein Tat binds to the RNA element known as the 
transactivation response element (TAR). The 5’ TAR element is located in the 
5’repeat region of all HIV RNA transcripts; it is 59 nucleotides long and forms a 
based paired stem loop structure, with a tri-nucleotide unpaired bulge and a six 
nucleotide G-rich loop. The primary sequence information is contained in the terminal
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loop and bulge of TAR 54. The Tat gene is divided into two coding exons and 
produces a protein of 101 amino acids containing several functional domains. The N- 
terminal activation domain spans residues 1 -47, the hydrophobic core element, a basic 
segment which is essential for recognition and binding o f TAR and a glutamine rich 
C-terminal domain, thought to be involved in inducing post-translational capping of 
mRNA 308,318. Tat binds at the top o f the hairpin to the bulge structure recruiting 
several host proteins to form a complex known as the positive transcription elongation 
factor b (P-TEF-b) %. The association between Tat, TAR and P-TEF-b causes the 
hyperphosphorylation of the C- terminal domain of RNA polymerase II, this induces 
conformational changes which results in an increase in processivity and initiation of 
full-length transcript production.
1.3.5d Rev
Activation of the infected cell by HIV or other stimulatory chemokines results in 
transcription of the viral genome. Three classes of mRNA are produced in the 
nucleus, (i) completely spliced which encodes the proteins Tat, Rev and N ef (ii) 
partially spliced which is around 5kb in size and contains the env glycoproteins, Vif, 
Vpu and Vpr and (iii) unspliced resulting in Gag and Gag-Pol polyproteins 308. 
Initially, only the completely spliced, 2-kb class of viral mRNA is produced. Then 
due to the binding of Tat, viral gene expression increases (by greater than two logs 95) 
resulting in a switch to synthesis o f viral structural gene mRNAs 54. The transition 
from early regulatory gene expression phase to that of the later structural phase is 
thought to be promoted by critical levels of the Rev protein 54’95>209’308>338 j>e when Rev 
protein levels reach a certain level, the switch to late phase expression occurs, thus 
Rev down regulates its own expression.
Once inside the nucleus Rev interacts with a cis-acting element that is located in the 
env gene, present only in the partially spliced and unspliced viral RNA transcripts 298. 
The binding of Rev to the Rev response element (RRE) facilitates the transport of the 
aforementioned RNAs through the nuclear membrane, thus preventing their 
translation in the nucleus 298.
Rev is a 19kDa protein encoded by two exons, resulting in a protein o f 116 amino
95 318acids ’ . It contains two functional domains; a basic domain which is an arginine-
rich RNA binding motif that binds to the RRE 308 and is also involved in nuclear
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localisation. The second domain is a hydrophobic leucine-rich domain involved in
95 318nuclear export and is known as the effector or activation domain ’ .
The RRE is 250 nucleotides in length and folds into a series o f base paired stem loop 
structures emanating from a central unpaired region. Initially Rev binds to the second 
stem loop and this promotes the multimerisation of Rev on the RRE, eventually 
binding up 12 Rev monomers 95.
The main function of Rev is to shuttle between the cytoplasm and the nucleus 
initiating nuclear export of unspliced and incompletely spliced mRNA ’s As 
previously mentioned, Rev encodes both nuclear import and export signals which 
facilitate this chaperone activity. The RNA binding m otif of Rev is thought to be 
involved in the recruitment o f host nuclear import factors, importins to aid its nuclear
308localisation functions . The nuclear export of Rev-RRE also requires the formation 
of complexes with host proteins, such as chromosome region maintenance 1 (Crml). 
This is an evolutionary conserved protein that acts as a receptor for proteins 
containing nuclear export signals, which localises to the nuclear pore 96>308.
1.3.6 Assembly Maturation and Budding
Viral assembly and budding, takes place on plasma membranes in T cells and on
1 19 9 S Sendosomal membranes in macrophages ’ . These final processes o f the HIV viral
Life cycle include encapsidation of the viral RNA, congregation of the viral proteins, 
budding and release from the infected cell membrane and maturation of the virus 
particle. These steps of the HIV Life cycle are tightly regulated by the Gag precursor 
polyproteins, Pr55Gag and Prl60Gag'Po1, which are synthesised by unspliced transcripts
Q Q
in the cytoplasm . The envelope proteins are synthesised by the same cellular 
machinery as is used by the host to process its own surface proteins. The envelope 
glycoproteins are translated on ribosomes associated with the rough endoplasmic 
reticulum, into the precursor protein gpl60. The Env polyprotein contains a signal 
peptide region located in the N-terminal portion which facilitates its insertion into the 
bilipid layer. Trafficking of the gpl60 through the Golgi apparatus results in the 
attachment of N-linked glycans and also the cleavage of the precursor polypeptide by 
host proteases into the mature envelope glycoproteins gpl20 and gp41 30’94’95’149’155 
Lipid rafts play an essential role in HIV particle production, a definitive role for rafts 
and cholesterol association of HIV is suggested through comparisons of the
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composition of the virion lipid bilayer and that of the host cell membrane from which 
it is mainly derived. The virion bilayer is significantly enriched in cholesterol and 
sphingolipids compared to that of the host 238. The final steps in the production of an 
infectious virion are also controlled by the viral proteins encoded in the unprocessed 
polypeptide, Pr55Gag 46,95.
1.3.6a HIV Protease
The HIV Gag proteins matrix (MA), capsid (CA), nucleocapsid (NC), p6 and the 
spacers p i (also known as SP2), p2 (also known as SP1) are formed from the 
proteolytic cleavage of the Pr55Cag precursor by the virally encoded protease 238. 
Protease also cleaves a site in Nef, although the requirement for cleavage of N ef does
O Q
not seem to be functionally important . Protease is 99 amino acids long and is active 
as a symmetrical homodimer, the dimer is stabilised by interactions between N and C 
terminal ends of each monomer. Aspartic acid residues of each monomer are involved 
in catalysis in the active site; therefore it is termed an aspartyl proteinase 89. The 
active site is formed at the interface of the two subunits by three residues from each 
monomer; aspartic acid 25, threonine 26 and glycine 27. The residues 49 to 52 of each 
monomer form a flexible p hairpin structure or ‘flap’ region, that extends over the 
substrate-binding cleft, the flexibility is thought to be essential for enzyme activity 318; 
see Figure 1.8. Structural and proteolytic studies indicate that the binding cleft of 
protease can accommodate peptides of approximately seven amino acids in length. 
Three to four amino acids either side of the peptide bond that is to be cleaved; referred 
to as the scissile bond, with the N-terminal flanking amino acids denoted as P I, P2 P3 
etc. The C-terminal flanking bonds of the substrate peptide are known P I ’, P2’, P3’ 
etc and the subsites of the enzyme that interact with the peptide are termed, N- 
terminal SI, S2, S3 etc and C-terminal S I ’, S2’, S3’ etc 20’46’89. During cleavage of the 
substrate the aspartic acid residues at position 25 of both monomers are involved in 
the activation of a water molecule located between the active site aspartates, which is 
required for the hydrolysis of the scissile bond 25. The specificity towards the 
substrate appears to be dictated by protein secondary structure which unlike the 
primary amino acid sequence is well conserved 349.
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The initial steps in the processing of the Gag-Pol fusion protein involve the 
autocatalysis of protease in the Prl60Gag Po1. The Gag and Pol proteins are encoded by 
overlapping reading frames; gag contains its own initiation (AUG) and termination 
(TAA) codons whereas, processing of Pol requires a ribosomal -1 frameshift during 
translation. The slip site is located at C-terminus of the NC coding sequence and 
forms a stem structure that stalls the ribosome during translation 295. Protease 
cleavage of the Gag-Pol fusion protein results in the production of the four N-terminal 
Gag proteins (MA, CA, p2 and NC) as well as the transframe protein, protease, RT 
and integrase 337.
The mechanism by which protease becomes activated is thought to involve primary 
intra-molecular cleavages that are carried out by the Gag-Pol embedded immature 
protease in cis. As with the enzyme, which is active as a dimer, the immature protease 
requires the dimerisation o f the Gag-Pol precursors, this creates a partial active site 
and the initial cleavage in Gag-Pol occurs at the N-terminus of protease and leads to 
the release of a catalytically competent, C-terminally extended protease species 30,258'
260 313’ . This autocatalysis of protease occurs either at the plasma membrane or just
after the virus particle has been released from the infected cell membrane 298.
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Figure 1.8: S tructure of HIV-1 Protease. Colour indicates distinct regions. Flaps: 
residues 43-58, red; flap tips: residues 49-52, yellow; flap elbow: residues 37-42, 
magenta; residues 59-75, green; residues 10-23, orange and p-strand motif forming 
the dimer interface: residues 1-4 and 96-99, blue/cyan. Figure adapted from Homak, 
Viktor etal. 141.
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1.3.6b Gag Cleavage
The cleavage of the Pr55Gag precursor and the formation of the internal structural 
proteins, is referred to as maturation, and is thought to take place after the budding 
event has occurred. A linear representation of the gag gene is shown in Figure 1.9, 
along with the location of domains present within each product and below a summary 
of the functions of each domain.
The exact order of cleavage of the Gag substrate in vivo is still not fully understood, 
but the in vitro order of cleavage has been elucidated 24,262. The initial cleavage occurs 
at the N-terminus of NC (p2/NC); the liberation of the NC is thought to play a vital 
role in core formation and stability o f the RNA dimers. The subsequent cleavage step
t inreleases the MA protein allowing it to form membrane associations ’ . The second 
cleavage event by the mature HIV protease releases the matrix protein from the 
capsid/p2 polyprotein, this is thought to induce major structural and morphological 
changes in the virion, during condensation of the core protein 30,94. The next cleavage 
event takes place at the p l/p6 site followed by the penultimate cleavage at pl/p7 24. 
The final Gag cleavage event is the release of the mature capsid protein, this cleavage 
occurs between CA/p2, even though this is one of the fastest HIV-1 processing sites, 
the negative regulation by the p2 protein slows the cleavage, so that this becomes one 
of the slowest Gag sites to be cleaved 262. The order of cleavage is fundamentally 
important to the production o f infectious viruses. Incorrectly cleaved Gag leads to the 
formation of immature virions with viral cores that appear doughnut-shaped by 
electron microscopy, as opposed to the conical-shaped cores adopted by mature
89retroviruses .
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Figure 1.9: L inear representation of the HIV-1 gag region, (a) entire Gag 
polyprotein (b) matrix and the domains located within (c) capsid domain (major 
homology region (MHR)) (c) p6 protein. Figure adapted from Freed 94.
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1.3.6c Gag Domians
1.3.6d Matrix (MA)
MA is largely responsible for membrane targeting and binding, as mentioned 
previously the N-terminus of MA is co-translationally modified by N-terminal 
myriystolyation, this modification is essential for the membrane transport and binding 
function of MA 30,95. The positively charged basic residues on MA are thought to 
interact with the negatively charged residues on the inner surface of the plasma 
membrane, thus stabilising membrane association 30,95. The overall structure o f matrix 
is thought to be trimeric and this may be functionally relevant for assembly. Matrix is 
also involved in the incorporation of full-length envelope into virions, a direct 
interaction takes place between the cytoplasmic tail of gp41and matrix 94.
1.3.6e Capsid (CA)
Both CA and MA have functional roles during both early and late events of the HIV-1 
Life cycle. The CA proteins form a cone-shaped structure located centrally in the 
mature virus, surrounding the complex required for proviral DNA synthesis and 
integration. As mentioned earlier a region located in CA forms an exposed loop 
structure which is responsible for the binding of cyclophilin A. The C-terminal 
domain contains a region which displays significant homology amongst retroviruses, 
known as the major homology region (MHR), mutations in this area produce 
assembly, maturation and infectivity defects in progeny viruses 94. The dimerisation 
domain of CA also interacts with the MHR region, forming hydrogen bonds which
OQ
contribute by stabilising the structure of CA 
1.3.6f Nucleocapsid (NC)
The NC protein like other Gag proteins serves a multifunctional role with HIV Life 
cycle. Its major role is in the binding of RNA, particularly to an area in the 5’-UTR, 
which contains a specific stretch of RNA that forms several stem loop structures 
thought to be essential for the packaging of viral RNA into the virion. The packaging 
signal or 4*, is 120 nucleotides long and is located between the 5’-LTR and the gag 
start codon. The analogous region to the packaging signal in the 3’ repeat region
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contains the polyadenylation signal 237. The RNA/NC interaction occurs primarily 
through secondary structure interactions, as there is little sequence conservation of 
this region 131. The two zinc finger motifs of NC are joined by a flexible basic linker 
region. Mutations that abolish zinc binding also result in loss of infectivity and 
diminished genome encapsidation 30. The NC/RNA interactions also include the 
coating of viral RNA in the mature virion and binding of the tRNAlys primer. All these 
interactions can be attributed to the ‘nucleic acid chaperone’ function o f NC, which
OQ
may also carry out functional roles in reverse transcription and integration . The N- 
terminal domain of mature NC is thought to play a role in Gag multimerisation by 
binding to Pr55Gag, and through interactions with host proteins is also thought to be 
involved in assembly and transport89.
1.3.6g p6 Protein
The C-terminal protein to be released from the Pr55Gag precursor is the proline rich
89p6, which is only found in primate lentiviruses . It plays an essential role in the final 
budding step and also by incorporating Vpr. A motif within Gag known as the late 
domain is thought to interact with host endosomal sorting machinery. The amino acid 
sequence P(T/S)APP near the N-terminus of the protein has been shown to promote 
budding of the virion from the membrane by binding to components of the ESCRT 
(endosomal sorting complex required for transport) I, II and III pathway 96. The 
transframe protein p6po1 has been implicated in the regulation o f protease activity, 
truncation of the C-terminal portion of p6 are thought to increase gag  processing
246,337
1.4 Inhibitors of HIV Replication
HIV-l primarily infects CD4+ T-lymphocytes, monocytes/macrophages, astrocytes 
and cells o f the central nervous system such as brain microglial cells 89’255 294. 
Infection spreads to the lymphatic tissue, it is thought that follicular dendritic cells act 
as a site for virus latency. Continued virus replication leads to the slow and 
progressive destruction of the immune system and in some cases, the central nervous 
system, leading to dementia 184 242. The development of small molecules to block the
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replication of HIV-1 in infected individuals and delay the course o f disease 
progression has been the subject o f dedicated research efforts over the past decades.
1.4.1 RT Inhibitors
1.4.1a Nucleoside RT Inhibitors
Inhibition of HIV using antivirals has centred around using specific targets within the 
replication cycle. The first inhibitors to be shown to have an effect on HIV were those 
directed at the reverse transcription step o f the Life cycle, termed the RT inhibitors 
(RTIs). The first reported demonstration of the efficacy of inhibiting reverse 
transcription was shown by Mitsuya et al. in 1984; the drug Suramin, originally used 
for the treatment of African sleeping sickness, demonstrated protection o f T-cells 
from the cytopathic effect of HTLV-III in vitro. The mechanism of action of this 
compound was through the inhibition of retroviral reverse transcription and this lead
to the initial research and development of agents which could inhibit this replication
210process
1.4.1b Nucleoside Analogues
The first compound to be licensed as an antiviral against HIV was 3'-azido-3'-
deoxythymidine (AZT, Zidovudine), which was originally developed in the 1960s to 
80 211 212treat cancer ’ ’ . AZT is an analogue of the pyrimidine, thymidine, one of the
natural cellular substrates for RT and host DNA polymerases. In order for nucleoside 
analogues to be effective as antivirals they require three sequential phosphorylation 
steps to convert the dideoxynucleoside into the active triphosphate form. The 
triphosphate form then competes with natural nucleoside triphosphates and when 
incorporated, results in chain termination of the viral DNA, due to the lack of a 3'-OH 
on their ribose or ribose mimic moiety 212. The initial phosphorylation event is 
thought to be the most discriminating step, as a result only some nucleoside analogues 
are phosphorylated and are able to demonstrate reduced HIV replication 236. The 
discovery that nucleoside analogues could provide suitable compounds for HIV-1 
inhibition lead to the subsequent development of other similar antivirals, there are 
now at least 7 approved for use in HIV therapy, see Figure 1.10a.
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1.4.1c Nucleotide Analogues
AZT is a prodrug in that it requires phosphorylation by cellular kinases to generate the 
active form, AZT-5’-triphosphate 212. The use of the active triphosphates as antivirals 
has not proved successful, primarily due to cleavage of the phosphate groups by 
extracellular enzymes and reduced intracellular levels due to poor uptake by the cell 
236. The development of nucleotide analogues i.e. a nucleoside with a phosphate group 
attached to the carbon 5 instead of the hydroxyl group; avoids the need for the 
intracellular triphosphorylation. The only nucleotide analogue to be approved by the 
Food and Drug Administration (FDA) is an acyclic nucleoside monophosphate diester 
analogue of adenosine, 1-(6-Aminopurin-9-yl) propan-2-yloxymethylphosphonic acid 
(PMPA) or Tenofovir disoproxil fumarate , see Figure 1.10a. This compound is 
more stable than the nucleoside RT inhibitors and is hydrolysed by intracellular 
esterases, which results in the monophosphate form, PMPA. This undergoes further
OA
phosphorylation to the active triphosphate form
1.4.1d Pyrophosphate Analogues
The only pyrophosphate analogue to be marketed is Foscamet, although it has not 
been approved for treatment of HIV-1 infection due to very low bioavailability and 
toxicity, it has been used for treating cytomegalovirus retinitis in AIDS patients 80. It 
acts by interfering with the exchange of pyrophosphate from deoxynucleoside 
triphosphate during viral replication by binding to a site on the HIV RT 166.
1.4.1e Non-Nucleoside RT Inhibitors
This final group of compounds that are classified as RT inhibitors are unlike the other 
compounds within this class; they are non-competitive inhibitors that bind to a 
hydrophobic pocket near the polymerase active site and exert thier antiviral effects 
allosterically i.e. they prevent the enzyme from functioning optimally via a non­
substrate binding mechanism. NNRTI binding induces structural changes in RT, 
which result in termination of the polymerisation reaction, caused by the displacement 
of active site residues, relative to the polymerase binding site 62’304. This causes the 
active site in the p66 subdomain to be locked in an inactive conformation, similar in 
structure to the inactive p51 subunit 61. This mechanism of inhibition only affects the
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RT of HIV-1, both RTs o f HIV-2 and SIV are insensitive to NNRTI’s since they share 
only 60% homology with HIV-1 RT l43. The elucidation of the structure o f HIV-1 RT 
facilitated the design of NNRTIs; although the discovery of NNRTIs was initially 
through the screening of compound libraries 61. Currently, there are 3 NNRTIs 
licensed for the treatment of HIV-1 infection, Nevaripine, Efavirenz and Delavirdine, 
see Figure 1.10b. Nevaripine was the first NNRTI to be licensed in 1997, although 
the discovery of this compound class of inhibitor occurred nearly a decade previous to 
that with the discovery o f the HEPT(l-(2-hydroxyethoxymethyl)-6-(phenylthio) 
thymine) and TIBO (tetrahydroimidazo [4,5,1 - jkj] [l,4]benzodiazepin - (l//)-one 
and -thione) compound series 61.
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Figure 1.10: Clinically approved RT inhibitors, (a) Nucleoside and nucleotide RT inhibitors (b) Non- nucleoside RT inhibitors
1.4.2 Protease Inhibitors
The use of rational design in the discovery of potent inhibitors o f HIV-1 was also 
applied to the development of protease inhibitors (Pis). Roberts et al. used the 
knowledge of the unusual cleavage of Phe-Pro and Tyr-Pro peptide bonds by HIV-1 
protease in the design of the first Pis. The cleavage of amide bonds of proline residues 
is not seen with mammalian endopeptidases, therefore, this seemed like an excellent 
potential target. It was also hypothesized that due to the small size of protease, 
resistance mutations to Pis would be difficult for the virus to accommodate whilst 
maintaining protein function ’ . Research resulted in the development of the first PI
Saquinavir, which was licensed in 1995, followed by Ritonavir and Indinavir in 1996. 
There are now nine Pis approved for the treatment of HIV infection, see Figure 1.11. 
Like NRTIs, Pis are also competitive inhibitors. The first Pis were small oligopeptide 
derivatives which mimic the natural substrate of protease. These Pis contained non- 
hydrolysable groups at the positions either side of the scissile bond at positions P 1 and
89PL , this modification prevents cleavage by protease . The next Pis to be developed 
and approved were Nelfinavir which is a non-peptidic inhibitor and Amprenavir, both
90these Pis were designed based on the protein crystal structure of protease . Pis exert 
their antiviral effect at a late stage in the HIV replication cycle; they prevent the 
cleavage of the Gag polyproteins by the viral protease and therefore, interfere with 
viral maturation during or after budding. Electron microscopy of viruses produced in 
the presence of Pis show immature particles that lack the conical core of mature 
virions 52.
The newest Pis to have been approved by the FDA are, Tipranavir and Darunavir 
(TMC 114), which received approval in 2005 and 2006 respectively 
(www.fda.gov/oashi/aids/virals.html). Both these inhibitors were designed to show 
activity against PI resistance viruses (see section on resistance 1.6.3), Tipranavir has 
demonstrated excellent antiviral activity against HIV-1 clinical isolates resistant to
1 6S 999other Pis ’ . Tipranavir and Darunavirs activity against multi PI resistant HIV
occurs through the establishment of hydrogen bonds with the backbone atoms of 
protease, these interactions more closely resemble those that occur between substrate 
and enzyme 165. Older generation Pis form hydrogen bonds with the side chains o f the 
amino acids which are readily changeable by without affecting function. Tipranavir is 
the only PI that establishes a direct hydrogen bond interaction to the flap region,
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traditional peptidomimetics utilise a ubiquitous water molecule to mediate this bond
222,349. Direct hydrogen bond interactions are considered to be more energetically
222favourable than those mediated by water
Many of the antiretrovirals are substrates for the P-glycoprotein cellular transport 
system, which facilitates their transport out of the cell, resulting in reduced 
intracellular levels of the compounds and therefore decreased virus inhibition 305. To 
abrogate this effect, regimens routinely contain Ritonavir, used as a pharmalogical 
enhancer it has two effects. Firstly, it inhibits the P-glycoprotein cellular transport o f 
Pis and it also inhibits cytochrome-P450 mediated metabolism of antivirals; regimens 
that utilise Ritonavir this way are known as Ritonavir boosted therapies 67.
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Figure 1.11: Clinically approved PI inhibitors.
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1.4.3 Fusion and Entry Inhibitors
One of the first approaches to inhibit the fusion process centred around the primary 
receptor for entry, CD4. During this time it was understood that CD4 was not the only 
requirement for virus receptor mediated entry, but the discovery o f chemokine 
receptor involvement was some 4 years away 212. Initial attempts with soluble CD4 
proved very successful in vitro, however these excellent viral inhibition profiles were 
not mirrored in vivo. The sensitivity seen in vitro was attributed to the ability o f the 
soluble CD4 to remove gpl20 from the surface of virions. However, this was not the 
case in vivo, as here failure was attributable to the increased stability of the envelope 
complex in primary isolate virions and also to the reduced affinity levels of soluble 
CD4 in vivo 39. Another one of the early approaches to fusion inhibition was the use 
of various sulphated sugars, such as low mass dextran sulphate. This and other 
compounds such as heparin were shown to block the binding of HIV to CD4 by 
binding to sites on gpl20, however, clinical trials suggested little efficacy ’ .
The first fusion inhibitors to be developed and used for treatment o f HIV infection 
were synthetic peptides that mimicked a region within gp41. The extracellular domain 
of gp41 contains four major regions, a hydrophobic N-terminal fusion domain, two 
leucine zipper-like repeat regions known as heptad repeats (HR). HR1 is N-terminal 
and HR2 C-terminal; and a hinge region containing two cysteine residues which 
forms a disulphide-bonded loop structure, linking the HR1 and HR2 regions. During 
the fusion process the HR1 regions form a trimeric coiled-coiled structure, whereas 
the HR2 domians bind with high affinity to grooves on the outside of this trimer. This 
formation of a six-helix bundle, ‘hair pin’ structure brings the cellular and viral
39 118 275membranes in close proximity ' . T-20, also known as Enfuvirtide is a
subcutaneously injected, 36-amino-acid peptide, based on the sequence of the HR2 
domain in the gp41 subunit. It interferes with the binding of HR2 and HR1 domains 
and prevents the formation of the ‘hair pin’ complex. The interaction of T-20 and the 
HR1 domain can only occur after CD4 interaction and before engagement of 
coreceptors in a ‘pre-hair pin’ intermediate stage that exists for several minutes 118 276.
As mentioned earlier the requirements for entry necessitates engagement of both CD4 
and coreceptor, the discovery of coreceptor mediated entry provided a new
87therapeutic target . The viability of CCR5 as a target was further enhanced by the
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redundancy associated with CCR5, especially in light o f the ACCR5 allele. Several 
CCR5 chemokine receptor antagonists have been developed which bind to the
o  I n
coreceptor in a cavity formed between CCR5 transmembrane helices . These 
compounds are small organic molecules with molecular weights of 800-1000 Da, are 
orally bioavailable and inexpensive to manufacture. The redundancy of CCR5 affords 
its use as an inhibitor. CXCR4 however, is a primordial chemokine receptor and its 
requirement is indispensable. Nonetheless, inhibitors of CXCR4 have been developed 
and have shown clinical efficacy, although some individuals enrolled in trials for one 
of the earliest compounds AMD3100, suffered from cardiac toxicities which
TO 717prohibited further development of this compound ’ . Although CCR5 inhibitors
317have proved to be successful in vitro and in early in vivo trials , the consequences 
of a CCR5 blockade and the possibility of selection of more virulent CXCR4 variants 
remains a possibility. Also, the use of CCR5 inhibitors in individuals homozygous for 
the ACCR5 allele may be less toxic than for those who possess the functional CCR5
7 f\allele or are heterozygous .
Other compounds that inhibit CD 4-gpl20 binding include, PRO-542(CD4-IgG2) a 
soluble recombinant antibody-like fusion protein, which mimics the CD4 receptor. A 
disadvantage of PRO-542, is that like T-20 it cannot be orally administered. Another 
CD 4-gpl20 interaction inhibitor, BMS-806 has been shown to bind with high affinity 
to HIV gpl20, blocking the conformational changes induced in gpl20 after CD4 
binding which allow the subsequent interaction with the chemokine co-receptor. An 
advantage of this compound is that it demonstrated good oral bioavailability 187’276.
1.4.4 Integrase Inhibitors
The integrase protein has no known functional mammalian homologue and the coding 
region is highly conserved among HIV-1 clinical isolates 32 and so, potentially 
provides an excellent therapeutic target for inhibitors. Integrase inhibitors can be 
divided into two categories based on their mode of action; (i) inhibitors of 3' 
processing, which act by docking at the HIV-1 DNA binding site of integrase and (ii) 
selective strand transfer inhibitors which compete with the target DNA in the strand
189 266transfer step ’ . The diketo acids were amongst one of the first series of
compounds to be explored as integrase inhibitors, they selectively inhibit the strand 
transfer reaction and are the most clinically advanced compounds in this class 172’266.
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These compounds bind to the catalytic triad at the core of integrase, they do not 
inhibit the 3’ processing step, and instead it is thought that these inhibitors prevent the 
viral DNA-integrase complex from binding to cellular DNA. The unintegrated viral 
DNA is then degraded by cellular enzymes and creates dead-end circular by-products 
called 2-LTRs. The increasing formation of 2-LTRs has been shown to correspond
• 172with escalating concentrations of strand transfer integrase inhibitors . Recently, two 
compounds from the strand transfer class of inhibitor have entered clinical trials and 
both demonstrated potent antiretroviral activity in short-term monotherapy 69 201.
1.4.5 Maturation/Capsid Inhibitiors
A new approach to HIV-1 inhibition has been to look at obstructing the assembly 
process of the HIV Life cycle. In one approach, small molecules were identified 
through a phage display screening process; peptides were selected that targeted the 
CA and NC proteins in Gag. These inhibitors are termed CA assembly inhibitors or 
maturation inhibitors and showed in vitro inhibition of both immature and mature 
virions. The mechanism of inhibition in immature virions is thought to be by means of 
preventing cleavage of p24/p2 site in the infected cells. Inhibition in mature HIV 
virions is achieved by binding to CA, preventing any further involvement in the virus
Tf|7
Life cycle . PA-457 [3-0-(3',3'-dimethylsuccinyl)betulinic acid] is another potent 
HIV drug candidate, it acts through inducing a defect in Gag processing by disrupting 
p25 to p24 conversion and preventing formation of mature CA protein 179.
1.5 Treatment of HIV Infection
The advancement in the understanding of the pathogenesis of HIV disease and the 
development of compounds that could, for a limited time control the rate of disease 
acceleration, led to a great accumulation in the knowledge concerning the impact o f 
inhibitors. Initially single drug dose regimens were evaluated and showed delayed 
progression of disease in symptomatic individuals. Subsequent trials involved the use 
of dual nucleoside analogues and indivduals on this treatment regimen were shown to 
suppress viral replication better than the monotherapy nucleoside group 212,278. The 
predictors of therapy success were initially based on CD4+ T cell counts, although 
now the most predictive marker is the patients’ actual plasma viral load (VL) ,69’206.
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The introduction of new classes of antiretrovirals, namely the NNRTIs and Pis 
increased the number of treatment options available to HIV infected individuals. 
Combinations of different classes o f inhibitors soon became the standard treatment 
option for patients in the developed world; the use of this potent combination of 
antirerovirals became known as highly active antiretroviral therapy (HAART) 80184. 
By 1996 mortality rates amongst HIV infected individuals had dramatically declined 
in western countries, the advent of HAART had changed the prognosis of HIV 
infection from a lethal to a potentially chronic disease 347. Successful HAART reduces 
viral load to undetectable levels, as measured by the most sensitive, routinely 
available viral load assays (typically below 50 copies/ml) and causes a reduction in 
mortality and opportunistic events, even in patients with very advanced HIV disease 
2 2 Also associated with successful therapy is a reconstitution in the number of CD4+ 
cells 21. This increased life expectancy of HIV infected patients led to the 
identification of adverse events related to HIV antiretroviral therapy. Initial toxic 
effects had been described from the onset of antiretroviral use, bone marrow 
suppression which required transfusion was reported after 6 months therapy in one 
third of patients enrolled on a phase II clinical AZT trial in 1986 2I2. One of the main 
toxicities associated with AZT is damage to the mitochondria and loss of 
mitochondrial function, known as mitochondrial myopathy. Investigations into the 
observed mitochondrial toxicity implicated the mitochondrial DNA polymerase, DNA 
polymerase y, although DNA polymerases (3 and y also appear to be sensitive to 
dideoxynucleoside-5’-phosphates 212347. More recently patients receiving either 
therapies including NNRTIs and Pis have been associated with elevated triglyceride, 
cholesterol levels and accumulation of central fat, also known as lipodystropy 89. The 
toxicity associated with HAART and other related complexities of drug regimens 
such as, pill burden, dosing frequency and food constraints at time of dosing, all 
combine to make compliance to a particular regimen a problem. Infrequent dosing of 
antivirals would lead to reduced levels of inhibitor in the patient, these concentrations 
may not be enough to sustain antiviral efficacy and may lead to the generation of 
resistant variants (discussed in the next section). The level of adherence required to 
maintain regimen efficacy in a PI based regimen has been estimated to be greater than 
95%, although, still resulting in 22% of patients experiencing virological failure. 
Substantially more regimen failure occurred in 80% of patients with compliance
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levels of less than 80% 247; unfortunately, population based studies o f adherence have 
estimated compliance levels to be only around the 70% mark 67. The in vivo efficacy 
also depends on access of the antivirals to the intracellular sites where HIV-1 
replication occurs. As mentioned previously, P-glycoprotein (multi-drug resistance 
protein) interacts with antivirals causing its activation and pumps the antivirals out 
across the plasma membrane, thereby reducing intracellular accumulation of drugs 
305,347 mechanism for exclusion of antiretrovirals occurs in lymphocytes and 
macrophages as both these cell types express the multi-drug resistance protein. All 
these mechanisms can severely impair the efficacy of regimens due to sub-optimal 
drug concentrations, this in turn leads to resistance and the generation of variants that 
require even greater drug concentrations in order to successfully suppress any further 
virus replication.
1.6 Resistance to Antiretrovirals
The use of antivirals has resulted in reduced viral burden in infected individuals and 
also prolonged life expectancy. As mentioned previously, the replication strategy of 
HIV includes certain events that facilitate the development of heterogeneity, such as, 
inter-strand transfer and error-prone polymerase activity during viral genome 
replication. These events coupled with a high viral turn-over allow the virus to 
generate an enormous swarm of mutants known as viral quasispecies 72’88, which may 
or may not generate fully-functional virions. In the context of this virus species being 
present in an individual receiving therapy, then it is likely that these same 
mechanisms coupled with the potential for non-compliance to drug regimens, could 
lead to the development of viruses that replicate better in this environment, due to 
some mutation(s) incorporated during error-prone replication. The development of 
resistance to all the classes of drugs that have been approved is the main reason for 
the need for new antiretrovirals and is also the reason most therapeutic regimens 
require constant evaluation regarding their effectiveness. The genetic barrier is a 
quantity that refers to the difficulty for the virus to escape from the selective pressure 
of the drug by developing escape mutations 15. Some antivirals show a low genetic 
barrier, such as 3TC, which requires only a single base substitution; ATG-GTG 
(Ml84V) in order to negate antiviral efficacy. Due to the high viral turnover and the
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error prone replication o f the HIV genome (see section 1.3), such single mutations are 
more likely to pre-exist in the viral quasispecies and thus, are more likely to be 
selected. Other compounds such as Pis have high genetic barriers with several 
mutations required in order to reduce susceptibility to the compound and so are less 
likely to pre-exist in the viral swarm within an infected individual. A high genetic 
barrier compound(s) for the initial regimen may be preferable, in order to minimise 
the risk of resistance and treatment failure.
The resistance mutations of each class of inhibitor are shown in Figures 1.12 (a), (b), 
(c) and Figure 1.13.
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Figure 1.12 M utations in RT associated with NRTI resistance, (a) and (b)
Nucleoside and nucleotide RT inhibitors (c) Non- nucleoside RT inhibitors. Figure 
adapted from Update of the Drug Resistance Mutations in HIV-1: 2007 l46.
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Figure 1.13 M utations in Protease associated with PI resistance. Figure adapted from Update o f the Drug Resistance Mutations in HIV-1
2007 146
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1.6.1 Resistance to NRTIs
As AZT was the first compound to be licensed for use as an anti-HIV compound,
2 1 2 'mutations were first reported in patients receiving Zidovudine monotherapy . Virus
isolated from patients who were on prolonged AZT therapy showed the presence of
mutations in the RT gene, the order of appearance of mutations that confer increasing
0 1resistance to AZT was also determined . This indicated that an initial resistance 
mutation at codon 70 in RT appeared, transiently and conferred only low level 
resistance. This mutation was then replaced by the primary resistance mutation at 
codon T215Y/F which conferred increased resistance levels to AZT, followed by 
additional mutations at 67 and 219 in some patients. However, it was demonstrated
that the development of highly resistant isolates was not required for treatment failure
21and progression to AIDS in treated individuals . Trials involving the use of dual 
NRTI therapy showed promising results when virus isolated from patients enrolled in 
a dual NRTI trail demonstrated reduced in vitro sensitivity to AZT or ddl. However, 
when mutations conferring resistance to both NRTIs were present on the same 
genome the virus displayed increased sensitivity to AZT 306. The potential for 
suppressing viral replication completely was further enhanced by in vitro work that 
demonstrated the effectiveness of combinations of NRTIs. In this study, researchers 
failed to generate drug resistance variants, through step-wise increases in the 
concentrations of NRTIs over a 10-week period 103. However, these combination 
therapies eventually failed in patients and the development of further mutations that 
resulted in dual NRTI resistance were eventually identified 9’152. Research efforts to 
determine the role of mutations identified in patients receiving antiretrovirals was 
greatly enhanced by early in vitro work using a novel vector system, developed by 
Kellam et al. This was composed of a live HIV vector with a deleted RT gene. 
Introduction of the RT deleted genome and separate RT gene, allowed for the 
recombination with RT genes containing specific mutations conferring resistance to 
NRTIs introduced through site directed mutagenesis. This enabled the study into the 
effects of resistance mutations on the growth ability and sensitivity of these 
recombinant viruses to NRTIs. The system became known as the recombinant virus
153assay system, RVA and has been widely used and adapted to further advance the 
study of HIV resistance mutations and their modulation o f sensitivity to 
antiretrovirals.
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1.6.1a Thymidine Analogue Mutations
The mutational pattern associated with AZT resistance was also shown to occur with 
another thymidine nucleoside analogue, Stavudine or 2'-3'-didehydro-2'-3'- 
dideoxythymidine (d4T). Accordingly the mutations, M41L, D67N, K70R, L210W, 
T215Y/F and K219Q, are grouped as the thymidine analogue mutations (TAMs); 
TAMs may also be selected for by ddl 80’329’349. The mechanism by which these 
mutations reduce the sensitivity of the mutated RT to NRTIs is by removal of the 
blocking nucleoside analogue, by a hydrolytic mechanism, termed primer unblocking. 
The excision o f the nucleoside analogue is an Adenosine triphosphate (ATP)- 
dependent process and TAMs cluster around the ATP-binding pocket and enhance the 
binding of ATP to boost the excision process 349. The chain termination mechanism of 
NRTIs firstly requires the competition for binding with natural dNTPs, if successful 
the NRTI-monophosphate enters the binding site in the catalytic core of RT. The 
incorporation of the NRTI-monophosphate causes a structural shift in the enzyme 
resulting in the translocation of the NRTI-monophosphate to the priming site in the 
active site, which frees the binding site to accept the next incoming dNTP. However, 
the lack of the 3’-OH group prevents the binding of the incoming nucleotide, which 
now occupies the binding site, resulting in a dead end complex, terminating chain 
extension. TAMs are thought to facilitate the excision of the bound NRTI, by either 
preventing the binding of the next dNTP, which in turn allows the removal of the 
blocking NRTI. Or TAMs may increase the affinity of the NRTI for the binding site, 
preventing its translocation to the priming site 80’329’349. Either of these mechanisms 
contributes to the development of resistance by TAMs to NRTIs.
1.6.1b Other NRTI Resistance Pathways
Another set of mutations associated with NRTI therapy, exert their resistance effect 
through the increased discrimination of the incoming dNTP by the mutant RT. 
Resistance mutations appear to alter the contact between the enzyme, the template and 
the incoming dinucleotide in such away as to allow the natural substrate to be 
preferentially incorporated. However, the bulky side chains of the nucleoside 
analogues, prevents their incorporation 349. The mutations that are involved in this
type of resistance pattern are located around the dNTP-binding site. Residues that are 
in close proximity to the incoming dNTP’s and are also associated with this 
mechanism of resistance include, K65R L74V, D113, Y115, FI 16 and Q151 64’80’329. 
The K65R mutation which is located in the fingers domain of RT, causes reduced 
sensitivity to ddC, ddl and Abacavir, it is also the only mutation to be selected for by 
Tenofovir in vitro. The development of multi-drug resistance (MDR) has been 
reported and involves a Q151M change that appears initially, followed by the step­
wise accumulation of other mutations located in or close to the dNTP binding pocket; 
V62A, V75I, F77I and FI 16Y. The initial appearance of the Q151M mutation causes 
a moderate increase in resistance to NRTIs, however, accumulation of additional
mutations results in the development of high level resistance 64 329’349. The MDR
80complex causes resistance to all NRTIs except Tenofovir ; Lamivudine provides 
partial suppression of viral replication although high level resistance soon emerges 289. 
The M184V/I change in the highly conserved YMDD region, which contains two 
catalytically important aspartic acid residues, results in the development of high level 
resistance to 3TC and FTC. In the case of 3TC, the appearance of the M l 84V change 
results in the development of up to 1000 fold resistance and it can develop rapidly in 
vivo, in as little as two weeks n . These compounds are analogues o f cytosine and 
contain a sulphur atom located on the ribose sugar moiety, this bulky ring and the 
presence of the M184V/I mutation leads to increased contact of the enzyme with the 
dNTP or NRTI and therefore increases discrimination in terms o f nucleotide 
incorporation 64’80>329.
1.6.1c Insertions and Deletions leading to NRTI resistance
The long-term use of NRTIs has lead to the appearance of divergent strains of HIV 
with distinctive genotypes causing variation of inhibitor activity. Insertions in RT in 
response to NRTI therapy have been reported; in all cases the HIV-RT contains a 
dipeptide insertion between codons 69 and 70 usually SG, SS or SA, as well as a 
T69S mutation, leading to the nomenclature T69S+XX 22>64’342. This insertion occurs 
in the fingers region of RT, in a loop which makes contact with the incoming dNTP 
during polymerisation 64. The use of site directed mutagenesis showed that the 
insertions alone cause only a moderate increase in resistance to NTRIs which explains 
their 95% association with other TAMs. The insert containing RT with additional
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TAMs may have higher excision rates for thymidine analogues 342. Nucleotide 
sequence analysis of the insertions demonstrated that they are duplications of 
neighbouring sequences, probably generated by RT stalling or slippage during reverse 
transcription. Such insertions in RT have been linked to NRTI exposure as there are 
no reports of insertions in therapy naive individuals 342.
Deletions that occur in the same fingers region of RT as the insertions have also been 
reported, these single peptide deletions are located at codon 67 and are also associated 
with TAMs. These deletion variants may have a replication advantage in quiescent 
cells, as it has been shown they were able to effectively carry out polymerisation in 
low dNTP levels and were also efficient at excision of both AZT-monophosphate and 
PMPA at lower ATP concentrations 22,342 .
Other potential mechanisms for NRTI resistance have been attributed to the RNase H 
domain of RT in conjunction with other TAMs and also to the p6 protein in Gag
64,256,349
1.6.1d Hypersensitivity to NRTIs
As discussed earlier, the mutations that cause resistance to ddl, caused 
hypersensitivity or hypersusceptibility, i.e. increased sensitivity to AZT 306. This 
effect has also been seen with TAM containing RTs and the addition of M l84V, 
L74V and K65R mutations. RTs that contain a resistance mutation Y181C, which 
emerges in NNRTI therapy, are also associated with increased sensitivity to AZT, 
with additional TAMs 329. Hypersensitivity to NRTIs is through accumulation of these 
mutations and is associated with AZT, Tenofovir and Stavudine 80. This re­
sensitisation to AZT with the M l84V mutation occurs by reducing the ATP-mediated 
excision of the AZT-monophosphate, through alteration in the polymerase active site 
23. The re-sensitisation to NNRTIs is also thought to occur in HIV-RTs which contain 
the T69S+XX mutations 342.
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1.6.2 Resistance to NNRTIs
NNRTIs exert their effect through steric hindrance rather than participation in a 
biochemical event as is the case in NRTIs, due to this their effect can be acutely 
negated by the addition of a single mutation that prevents binding in the hydrophobic 
pocket. The hydrophobic pocket does not exist in RT that is not bound to a ligand, in 
the bound state the pocket is formed through side chain interactions of the 
surrounding amino acids 80. Due to the structural diversity of the NNRTIs (see Figure 
1.10b), the binding and subsequent structural constraints inferred on RT by each of 
the compounds differs; therefore each exhibits slightly different interactions with the 
enzyme. As binding of all currently approved NNRTI requires interactions with the 
hydrophobic pocket, there is extensive clustering of residues that are involved in 
NNRTI resistance 64. Common NNRTI resistance mutations include L I001, K103N, 
V106A, Y181C, Y188L and G190A. The K103N is the most clinically significant 
NNRTI mutation, acquisition of this mutation results in a substantial loss in efficacy 
of the regimen 56. The asparagine side chain of this mutant forms a hydrogen bond 
with the amino acid at codon Y188, causing a structural rearrangement of the pocket, 
similar to that of the unbound state 349.
Recently, alternative methods for the mechanism of action of NNRTIs have been 
proposed. One study suggests that the susceptibility of HIV-1 to NNRTIs is 
influenced by the level of RT activity and that NNRTI hypersensitivity is related to a 
reduction in RT activity. This mechanism did not affect NRTIs such as Lamivudine 
which were not affected by the level of RT per virus particle 1. Another more recent 
study suggests the mechanism of action of NNRTIs involves the preferential 
inhibition of the initiation o f plus-strand viral DNA synthesis. This in vitro effect was 
seen only in wild-type RT enzymes and not in those that contained NNRTI mutations. 
The mechanism for inhibition of viral DNA synthesis appears to involve competing 
with incoming dNTP for the binding site in RT. This data is contrary to previous 
reports; this opposing conclusion could be due to the different template used in the 
different experiments. Grobler et al. demonstrated that NNRTIs do compete with 
dNTPs for binding, but only with RNA-DNA template substrates and not with DNA- 
DNA as most previous studies had used 120.
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1.6.3 Resistance to Pis
Protease cleavage of Pr55Gag is an essential step in the replication cycle o f HIV, both 
the correct order of cleavage and the cleavage products themselves are a requirement 
for the formation of a mature infectious virion 20,77. The X-ray crystal structures of 
several HIV protease-PI complexes have been solved and used to assist the process o f 
inhibitor development 84. The elucidation of these structures has facilitated the 
understanding of the interplay in the many associated drug binding and resistance 
mechanisms at an atomic level. Such as, the pattern of hydrogen bonding between 
inhibitor and enzyme backbone atoms, compared to that with the natural substrates. 
The identification of these types of interactions can aid the discovery of mutations at 
specificity determining residues that could impact on inhibitor binding but not that of 
the substrate, and would therefore be a potential mechanism for the development of 
resistance to Pis. These types o f mutations that envelop the active site and usually 
interfere with PI binding are referred to as primary resistance mutations and cause a 
reduction in sensitivity to Pis 20,84. Pis were designed to fit into the protease binding 
site, the appearance o f primary mutations changes the shape of this substrate cavity, 
causing the drug to significantly lose its inhibiting potency. Although most primary 
mutations are located near the protease catalytic site, each PI has its’ own primary 
resistance mutation. The first PI, Saquinavir initially selects for the G48V primary 
mutation, although the appearance of the L90M is also seen 20’84>292. Nelfinavir selects 
for the D30N, Amprenavir and the new PI Darunavir, an analogue o f Amprenavir, 
both select for the I50V mutation, which resulted in a rapid increase in viral 
replication during in vitro selection experiments with Duranavir 3 5 Two primary 
mutations that are located in the active site and are associated with failing PI therapy 
are the 184V and V82A/I/F/T. The V82A change occurs primarily with the older Pis 
Ritonavir and Indinavir, it results in significant changes in the flap and disruption of 
side chain interactions with PI, but not the backbone-backbone interactions with the 
substrate 349. The I84V mutation is selected for by all failing PI therapies except 
Nelfinavir, its role in mediating resistance is unclear, but it has been suggested that it 
may protect the protease from autocatalysis 64 349.
Resistance mutations associated with PI resistance have been mapped to terminal 
domains, core domain and flap domain, PI resistance mutations have been reported at
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45 of the 99 amino acids positions of protease 344. Many o f the PI associated 
mutations are not located within the substrate binding site and do not affect resistance 
levels to Pis 84. These mutations are referred to as secondary resistance mutations 
because they appear with primary mutations and seem to restore the deleterious 
effects of the primary mutations on protease; these changes are also known as 
compensatory mutations. The effects of these secondary resistance mutations are 
largely unknown, theories as to how they mediate their effects could be through a
OA
mutated enzyme with enhanced catalysis . Studies into the effects o f non-active site 
mutations by measuring the binding affinities of resistant proteases to substrate and 
inhibitors, suggests that they can directly affect the binding of Pis without the 
presence of primary PI mutations. The development of non-active site mutations also 
revealed increased stability of the mutants, with or with out the primary resistance
223mutation over the wild-type enzyme . However, another similar study which 
employed a less heavily mutated protease, demonstrated a solely compensatory role
9 S ^for the flap residues M46I and I47V . The appearance of compensatory mutations is 
not limited to the targeted protein; Pis have been shown to induce changes in the 
protease substrate, Gag. The development of high level resistance to Pis requires the 
accumulation of multiple resistance mutations; multi-PI resistant protease, containing 
several resistance mutations has been shown to contain an expanded active site cavity 
349. Such effects of PI mutations not only impact on the binding of Pis, the 
processivity of protease, but also impact on the binding of the substrate. Therefore, 
another proposed mechanism for PI resistance was through the enhanced processing 
by mutant enzymes for a mutant substrate. The appearance of compensatory cleavage 
site mutations (CSMs) was first shown to occur in vitro using a peptidomimetic PI 
and a highly resistant protease with multiple resistance mutations 77. The initial CSM 
was a Leu to Phe change at position P I ’ of pl/p6 and was present in nearly all the 
clones isolated from the PI passaged virus. This was followed by a second double 
mutation at NC (p7)/pl, which also acquired additional protease mutations; removal 
of the gag mutations severely impaired the growth of the PI resistant protease. The 
initial CSM was shown to appear with the I84V mutation and resulted in 100-1000 
fold increase in resistance to the PI 77. The first in vivo appearance of CSMs was 
reported during Indinavir therapy. The emergence of mutations at position P2 of the 
p7/pl cleavage site was paralleled by the serial acquisition of protease mutations, 
unlike the in vitro work of Doyon et al., which demonstrated a requirement for the
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358appearance of multiple PI resistance mutations prior to the CSMs . The emergence
of mutations in cleavage sites is thought to modify the substrate for the mutant
77proteases and generates a better peptide for the protease in vitro . Due to the multi­
functional role of Pr55Gag and its cleaved proteins in HIV replication, it is also 
possible that mutations could arise elsewhere in the HIV genome leading to improved 
viral growth in the presence of Pis.
Newer Pis such as Darunavir (TMC114) require several novel protease mutations in 
order to cause an increase in resistance to the compound. Viruses generated by in 
vitro passage which contained mutations R41T and K70E showed reduced
susceptibility to TMC114 of approximately 10-fold compared to wild-type, but
replicated poorly. However, when these mutations were introduced into a molecular 
clone through SDM, no reduction in susceptibility to TMC-114 was detected. This 
implies that other mutations had arisen in regions other than protease, most likely the 
Gag polyprotein and may play a key role in determining susceptibility to TM C114 65.
A recent publication suggests that Darunavir use in patients with prior PI therapy and 
specific baseline PI resistance mutations (V III, V32I, L33F, I47V, I50V, I54L/M, 
G73S, L76V, I84V, and L89V ) may be associated with a poor in vivo response to 
Darunavir 133,170.
Recently, in vitro selection experiments using a novel PI (RO033-4649) demonstrated 
the selection of Pi-resistant viruses. However, unlike older generation Pis, no 
substitutions were shown to occur in the viral protease. Sequencing of the Gag 
polyprotein revealed the presence of mutations at the NC/pl cleavage site (K436E 
and/or I437T/V) in all resistant viruses. The mechanism leading to PI resistance is 
thought to be through increased mutant Gag polyprotein processing by wild-type
231protease
1.6.3a Insertions and Deletions leading to PI resistance
Like RT inhibitors, Pis also select for insertions in the protease gene, several 
insertions have been reported ranging from 1 to 6 amino acids in length. The location 
of the inserts also varies and has been mapped at or between codons 35 and 38, 17 and 
19, 21 and 25, 70, or 95 and 96. Like the insertions in RT, sequence analysis 
demonstrated the insertions were duplications of proximal sequences, possibly due to
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RT slippage during reverse transcription. Construction of recombinant clones in 
which the inserts were removed, but primary and secondary PI resistance mutations 
remained, revealed they were no more resistant than the viruses carrying PI mutations 
and inserts, but provided a borderline advantage in replication. 24 I56’309’3I4’34I>342 
Emergence of CSMs in the gag substrate can occur with the acquisition of PI 
resistance mutations in vivo, resulting in reduced sensitivity to Pis, insertions and 
deletions have also been seen in gag. Two independent studies have revealed the 
duplication of the PTAPP motif after prolonged exposure to Pis 171,31'. As mentioned 
earlier, the PTAPP motif has been implicated in facilitating the late budding event 
from the cell membrane. The first study demonstrated the appearance of either partial 
or complete duplication of the PTAPP motif in virus isolated from patients after 
Amprenavir therapy. The duplications were significantly associated with the 
V82A/F/T/S mutation and a reduced response to therapy 171. Insertions in gag occur in 
several other regions other than the PTAPP motif. This was looked at in the second 
study where insertions at the N- terminus o f gag, around the pl7/p24 cleavage site 
and also PTAPP insertions at C-terminus were found in multi-antiretroviral 
experienced patients failing therapy. Construction of full-length clones revealed the 
contribution of these insertions was required in order to rescue efficient Gag
Tilprocessing of the mutant viruses
1.6.4 Resistance to other Antivirals 
1.6.4a Fusion Inhibitor Resistance
The development o f resistance to T-20 (Enfuvirtide) was determined by early in vitro 
passage experiments, these selected for resistant viruses carrying mutations located in 
a highly conserved region of the N terminus of HR1. Initially changes at codons G36S 
and V38M were detected, but it appears that the development o f resistance is 
associated over a greater region of gp41, amino acids 36-45 with most changes in an 
amino acid triad (GIV) at positions 36-38 in the HR1 region of gp41 118’273. The 
location of these mutations supports the proposed involvement of HR1/HR2 binding 
in the fusion event, and that homologues of HR2, like Enfuvirtide, block this 
interaction. Changes in the HR2 region have also been implicated in reduced 
susceptibility to T-20, residues N126K, E137K and S138A. The N126K change is 
thought to eliminate a glycosylation site and changes at positions 137 and 138 are
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thought to coexist with changes in HR1, predominantly at codons 42 and 43. Structure 
predictions of the HR1-HR2 six helix bundle structure indicate these residues lie in 
close proximity to each other 1181,9
Single substitutions such as the G36D substitution exhibit a 5 to 10 fold reduction in 
susceptibility to Enfuvirtide in vitro and double amino acid substitutions displayed 
> 100-fold reduction 119. The impact that this may have in a clinical setting is less 
clearly understood as variation in T-20 susceptibilities of primary isolates containing 
single mutations varied in resistance levels from 4 to 450 fold. The in vivo incidence 
of genotypic changes at amino acids associated with Enfuvirtide resistance is low in 
naive populations, implying that this is a conserved region, critical for viral fusion
118,119
Research has also determined Enfuvirtide resistance does not preclude the use of other 
classes of entry inhibitors, as in vivo derived resistance to T-20 did not appear to affect 
the activity o f other coreceptor inhibitors 273. In a separate study it was found that 
some HR1 mutations conferred increased sensitivity to a subset o f neutralising 
monoclonal antibodies. The mechanism for this enhanced neutralisation could be due
97 f \to reduced fusion kinetics
Effectiveness of this class of compound is likely to abrogated by the natural gpl20 
variability among different HIV-1 subtypes. CD4-gpl20 binding inhibitors although 
not clinically approved have showed effectiveness in in vitro work. Resistance to 
these compounds is primarily caused by changes within gpl20 surrounding the ‘Phe- 
43 cavity’ 187; a cavity created by the binding of the three gpl20 core domains and 
CD4, in which Phe 43 of CD4 is the only CD4 residue that binds to this cavity.
1.6.4b Chemokine Inhibitor Resistance
Resistance to CCR5 and CXCR4 antagonists can possibly result from a switch in 
coreceptor usage. Incidences of this occurring are rare and viruses that are resistant to 
CCR5 inhibitors, tend to continue use of this receptor. Selection experiments 
performed in increasing concentration of a CCR5 inhibitor resulted in the 
development of a phenotype conferring >20,000 fold resistance by 19 passages, this 
virus continued to display an R5 entry preference 311. Resistance to CCR5 antagonists 
can be mapped to both the variable and conserved regions in HIV envelope, whereas, 
CXCR4 resistance can mainly attributed to changes in the variable regions. Changes
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in V3 account for resistance to both CXCR4 and CCR5 inhibitors, which can result in 
the development of cross-resistance to inhibitors of this class 26.
Maraviroc, a recently developed CCR5 antagonist failed to select for resistant variants 
after serial passage experiments using laboratory adapted and clinical isolates of HIV- 
1. Although, high-level maraviroc resistant viruses were eventually selected after 
passaging of primary isolates in PBMCs 336. As mentioned in the previous section, 
natural gpl20 variability among different HIV-1 subtypes may account for differences 
in baseline susceptibility to these types of inhibitors and may thus affect the 
mutational pathway to resistance 76. It has also been proposed with this class of 
inhibitor that most resistance mutations are specific for each of the different
9 f tcompounds, which may hopefully limit cross-resistance . However, further research 
with other CCR5 antagonists has demonstrated that cross resistance between 
structurally related molecules such as, AD 101, SCH-C, and vicriviroc, can exist 336. 
The most common mutations associated with maraviroc are changes at amino acid 
positions A 316V and 1323V, a three-amino-acid deletion in the V3 crown at codons 
315-317 (QAI), T163K in V2, N355Y in C3, S405A in V4, D389N in V4, N442K in 
C4, E509K in the gpl20/gp41 junction and S132N in VI 336.
1.6.4c Integrase Inhibitor Resistance
Resistance to this class of inhibitor results from changes in the enzyme structure that 
cause changes in the integrase catalytic site and can also affect metal ion coordination, 
which can be detrimental to enzyme activity, often producing non-infectious progeny
i nj
. Development of resistant strains in vitro can take up to 6 months and requires the 
accumulation of multiple changes in order to confer high level resistance. Changes at 
codon T66I, L74M, F121Y, T125K, G140S, S230R, V249I and C280Y have been 
reported in conjunction with resistance in this class and these have not been reported 
to occur as natural polymorphisms 122. Raltegravir (MK-0518) and elvitegravir (GS- 
9137) are two integrase inhibitors in late-phase development; both compounds are 
classed as integrase strand transfer inhibitors. In a recent study, raltegravir was used 
as salvage therapy for nine heavily pre-treated patients. Resistance was detected and 
four different mutational profiles were identified containing combinations of the 
mutations E92Q, G140S + Q148H, N155H and E157Q. The study also reported the 
observation that the HIV-1 viral load was able to rebound to the pre-therapeutic levels
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for viruses harbouring only a single mutation l90. This would suggest that the genetic 
barrier to resistance of this compound is low.
Although the aforementioned compounds, raltegravir and elvitegravir, are the only 
two compounds to have been developed for clinical use, several others have also been 
tested and have shown potent antiviral activity. The diketo acid derivatives L- 
731,988, L-870,810 and S-1360, have been described and in in vitro resistance 
selection experiments were shown to display a similar resistance profile to the two 
most advanced compounds. Active site mutations, T66I, S153Y, and M l541 were 
shown to appear with L-731,988 and S-1360. Whereas, L-870,810 produced a unique 
resistance profile in in vitro resistance passage experiments, with mutations V72I, 
F121Y, T125K, and V I5 II, also located in and around the active site 297.
1.6.4d Capsid / Maturation Inhibitor Resistance
The potent maturation/capsid inhibitor PA-457 prevents the late stage cleavage event 
that releases capsid from the spacer protein p2. Resistance to this compound was first 
described after serial passage experiments selected for resistance mutations that were 
mapped to the p24/p2 site. A single A to V change at codon 231 of capsid or P 1 ’ of 
p24/p2, resulted in resistance to PA-457, as was determined by correction of cleavage 
patterns and also restoration of morphological impairments visualised by electron
1 70microscopy (EM) . In a separate study an L230F mutation at the PI site was also 
found to confer resistance to PA-45 7 359. More recent work has identified an 
additional two more sites located slightly more distal from the scissile bond that also
7 1 07confer resistance to this compound ’ .
1.7 Transmission and Fitness
There are many biological determinants that influence the transmissibility o f different 
viral variants from within the quasispecies present in the original host or donor. As 
mentioned in the Life cycle section 1.3, co-ordination is needed by virus and host 
factors in order to establish a productive infection. A virus which contains a high 
density of CCR5 receptors stands a better chance of gaining entry 354, although if  the 
host contains a ACCR5 allele, then entry will be blocked or diminished. Even before
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entry into the cell, other host and viral factors are again required to work in tandem, 
such as CyPA binding to capsid, glycoslylation of Env and V if inhibition o f 
APOBEC3G packaging; these and many other interactions will determine the success 
of an infection.
1.7.1 Transmisson
The immediate bottle-neck imposed on the infecting virus, is entry, this is 
demonstrated by the homogeneity o f env V3 sequences and the observed 
heterogeneity of other regions of the genome in viruses isolated from recently infected 
individuals 71. In one study, the V3 regions from viruses isolated during primary 
infection from five separate patients demonstrated complete homogeneity in all intra- 
patient samples and only showed variability in 6 out of the 35 residues of V3 
These results suggest that viruses share a genetic signature across individuals due to 
site-specific selective pressures that are common across hosts, specifically located in 
the V3 region. The mode of transmission may also influence the diversity of the 
genotypes that infect the recipient. Infections termed as vertical transmissions are 
defined as those that are transmitted from donor to the donors progeny, as occurs from 
mother-to-child. Horizontal transmissions are those that occur from donor to another 
host within the species, such as through sexual contact and blood transfusion products 
16. Vertical transmission in thirteen mother and infants pairs demonstrated that more 
than half of the samples had a heterogeneous virus population; this is more diversity 
than detected in the previous mentioned horizontally transmitted study. The increased 
inoculum levels and elevated exposure times associated with vertical transmissions 
were thought to contribute to this observed increase in heterogeneity 328. However, 
Zhang et al. demonstrated that the inoculum size may not necessarily contribute to 
viral diversity during primary infection, as several patient samples used in this study 
were from transmissions through contaminated factor VIII 357. Another factor that has 
been associated with a greater heterogeneity in pre-seroconverters is gender; several 
studies have reported the that virus samples isolated from women recently infected 
have contained a more diverse quasispecies when compared to those in men 71,183. 
This may possibly account for the higher transmission rates seen in women, who are 
up to 5 times more likely to become infected than men 294.
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The worldwide predominant HIV subtype is subtype C (see Figure 1.2), it accounts 
for approximately 50% of worldwide infections possibly through the enhanced 
replication in the GALT 36. A consequence of this high viral turnover is the increased 
detection levels in semen. Viral loads of subtype C are 3-4 fold higher than subtype B, 
leading to estimated transmission frequency increases of 2% to 6% for subtype B 
compared with 7% to 24% for subtype C 264.
The impact of host genetics on selection and divergence of infecting strains over time 
was illustrated in an interesting article in which two individuals acquired HIV through 
blood transfusion from a donor who was classified as a long term non-progressor 
(LTNP). Both the recipients developed AIDS and samples taken over the course o f 
infection from all three individuals revealed that the main variation in HIV sequence 
appeared to be an insertion in the N ef gene, present only in the LTNP. However, both 
N ef alleles, with and without the insertion, were present in the LTNP; this suggests 
that there may be a host effect elicited by the LTNP donor, which suppressed the 
more pathogenic strain in this host. The major contributing factor driving the 
transition to a more virulent form was specifically thought to be Human Leukocyte
86 207Antigen (HLA) type ’ . Another demonstration of the modulation o f virulence or
pathogenicity was established using the primate lentivirus, SIV. This infects African 
green monkeys and sooty mangabeys, producing high levels o f viremia, with no 
immune pathogenesis to the primate host. However, SIV infection in macaques results 
in high titre virus and the development of AIDS like symptoms 112.
1.7.2 Drug Resistance and Transmission
Effective HAART reduces VL to undetectable levels and increases the number of 
circulating CD4+ T cells 228, significantly delaying clinical and immunological 
deterioration related to HIV infection The effectiveness of regimens is halved with 
prior exposure to antiretrovirals, presumably through the lack o f decay of previous 
resistant viruses and their subsequent selection on recommencement of therapy ,84. 
This finding has implications for the transmission of such resistant variants and the 
potential failing of therapies initiated.
Transmission of resistant viruses was first reported by Erice et al.\ primary infection 
with an AZT resistance strain carrying the T215Y/F mutation was detected in a
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recently infected individual, without any prior exposure to AZT. Initiation of 
Zidovudine treatment 7 days after reporting symptoms resulted in no clinic benefit 
and the patient was eventually switched to a ddl containing regimen. The 
identification of this case and the subsequent failure o f treatment, prompted the 
researchers to postulate that, AZT treatment of primary infection with a resistant virus 
may have favoured a faster progression of the disease, possibly to due inhibition of 
immune functions by antiviral drugs and the lack of suppression selecting for a
83resistant strain with a higher virulence .
Further studies of transmission of multi drug resistant virus has demonstrated that 
these variants are less transmissible than drug sensitive (wild-type) viruses I75 348. 
These studies were the first to demonstrate that HAART can significantly reduce the 
possible spread of the HIV infection by reducing the potential of transmissions.
The reduced rate of transmission of drug resistant variants may also be as a result o f 
the apparent compartmentalisation that occurs between plasma or blood derived virus 
and that from the genital tract . The lack of penetration of some antiretrovirals into 
seminal fluids 312 leading to reduced levels of antivirals could promote the appearance 
of resistance mutations in this compartment. However, most resistance testing is 
carried out on blood derived virus, which may be more suppressed and thus, carry a 
divergent resistant pattern to that of the seminal fluids. This could produce some 
discordant results when comparing viruses isolated from sexually transmitted, 
epidemiologically linked couples. Estimates of prevalence of transmitted drug 
resistance range from 10-20%, with some studies reporting rates of up to 27% 56.
1.8 Viral Fitness
Survival of the fittest is a Darwinian concept that was originally applied to explain the 
impact of evolutionary pressures on organisms 59. These evolutionary forces either 
result in the adaptation o f the organism through acquisition of beneficial mutations or 
result in its extinction. Viral fitness can be defined as the ability o f a virus to replicate 
and produce infectious progeny in a host environment56’67 323. This definition includes 
the concept of survival of the fittest as viruses are required to respond to evolutionary
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pressures exerted by host selection/adaptive forces and they may also have to respond 
to drug pressure, through use of antiretrovirals. The term replication capacity defines 
the ability of a virus to replicate in a fixed environment. It has also been used in the 
place of fitness; however, this is essentially one of the many components that make­
up viral fitness and lacks the myriad selection forces within a host environment.
The bottle-neck effect of transmission is caused by the transference o f a small fraction 
of the quasispecies present within the donor 285. It is a chance event and due to the 
high error rate and viral turnover of RNA viruses, it is predicted that the successful 
virus will likely harbour a deleterious mutation compared to the original wild-type 
virus population. This results in the loss of the fit variant from the population and 
causes an overall replication deficit to the viral quasispecies. This principle which 
describes the tendency of small populations of asexual organisms to lose fitness, due 
to the accumulation o f deleterious mutations is called Muller’s ra tchet16.
A few in vitro bottle-neck experiments have shown Muller’s Ratchet effect in 
dramatically reducing the fitness of HIV during repeated bottle-neck, plaque to plaque 
passage experiments. The high fitness heterogeneity among the initial passage was 
subsequently lost through serial passaging, resulting in the loss of 4 of the initial 10 
clones before completion of passaging 355. The observed mutation frequency did not 
correlate with the lack of growth and all clones demonstrated conservation of the V3 
sequence; the most variability in the ‘unfit’ clones was found to occur in gag  353. 
However, Muller’s ratchet is not likely to have such a dramatic effect in vivo, 
especially once infection has been established; this is possibly due to the high rates of 
replication and availability of target cells 16 355.
The disease course in horizontal HIV transmission can also be explained in terms of 
maintaining fitness in the host. First HIV establishes an R5 infection phenotype, 
which is less pathogenic than X4 and this allows the intra-host infection to spread. For 
a long period of time the host remains asymptomatic and produces high amounts of 
virus that would facilitate any transmission through horizontal means which tend to be 
associated with a lower viral dose inoculum l6. The switch to an X4 phenotype could 
be due to the limiting amount of target cells, as the initial infection with R5 virus has 
reduced the supply, therefore forcing the coreceptor switch to maintain infection. The 
X4 virus accelerates the disease status, leading to death. The most successful in vivo 
HIV is the subtype C virus and has been shown not to carry-out the coreceptor switch,
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instead maintaining an R5 virus, possibly increasing survival of host and leading to 
increased transmission potential39.
1.8.1 Drug Resistance and Fitness
The interplay among the various amino acid substitutions appears to be a highly 
intricate process in which the order of appearance of mutations plays a key role. The 
requirement for replication in the presence of inhibitors is paramount for the 
development of resistance; this would seem to be the first counter measure taken by 
the virus to adapt to its new environment. This first move results in the acquisition of 
resistance mutation(s), which may slightly impair the viruses’ enzymatic processes, 
targeted by the inhibitor 228. The acquirement of further mutations, leads to greater 
reductions in sensitivity to the antiretroviral(s) and additional impairment of enzyme 
function. The targeting of another protein, or in the case of NRTIs and NNRTIs, 
another functional region of the same protein, can result in the appearance of a multi­
drug resistant virus, which incorporates non-synergistic mutations. The initial hope of 
this kind of multi-drug therapy was to force the virus into a series of fatal
combinations leading to lethal mutagenesis. This theory called ‘convergent
combination therapy’, was likened to a game of chess in which HIV moves through 
the acquisition of mutations to avoid the counter measures of the opponent i.e. 
antiretrovirals 278.
Another theory similar to the ‘chess’ paradigm, views all the possible mutations as a 
three-dimensional space; this ‘landscape’ contains ‘peaks’ and ‘troughs’ which 
represent levels of fitness. The space occupied by the wild-type virus may be at the 
top of a local peak, representing its’ high level of fitness. Changes in environmental 
pressures, such as drug therapy will result in a change in the landscape occupied by 
the virus. Globally, the new landscape may now contain other peaks which are greater 
in height and therefore represent an improved level of fitness. This change in
landscape may also result in the wild-type virus now occupying a relatively lower
peak. In order to traverse this landscape and reach the higher peaks, the virus must 
contain the correct combination of mutations to move through the landscape. This 
may be achieved through the acquisition of new mutations, or the loss o f mutations 
already present and possibly conferring a mutational pattern that results in the 
development of a maladapted virus, compared to the original strain. However, if this
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reduction in fitness is not achievable i.e. unlikely to be selected for, then the virus 
will remain in this unfit state. Or the maladapted stage may only be a transitory state 
that is compensated for by other mutations, either lost or gained, leading to the
r  r - .  1 6 .2 3 0 .3 5 3 ,3 5 5generation of a more tit species
Studies have revealed the transmission of viruses that carry ‘relics’ of a previous high 
level resistance phenotype. The viruses that were transmitted only conferred a low 
level resistance to NRTIs and therefore the growth characteristics displayed were less 
impaired. These viruses contained either single or double amino acid substitutions and 
were able to replicate better than wild-type virus in low and high levels of AZT. The 
transmission of these viruses would result in limited treatment options for the recently 
infected individual 104.
As mentioned earlier, viruses that display high resistance tend to have a reduced 
replication capacity and therefore have lower circulating VL, leading to reduced
1 7^transmissibility . The use of in vitro methods have demonstrated that several MDR 
HIV-1 viruses containing resistance mutations were more fit than wild-type virus in 
the presence and absence of drugs 164. There have also been several in vivo reported 
cases where the transmitted virus has been multi-drug resistant and also showed high 
pathogenicity 200’269. Recently, a case involving a newly infected homosexual male 
received a great deal of media attention, as it raised the possibility of a sudden 
widespread outbreak of a new ‘supervirus’. This highly pathogenic, MDR HIV strain 
was feared to have spread among a very promiscuous, sexually active group of Men 
who have Sex with Men (MSM) and resulted in the rapid progression to AIDS of the 
infected individual. The virus coreceptor usage demonstrated the presence of equal 
proportions of both R5 and X4 i.e. dual tropic (X4/R5) variants, VL was 280,000 
copies/ml and the genotypic and phenotypic data suggested Enfurvitide (T20) and the 
NNRTI, Efavirenz remained the only viable treatment options.
It is possible that due to the highly sexually active behaviour seen in some cases of 
infection of MSM, this virus had under gone serial bottle-neck events in several other 
hosts before infecting this individual. However, instead of Muller’s ratchet selecting 
for the accumulation of deleterious mutations, a Darwinian selection mechanism may 
already have occurred selecting for a highly fit virus. The phenotype of this virus, 
MDR and highly pathogenic, could have been achieved if this virus had been exposed
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to multiple MSM, who were also antiretroviral experienced and possibly, already 
infected, which would allow diversity to accumulate through recombination. This 
‘filtration’ through several hosts resulted in the selection for an entry competent, 
highly resistant, pathogenic strain. The development of pathogenic strains is more 
likely to occur through horizontal means than vertical means, as the former does not 
require the host to reproduce 16. Thus, the development of a highly virulent strain that 
infects and kills target cells, releasing equally or more pathogenic progeny, is not 
harmful to the overall success of horizontal infections 16. Such a potential for the 
emergence of an extremely virulent virus has been demonstrated using an SIV model. 
The appearance of a highly pathogenic strain of SHIV (a chimeric SIV/HIV virus) 
was reported in vivo after rapid serial passage in rhesus macaques. The chimeric clone 
SHIVSFi62, was initially a non-pathogenic, M-tropic, CCR5 primary strain which was 
poorly transmissible by the intra-vaginal route. Upon serial passage through several 
macaques, the virus became highly pathogenic, maintained R5 phenotype and infected 
2 out of 3 macaques via the vaginal mucosa 142.
Fitness differences can to some extent explain the complex patterns of resistance and 
compensation that are seen in vivo and in vitro. Viruses that confer resistance but 
demonstrate poor growth characteristics are not directly selected for, as is seen by the 
gradual accumulation of resistance to most antiretrovirals. Such an understanding of 
the complexities of resistance pathways have been derived from in vitro work that has 
tried to dissect the mechanisms associated with fitness and determine their impact on 
viral phenotype.
1.8.2 Resistance and Fitness Assays
The appearance of mutations associated with antiretroviral therapy impacts on the 
virus protein function, overall protein levels and virus replication capacity. All these 
effects have been utilised as a means of measuring the effects of therapy associated 
mutations, by comparing the abilities of viruses with mutations to perform against 
reference strains. The potential examination of fitness raises many questions such as 
the cell type to be used, PBMCs vs T-cell lines; it has been demonstrated that the 
debilitating effects of protease mutations were accentuated in T-cells compared to 
PBMCs l9. The use of primary isolates over recombinant clones is also another factor
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that should be considered, as is demonstrated by the effects of Pis on the appearance 
of gag mutations and the possible association of p6 mutations with NRTI therapy 256. 
Also, the identification of pleiotropic effects is more likely to be observed if the 
whole genome is used 19. Therefore, fitness studies require a precise understanding of 
the possible limitations of the methods used to answer the questions being addressed.
Figure 1.14 Different approaches used for measuring HIV-1 fitness and 
replication capacity. In vivo assays use viral kinetics such as RNA viral load and 
together with sequence analysis are able to determine the fitness of the viral 
population. All other assays are ex vivo and measure virus replication capacity or 
viral enzyme activity.
Adapted from 272.
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1.8.2a Assessment of Enzyme function
Measurement of RT activity of mutations associated with AZT resistance, 
demonstrated that these mutations conferred only small changes in enzyme
t  z 7  1 Z O
efficiencies which did not reflect the levels of resistance seen in the viruses ’ . The
study into the effects of Lamivudine mutations M 184V/I, revealed a reduced fitness 
of these mutations compared to the wild-type strain, primarily in primary cells or 
those where dNTP pools are limited. These were the first studies to report an impaired 
replicative fitness of mutations associated with therapy 11.
In the context of Pis, the impact of primary resistance mutations on catalytic activity 
and affinity for substrates was used as the first in vitro measure o f fitness and was 
termed enzyme vitality 84. The vitality value is the cleavage efficiency o f mutant 
compared to that of the wild-type protease in the presence or absence of inhibitors. 
Vitality is essentially a measure of enzymatic or biochemical fitness. These studies 
highlighted the reduced catalytic effects of HIV protease containing primary
230 253mutations and the compensatory effects of other mutations ’ . However, these
methods are unable to address the role of such modulations in enzyme activity on 
other processes within the life-cycle, such as increased proteolytic activity, which has 
been shown to be detrimental to infectious virion production
1.8.2b Replication Assays
The development of the RVA by Kellam et al., was initially used to asses the impact 
of changes in RT on RTI sensitivity 152153; since its’ conception it has been utilised 
and adapted further and forms the basis for many of the in vitro fitness assays 
involving virus replication. These assays are performed by cloning the coding 
region(s) of interest into a standard viral backbone, usually from a sub-type B 
molecular clone such as, HXB2 or NL4.3. The source for the coding region to be 
cloned can be either a wild-type gene with specific mutations introduced through site- 
directed mutagenesis or it can be derived from a patient virus with prior exposure to 
antiretrovirals. These methods provide a constant background in the context of 
minimising the effects of other coding regions on the recombinant virus, other than 
those outside the coding region of interest. Assessment of viral replication kinetics
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can be carried out by measuring the rate of growth of the different viruses over time, 
usually through differences of p24 levels between the cultures or differences in RT 
activity 323. These methods are only able to detect large fitness differences in 
populations, as they are subject to a great deal of variation due to each virus being
272grown independently in a parallel infection
1.8.2c Growth Competition
Quantification of initial input of viruses to be tested in fitness assays is o f extreme 
importance, as any small differences in the initial phases will be several magnitudes 
higher after multiple rounds of replication. Competing two viruses together in the 
same culture also known as growth competition studies, allows for the detection of 
much smaller fitness differences . By monitoring the starting ratio and the ratio of 
the two competing viruses in subsequent passages, divergence in the proportion of 
each virus after passaging is used to indicate the differences in fitness. The amount of 
each virus present in each passage can be determined by sequencing o f viral 
DNA/RNA and comparing relative peak heights at nucleotides positions known to be
1 RSdifferent between the two competing viruses . These assays provide an accurate 
means of distinguishing small fitness differences, but are more labour intensive due to 
the extensive amount of sequencing required. Comparing of relative peak heights is a 
relatively imprecise method of end-point determination and more accurate ways to 
determine the amount of viruses present in competition growth studies have been 
developed (see below). This growth competition type of assay system was employed 
to elucidate the possible mechanisms for the preferred appearance of the T215Y 
mutation pathway to NRTI resistance over the Q151M; even though the latter confers 
greater resistance. In competition growth cultures the Q151M virus was able to out 
compete the T215Y virus in the presence or absence of AZT. Both these mutations 
require a two base change Q151M (CAG—»ATG) and T215Y (ACC—>TAC). 
However, it was demonstrated that the Q151M intermediates competed poorly 
compared to the T215Y intermediates. The T215Y intermediates have been found in 
vivo and have also been shown to replicate better n5116. This study may also explain 
the late emergence of the Q151M viruses and the acquisition o f compensatory
164mutations
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Several methods have been developed to circumvent the imprecise and labour 
intensive use of peak heights to determine virus ratios. The heteroduplex tracking 
assay (HTA) utilises the fact that DNA heteroduplexes formed between related 
sequences have a reduced mobility in polyacrylamide gels and the migration rate is 
proportional to their degree of divergence 272. This assay involves the hybridisation of 
a radioactively labelled probe to a PCR product, derived from the total viral 
population. This generates a probe-PCR product heteroduplex which is specific for 
the two competing viruses. The heteroduplexes can be separated by gel 
electrophoresis; a drawback to this approach is that the design o f probes limits the 
HTA to systems with known mutations 72,73. A more recent approach has been to 
develop vectors that contain marker regions in the genome of the virus. This method 
called the recombinant marker virus assay (RMVA) generates recombinant virus 
clones of HIV-1 in which the N ef  gene contains either the Salmonella typhimurium 
histidinol dehydrogenase (hisD) or human heat-stable placental alkaline phosphatase 
(PLAP) gene. The HisD and PLAP containing viruses then can be grown in 
competition and the proportion of each virus in the population can be assessed by 
quantifying the linked hisD or PLAP marker gene, using real-time PCR 185. A similar 
approach was used by Ali et al., in which two variants of the murine heat stable 
antigen (HSA) protein were used as reporter genes 4. One variant of the protein 
contained nine amino acids from the extracellular domain of influenza hemagglutinin 
(HA) antibody epitope. This enabled the use of immunofluorescent antibodies against 
HSA and the modified HSA, to specifically detect cells infected with each virus. End­
point determination was by real time PCR quantitation or by fluorescence-activated 
cell sorting (FACS) analysis.
1.8.2d Virus Production Assays
These assays were originally utilised for drug susceptibility purposes 257, but have 
now been adapted to measure replication capacity of virus isolates derived from the 
protease and RT regions of patients on antiretroviral therapy 31. This assay uses a 
replication defective HIV clone containing a luciferase reporter gene inserted within a 
deleted region of env. The PR-RT region is cloned into the DNA vector and viral 
stocks are prepared by cotransfecting cell cultures with the cloned protease-RT vector 
and an expression vector that produces the envelope proteins of murine leukemia
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virus (MLV). Pseudotyped virus particles harvested from the transfected cell cultures 
are used to infect fresh cells. Because the protease-RT vectors contain a reporter gene 
within the env region, the production of luciferase in target cells is limited to one 
round of virus replication. The amount of luciferase activity detected in the infected 
cells is used as a direct measure of replication capacity. Differences between the 
amount of virus produced from the cloned protease-RT vectors and a recombinant 
reference virus derived from NL4-3 are expressed as the percent replication compared 
to the reference strain. 31. This method is unable to be used to determine the 
comparative fitness of viruses, as these assays do not measure the competitive growth 
of different viral species. However, they are less labour intensive than competition
323experiments and also very accurate
1.8.2e In vivo Fitness Determinations
The development of an SIV model for examination of in vivo resistance to NNRTIs 
has been described 6. As SIV-RT in not susceptible to NNRTI inhibitors, RT 
substitutions were introduced; tyrosines at codons 181 and 188 were added to confer 
NNRTI susceptibility on SIV-RT and also another SIV clone was created that 
contained the whole of HIV-l-RT. Both these viruses produced decreased levels of 
RT activity compared to wild-type SIV and HIV and were also susceptible to the 
NNRTIs Efavirenz and Nevirapine. Passage of these viruses also resulted in the 
appearance of mutations associated with NNRTI therapy. Although this system has 
not yet been used to infect macaques and asses the rate of progression of these viruses 
compared to wild-type SIV, it may be a useful model for the preclinical evaluation of 
NNRTIs and for the development o f drug resistance to these compounds in vivo.
Many in vivo studies o f fitness have focused on the relationship between resistance 
mutations present during transmission and their evolution. Transmission cases 
possibly represent the best cohorts for the study of fitness, as the initial virus 
population size and diversity is small and it is forced to adapt to the milieu of the host. 
Such ideal environments can not be replicated in vitro and have enabled a greater 
understanding of the genetic barriers associated to the development of resistance. 
Delaugerre et al., reported the transmission of MDR virus in two individuals who
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maintained a homogeneous resistant population that persisted for 2  years without any 
treatment intervention. Due to the highly homogenous populations detected in the 
both donor and recipients, it is possible that the ability of the virus to traverse through 
the sequence landscape was limited to the development of mutations through error, as 
opposed to any potential recombination mechanism. This genotype represents an 
example where the virus is unable to back mutate due to genetic constraints and is 
forced to maintain an unfit genotype 70. The fusion inhibitor Enfuvirtide, represents a 
compound with a low genetic barrier to resistance, i.e. a compound that has a 
relatively easy pathway to resistance, this was demonstrated in primary isolates 
containing single amino acid substitutions which displayed 450-fold resistance 118. 
The fitness of viruses containing T-20 mutations is thought to be lower than wild-type 
in the absence of drug. Viruses with double amino acid substitutions were less fit than 
those with single substitutions, possibly due to reduced fusion kinetics. The effects of 
T-20 mutations in vivo have also suggested that these mutations are unfit. Following 
discontinuation of Enfuvirtide a rapid reversion to wild-type virus occurs, leading to 
outgrowth of the resistant virus and restoring replicative capacity 68118.
One study also suggests that maintaining suppression of R5 virus may prevent the 
acquisition of MDR viruses . In an in vivo study both R5 and X4 viruses 
demonstrated similar replication capacities, however, the R5 viruses were associated 
with a higher number of resistance associated mutations. This may suggest that R5 
viruses respond better to environmental changes i.e. have better adaptability, through 
a mechanism other than increased replication capacity.
One of the main assets o f studying fitness has been to demonstrate the possible 
advantages continuing with a potentially failing regimen in order to preserve an unfit 
but resistant virus phenotype. This reduced fitness approach as a therapy strategy is 
possibly the only way such research will benefit those individuals who are infected 
with a quasispecies, pre-exposed to antiretrovirals. However, in a antiretroviral 
experienced cohort, this strategy could possibly result in the development of highly 
resistant strains(s). It also is hoped that continued research into this area will lead to 
better management of patients who have limited treatment options and could lead to 
more effective treatment regimens with lower toxicities and costs. Although, the 
ultimate goal would be a form of ‘convergent combination’ therapy leading to lethal 
mutagenesis, this is highly unlikely with the arsenal of drugs available at the moment.
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Ultimately, there is a need for more new compounds, either at targets already 
addressed or at new targets all together. These compounds need to combat resistance 
and ideally lead to non-synergistic mutational pathways; there is also need for reduced 
pill burden and less complicated regimens to address compliance.
The best hope for a ‘reduced fitness’ antiretroviral therapy strategy in controlling 
viraemia may be early on in infection when the population is thought to be more 
homogeneous. Treating with the appropriate cocktail of drugs from the onset to force 
the virus to mutate to a more controllable form is a more realistic possibility.
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1.9 Project Overview
The treatment of HIV infection with antiretrovirals in most cases successfully reduces 
viral burden and may lead to improved immune response. Prolonged therapy selects 
for resistant virus species with reduced sensitivity to antiretrovirals. Individuals 
infected with HIV in the developed world often undergo routine testing to determine 
the genotype of the virus. Most genotypic and phenotypic tests only include the 
protease and RT regions, as these are the proteins targeted by the antivirals. The 
acquisition of mutations by HIV in response to Pis, leads to the emergence o f viruses 
with compensatory mutations in the gag gene. The effects of these mutations are not 
clearly understood, especially those that occur distal from the cleavage sites.
This study was undertaken to try and develop tools for characterising drug resistant 
viruses and to determine which gene products were required for the development of a 
replication competent virus in the presence of drug resistant and compensatory 
mutations. The initial approach was to utilise a single cycle replication assay system 
in which the gag gene products from patient samples were used to replace the wild- 
type gag and to determine the effects on viral production. The study also details the 
production of a live HIV vector system, derived from the sub-type B molecular clone 
NL4.3. This live virus cassette system enabled the transfer of single or multiple 
coding sequences; gag, protease and RT from HIV positive, antiviral treated patients. 
Vectors containing patient derived virus gene products were used to generate 
replication capable recombinant virus clones. During screening of samples to identify 
patients with prior PI experience and possible rebound virus, a highly resistant isolate 
with a novel two amino acid insertion was identified. This report describes the 
production of chimeras constructed from this virus isolate containing, gag, gag and 
protease and protease only genes derived from the patient virus. These recombinant 
clones were used to asses the impact of the resistant and compensatory mutations not 
only to antiviral sensitivity, but also to the growth characteristics of the virus itself. 
Drug susceptibility was determined by MTT assay. Growth kinetics were measured 
by comparing growth rates o f the viruses in MT-4, SupTl and GHOST cell lines. 
Sequencing of integrated proviral DNA was also carried out on passaged virus stocks 
to assess stability of the genotype. An attempt to compare replication capacity through
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dual competition experiments was instigated to determine the contribution to 
replication capacity of each of the gene products.
The importance of understanding gag's contribution to PI resistance through 
phenotypic analysis could assist in the development of algorithms to create better 
therapies based solely on genotypic data, therefore, resulting in cheaper and less time 
consuming analysis. As Gag performs a multifunctional role throughout the HIV life 
cycle, all regions of Gag would need to be included if a clearer understanding of its 
contribution to viral fitness is to ascertained. The aim of this study was to develop a 
system that would allow the whole gag region and the region upstream from gag , 
involved in packaging of viral RNA, to be analysed. Although the primary aims were 
to asses gag's contribution to replication capacity and drug resistance with and 
without the cognate protease, divergence from the clonal input sequence was also 
assessed. Adaptation to a new environment is a key concept in the Darwinian 
definition of fitness, this effect has also been examined in this study as a measure of 
proviral DNA sequence divergence from the input clone sequence. In this way any 
changes in sequence after passage of the virus would represent positions which are 
detrimental to virus growth and so are lost. Comparing sequences from viruses 
containing different combinations of wild-type and patient derived gag and protease 
regions may facilitate a greater understanding of the adaptive changes required to 
produce a replication competent virus.
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Chapter 2 Materials and Methods
2.1 General Molecular biology Techniques
Standard molecular biology techniques as described in Molecular Cloning: a 
Laboratory Manual, Maniatis et al. 197 were used throughout.
2.1.1 Preparation of competent bacteria
The following Escherichia coli (E. coli) strains were used: SCSI 10, DH5-a, 
H B lO l’s, MAX Efficiency® Stbl2™ (Invitrogen), XL-GOLD and XL-1 Blue 
(Stratagene). Bacteria were streaked onto S.O.B. (2% (wt/vol) bacto typrone, 0.5% 
(wt/vol) bacto yeast, 0.05% (wt/vol) NaCl, 0.02% (wt/vol) KC1, 4ml 1M NaOH/L)
i 2 q
after autoclave and prior to use 5ml 2M MgC12/L) (Hanahan’s Broth ) agar plates 
from a frozen stock and incubated at 37°C for 16 hours. A colony was picked and 
used to inoculate 5 ml Luria-Bertani (LB)-broth (1% (wt/vol) bacto typrone, 0.5% 
(wt/vol) bacto yeast, 0.5% (wt/vol) NaCl) with 50pg/ml (wt/vol) ampicillin and 
shaken at 37°C for 16 hours. This was added to 500 ml LB-broth and shaken at 37°C 
until the absorbance at 600 nm was 0.6 (around 3 hours). The culture was then 
incubated on ice to cool for 10 minutes. The bacteria were pelleted at 3000g for 10 
minutes at 4°C and resuspended in 15 ml of lOOmM calcium chloride (4°C). After 
incubation on ice for 30 minutes, the bacteria were centrifuged again and then 
resuspended in 2.5 ml o f 100 mM calcium chloride containing 15% glycerol by 
volume (4°C). The bacterial suspension was frozen on dry ice in 400 pi aliquots.
2.1.2 Introduction of plasmid DNA into E, coli
1 -200 ng of plasmid was mixed with 200 pi of competent E. coli and incubated on ice 
for 15-30 minutes. The cells were then heat shocked for 45 seconds at 42°C and then 
cooled on ice. 300 pi o f S.O.C. media (S.O.B. media plus 20 mM glucose) was added 
to the reaction and incubated at 37°C for 1 hour. The cells were then plated on LB- 
agar plates containing 50 pg/ml ampicillin or kanamycin and incubated overnight at 
37°C.
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2.1.3 Double Stranded Plasmid DNA purification
2.1.3a Mini-preps
Mini preps of plasmid DNA were produced using the QIAprep Spin Miniprep Kit 
(Qiagen) according to the manufacturer’s instructions. DNA was extracted from 3ml 
of LB-broth containing 50pg/ml ampicillin overnight cultures, inoculated using a 
single transformed E. coli colony.
2.1.3b Midi-preps
Midi preps of plasmid DNA were produced from 50ml of LB-broth containing 
50pg/ml ampicillin overnight cultures of single transformed E. coli colony, using the 
Plasmid Midi Kit (Qiagen) according to the manufacturer’s instructions.
2.1.3c Plasmid DNA maxi-preps
Maxi preps of plasmid DNA were derived by inoculating 500ml of LB-broth 
containing 50pg/ml ampicillin using a 10ml overnight culture, produced from a single 
transformed E. coli colony. The 500ml culture was grown a further 16-24 hours and 
the maxi prep was produced using the Plasmid Maxi Kit (Qiagen) according to the 
manufacturer’s instructions.
2.1.4 DNA Quantification
DNA quantification was performed using lp l DNA sample and a NanoDrop® ND- 
1000 UV-Vis Spectrophotometer (NanoDrop).
DNA was also quantified by visualization using Ethidium Bromide (Invitrogen) 
staining and agarose gel electrophoresis of a 5pl aliquot of purified DNA run along 
with a DNA molecular marker, Marker X (Roche).
2.1.5 Molecular Cloning
DNA insert and vector were digested with appropriate restriction enzymes, according 
to the manufacturer’s protocols and each product was separated and visualised using 
Ethidium Bromide (Invitrogen) staining and agarose gel electrophoresis. They were 
then gel purified using the StrataPrep® Gel Extraction Kit (Stratagene) according to
99
the manufacturer’s instructions. Also, prior to ligation, the vector was treated with 
shrimp alkaline phosphatase (Roche), to prevent self-ligation.
A typical ligation reaction contained vector:insert molar ratios o f 1:3, 1:5 or 1:8, , in a 
final volume of 21 pi and total DNA content of 200ng. Ligations were performed 
primarily using the Rapid Ligation Kit (Roche) and the ligation mixture incubated at 
room temperature for 5 to 15 minutes. Other ligation kits and T4 DNA ligases were 
also tested. These were Quick Ligation Kit and T4 DNA Ligase (New England 
biolabs), Fast-Link™ DNA Ligation (Epicentre), T4 DNA Ligase (Stratagene), all 
used in accordance with the manufacturer’s specifications.
2.16 Polymerase Chain Reaction (PCR)
2.1.7 High Fidelity PCR’s
Expand Long Template PCR System (Roche) and Phusion (New England Biolabs) 
polymerase kits were used according to manufacturers instructions.
2.1.7a Expand Long Template PCR System
The extension time, steps 4 and 8 , varied depending on the length o f amplicon 
generated; for small amplicons up to 1.5kb a 2minute extension was deemed 
sufficient, amplicons up to 3kb required 4 minute extension time and amplicons up to
lOkb had 8  minute extensions. The annealing temperature also varied depending on
which oligos were paired and was determined by the melting temperature (Tm) of the 
DNA oligo, which was derived from the PC application ‘VecNTi’ (Invitrogen).
Typical PCR cycling condition were:
1. 2 minutes at 94°C
2. 15 seconds at 94°C
3. 30 seconds at 55°C
4. 2 min at 72°C
Steps 2-4 an additional 10 times
5. 15 seconds at 94°C
6 . 30 seconds at 55°C
7. 2 min at 72 °C (+5seconds per cycle)
Steps 5-7 an additional 20 times
8 . Hold at 4°C
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2.1.7b Phusion High Fidelity PCR
The annealing temperature also varied depending on which oligos were paired and 
was determined by the Tm of the DNA oligo, which was derived from the PC 
application ‘VecNTi’ (Invitrogen).
Typical PCR cycling conditions were:
1. 1 minutes at 98 °C
2. 10 seconds at 98 °C
3. 20 seconds at 55 °C
4. 1 min at 72 °C 
Steps 2-4 an additional 35 times
5. 10 min at 72 °C
6 . Hold at 4 °C
2.1.8 ‘A’ Addition (‘A’ Tailing)
To facilitate the TA cloning of products generated with high fidelity polymerases, 
PCR products were heated to 95°C for 20 minutes, then to the 50pl PCR, 15jil of 
2mM dATP and 5 units of Taq Polymerase was added and the mixture incubated a 
further 10 minutes at 70°C. 2pl of the ‘A ’ tailed reaction was used in the subsequent 
TA cloning experiment
2.1.9 PCR TA Cloning using the pGEM-T-Easy vector system
The desired region was PCR-amplified using a high fidelity polymerase and ‘A ’tailed, 
see sections 2.1.13 and 2.1.10. The correct molecular weight product was separated 
and visualised using Ethidium Bromide (Invitrogen) staining and agarose gel 
electrophoresis. The desired product was subsequently excised and extracted using 
the StrataPrep® Gel Extraction Kit (Stratagene) in accordance with the 
manufacturer’s instructions.
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The pGEM-T-Easy vector system (Promega) ligation reaction was set-up according to
the manufacturers protocol as below.
5 (X 1 2X ligation buffer 
1 p  1 T4 DNA ligase 
1 jll 1 pGEM-T-Easy linear DNA 
1-3 |Li 1 PCR product 
0-2 p  1 H20
Ligation reactions were transformed into E. coli as described in section 2.1.2 and 
positive colonies were identified by blue-white-screening, PCR-screening or 
restriction enzyme digest of purified plasmid DNA as required .
2.1.10 DNA sequencing
DNA sequencing was carried out by Lark Technologies (now Cogenics 
(http://www.nucleics.com/DNA_sequencing_support/sequencing-service/lark- 
technologies.html http://www.nucleics.com/DNA_sequencing_support/sequencing- 
service/lark-technologies.html)
Typically lOOng of plasmid DNA or gel purified PCR DNA was sent for DNA 
sequencing along with the required primers at 10 pM concentration. Sequencing was 
performed with BigDye terminator chemistry and a 3730x1 Analyzer (Applied 
Biosystems).
2.1.11 Mutagenesis
Mutagenesis was performed with Pfu Polymerase (Stratagene), according to the 
Quickchange™ mutagenesis protocol (Stratagene). The site-directed PCR 
mutagenesis reaction contained 100-200 ng of plasmid DNA and 125ng of each 
forward and reverse primer containg the required mutation and incorporated the 
following PCR cycle:
1. 3 minutes at 94°C
2. 30 seconds at 94°C
3. 30 seconds at 60°C
4. 12m inat68°C
5. Steps 2-4 an additional 18 times
6 . 20 minutes at 70°C
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The extension time, step 4, was determined by the size o f the vector on which the 
mutagenesis was carried out. The protocol recommended an extension time o f 2 
minutes per kb, so for a 10 Kb plasmid the extension time was extended to 20 
minutes. This was followed by addition of Dpnl enzyme (lp l, lOunits/pl) to the 
reaction which was incubated for 2 hours at 37°C. 2 pi of the reaction was then 
transformed into E. coli bacterial strains (section 2.1.2).
2.1.12 DNA Oligonucleotides
Table 2.1 (below) lists the oligonucleotides (oligos) used in this research project, the 
oligos listed were used for cDNA synthesis, PCR amplification and DNA sequencing, 
those oligos used for mutagenesis are contained with in the text o f the section in 
which they are discussed.
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Oliao Name Oliao Seauence (5'—>3') 375’
3’Gag-Pvul ATACAGTTCCTTGTCGATCGGCTCC (2242) 3 ’
3 ’Integrase-Awa/ AGCTGCCATATCCCGGGGCTACAGTCTACTTGTCC (4418) 3 ’
3'Y*ro-SexAl GGGCCATCCATACCTGGTTTTA (2605) 3 ’
3'5gl.seq GGGAACCGGAGCTGAATGAAGCC (12651) 3 ’
3'p8.9 l£co/?-down AGTCTAGGATCTACTGGCTCC (5852) 3 ’
3'pos: 13985 ATCTCCATTTTGATGTGAAGG (13985) 3 ’
5'Gag-NarI TAGCAGTGGCGCCCGAACAGGGACTTGAAAGC (630) 5 ’
5'Gag-Pvul AGGAGCCGATCGACAAGGAACTGTATCC (2216) 5 ’
5'Gag-XbaI GCCCGAACAGGGTCTAGAAAGCG (640) 5 ’
5'Amp-R AATGCTTAATCAGTGAGGCACC (12283) 5’
5'Bgl.seq GGCTTCATTCAGCTCCGGTTCCC (12629) 5’
AQGAG5 ATACTGACGCTCTCGCACCCATC (810) 3 ’
AS3LTR CGCCGGCCCGGGTGCTAGAGATTTTCCACACTGAC (9721) 3 ’
ASGAG 5A+ CTCTCTCCTGCTAGCCTCCGCTAGTC (789) 3 ’
F122271 TAATCCTCATCCTGTCTACTT (5095) 3 ’
Gagl ATGGGTGCGAGAGCGTCAGTATT (790)
5 ’
Gag 3 CATCTAGTATGGGCAAGCAGGGA (886) 5’
GAG AS1 CAT CT GCT CCT GT AT CT AAT AG AGC (2340) 3’
GAG SE2 GCACAGCAAGCAGCAGCTGACAC (1132) 5’
Gag SE3 GC AGG A ACT ACT AGT ACCCTT C AGG A (1498) 5’
GAG SE4 GTT GG AAAT GT GG AAAGGAAGG AC ACC (2027) 5 ’
HG/F INotl
AT AGC GGC C GCT GGTG AG AG AT GGGT GCG AG AGCGT C AGT ATT 
A (781)
5 ’
HG/RJBclI CT AT G AGT AT CT G ATC AT ACT GT CTT ACTTT GAT AA (2445) 3 ’
pos:l 104(rev) CTTACTTTTGTTTTGCTCTTC (1125) 3 ’
pos.l 104 GG AAG AGC A AAAC AA AAGT AAG (1104) 5 ’
pos:1620 TAGCCCTACCAGCATTCTGG (1620) 5’
pos: 2122 CC AGGG AATTTT CTT C AG AG (2122) 5’
pos: 2619 T GGCC ATT G AC AG AAG A AAA (2619) 5’
pos: 3102 GAT G ATTT GT AT GT AGG (3102) 5’
pos: 3687 AT AGT AAT AT GGGG AAAG ACTCCT A A (3687) 5 ’
pos: 4150 CATGGGTACCAGCACACAAAGG (4150) 5 ’
pos: 4644 TTT GG AATTCCCT AC AAT CCC (4644) 5 ’
pos: 5071 T GGC AAGT AG AC AGG AT GAGG AT (5071) 5 ’
Table 2.1: Oligonucleotides used in this Study. Restriction sites are shown in bold. 
Numbers in parenthesise indicate the position of the 5’ nucleotide, according to those 
of HIV-1 vector pNL4-3, complete sequence (AF324493), except for oligo HG/F/Notl 
, where numbers in parenthesise indicate the position of the first HIV sequence 
nucleotide. 3’ or 5’ indicates if  the oligo is on the forward or complementary strand.
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2.1.13 cDNA synthesis
Viral RNA extraction had previously been carried out during routine resistance 
testing. cDNA was prepared from 7pl o f patient viral RNA (that had been stored at - 
80 °C) using Superscript™ II Reverse Transcriptase (Invitrogen) according to 
manufacturers instructions and using the oligonucleotide F I22271.
2.1.14 Clinical Patient samples
Patient samples were identified from a database search of patient samples undergoing 
genotypic resistance testing at UCL, London, UK. The criteria for selection was 
extensive prior PI therapy, high viral load and the presence of multiple PI mutations. 
As control samples some patients were also selected that had no prior therapy or no 
primary resistance mutations. Samples were originally submitted for resistance testing 
and AMPLICOR® HIV-1 Test (Roche).
The CD4 counts and viral loads for patient samples used in this study are shown in 
figure 2.1(a and b). The data is also given in tables 2.1a, b, c, d and e, the sample time 
point in bold indicates the sample used in this study. Regimen highlighted in grey box 
indicates a switch to new regimen.
Patient sample 1 dated 07/01/2003 had a viral load of 91300 copies/ml and had 
previous exposure to antivirals, although the dates of these were not known. 
Antivirals this patient was previously exposed to were Indinavir, Efavirenz, Ritonavir, 
Zidovudine, Saquinavir, Stavudine and Lamivudine. Antiviral therapy over the 1 year 
period during the time of sampling was Kaletra (Lopinavir, RTV boosted), 
Lamivudine, Nevirapine and Didanosine. This sample was selected as the patient 
showed no response to therapy and had extensive previous exposure to Pis. This 
patient also showed a genotype that indicated resistance to Pis, NRTIs and NNRTIs 
(see Table 3.1).
Patient 2 had been off antiviral therapy for 10-12 months and previous antiviral 
history was unavailable. This patient appeared to controlling viral load in the absence 
of therapy and was selected as a ‘no previous exposure to antiretrovirals control’.
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For the remainder of the patient samples all other previous antiviral history is shown 
in figure 2.1 (a and b) along with viral load and CD4 counts at the various sample time 
points available.
No adherence to regimen information was available for patients 1 and 2. Patient 3 was 
also selected as a non-responder. This patient had excellent adherence, however, the 
regimen of Nelfinavir and Combivir (AZT and 3TC) was switched due to increasing 
viral load. The switch to ddl, Abacavir and Nelfinavir was also unsuccessful at 
controlling viral load.
Patient 4 had poor adherence to the regimen and also showed no reduction in viral 
load during therapy and was also classed as a non-responder. Patient 5 had excellent 
adherence, and also showed possible rebound when therapy was switched from 
Trizivir (Abacavir, AZT and 3TC) and Efavirenz to Tenofovir, ddl and Nevirapine, 
which was also unsuccessful at controlling viraemia. (you keep on switching between 
generic names and abbreviations, use and stick to one or the other)
All samples were from patients attending clinic and obtaining routine viral load and 
genotype resistance data. The only patient material stored was RNA used in patient 
virus genotype identification. Routinely, patient serum or infected PBMC samples are 
not stored and so were not available and so all work was carried out with RNA that 
had been stored at -80C.
Table 2.1(a) Patient sample 1 Viral load, CD4 and previous antiviral history 
data.
Sample date VL copies/ml CD4 cells/ml Therapy
07/02/2002 1900 159
Nevirapine, Lopinavir, Didanosine, 
Lamivudine
02/04/2002 50000 317 “
28/06/2002 24300 141 “
29/08/2002 61300 183 “
07/01/2003 91300 “
N.B. Prior to 2002: Indinavir,Efavirenz, Ritonavir, Zidovudine, Saquinavir, 
Stavudine, Lamivudine.
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Table 2.1(b) Patient sample 2 Viral load data.
Sample date VL copies/ml
07/02/2002 58200
30/04/2002 <50
20/08/2002 27900
08/05/2003 34900
12/08/2003 <50
18/11/2003 <50
Table 2.1(c) Patient sample 3 Viral load, CD4 and previous antiviral history 
data.
Sample date VL copies/ml CD4 cells/ml Therapy
01/03/2001 155000 120 Nelfinavir and Combivir
01/03/2002 <50 200 Nelfinavir and Combivir
01/05/2002 400 226 Nelfinavir and Combivir
25/07/2002 1000 183 Nelfinavir and Combivir
01/10/2002 210 269 Nelfinavir and Combivir
08/11/2002 2700 212 Nelfinavir and Combivir
09/01/2003 2900 211 Nelfinavir and Combivir
03/04/2003 3700 155 Nelfinavir and Combivir
06/06/2003 14700 198 ddl, Abacavir and nelfinavir
05/08/2003 25100 Not known if continued
Table 2.1(d) Patient sample 4 Viral load, CD4 and previous antiviral history 
data.
Sample date VL copies/ml CD4 cells/ml Therapy
13/01/2003 25600 195
04/03/2003 77500 160 Nevirapine and Combivir
12/06/2003 69300 207 Nevirapine and Combivir
10/09/2003 52600 186 Nevirapine and Combivir
Table 2.1(e) Patient sample 5 Viral load, CD4 and previous antiviral history 
data.
Sample date VL copies/ml CD4 cells/ml Therapy
14/01/2003 110700 7 Trizivirand Efavirenz
11/04/2003 <50 68 Trizivirand Efavirenz
23/05/2003 <50 79 Trizivirand Efavirenz
04/06/2003 2100 Tenofovir, ddl and nevirapine
08/07/2003 700 Tenofovir, ddl and nevirapine
13/10/2003 73100
Tenofovir, ddl and 
nevirapine
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2.1.15 Vectors
The molecular clone, pNL4.3 was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: from Dr. Malcolm 
Martin The HIV-1 pHXB2D molecular clone was obtained from Drs. R Gallo and 
M Popovic through the AIDS Reagent Programme, NIBSC, Potters Bar, U K 91.
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2.2 General Tissue Culture Techniques
All cell and virus cultures were grown in humidified 37°C incubators with 5% CO2 
(10% CO2 for HEK 293T cells) in varying volumes and passaged as required.
2.2.1 Thawing cells
Cells were removed from liquid nitrogen and thawed rapidly at 37°C. MT-4 cells, a 
human T-cell line bearing human T-cell leukaemia virus type I (HTLV-I) and SupTl 
cells were obtained through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: from Dr. Douglas Richman and Dr. James Hoxie, 
respectively. Both cell lines were added to 10 ml of Roswell Park Memorial Institute 
(RPMI)-1640 medium (Invitrogen) with 10% foetal calf serum (FCS), (Biowest, 
France), 100 units (U)/ml penicillin and 100 p  g/ml streptomycin (Invitrogen) 
RMPI 10- The cells were then pelleted at 325g for 5 minutes, resuspended in 15 ml 
media and transferred to a T25cm flask. The following day the media was exchanged 
for fresh media.
HeLa, TE 671, and HEK 293-T cells were added to 10 ml of Dulbecco’s Modified 
Eagle Medium (DMEM, Invitrogen) with 10% FCS, (Biowest, France), 100 U/ml 
penicillin and 100 p  g/ml streptomycin (Invitrogen). The cells were then pelleted at 
325g for 5 minutes, washed once in 10ml of media and then resuspended in 15 ml 
media in a 10cm dish. The following day the media was exchanged for fresh media. 
The GHOST (3) R3/X4/R5 GFP Indicator cells used for HIV-1 infection were 
obtained through the NIH AIDS Research and Reference Reagent Program, Division 
of AIDS, NIAID, NIH: from Dr. Vineet N. KewalRamani and Dr. Dan R. Littman. 
These cells were thawed as described above although the media contained additional 
2pg/ml puromycin (Sigma) and G-418 500 pg/ml (Gibco) selection.
2.2.2 Passaging cells
MT-4 and SupTl cell lines were sub-cultured twice a week at a density of 
approximately 3 x 1 0 5 cells/ml in RMPI10 and grown in 5% C 0 2 at 37°C.
HEK 293-T, TE671 and HeLA were maintained in complete Dulbeccos minimal 
essential medium (DMEM) (Gibco) supplemented with 10% FCS (Gibco), 100 U/ml 
of penicillin, and 100 pg of streptomycin per ml.(Gibco). The GHOST (3) R3/X4/R5 
GFP Indicator were maintained in complete DMEM (Gibco) supplemented with 10%
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FCS (Gibco), 100 U/ml of penicillin, and 100 pg/ml o f streptomycin (Gibco) 2pg/ml 
puromycin (Sigma) and G-418 500 pg/ml (Gibco). Cells were washed with phosphate 
buffered saline (PBS) (137 mM NaCl, 2.7 mM Kcl, 4.3 mM Na2H P04, 1.4 mM 
KH2PO4), incubated with trypsin (0.5 g/1) EDTA (0.2g/l) (Invitrogen) until detached 
from the tissue culture plastic and then resuspended in media. Cells were split 1:4 to 
1 :8 , depending on cell density and rate of growth, two or three times per week and 
grown in 5% CO2 (HEK293T cells were grown in 10% C 0 2) at 37°C.
2.2.3 Freezing cells
Cells were centrifuged at 325g for 5 minutes and resuspended at lxlO 7 cells/ml in 
40% complete media (as described above), 50% FCS and 10% dimethyl sulphoxide 
(DMSO, Sigma, UK). Cells were aliquoted into cryovials (Nunc, USA) and gradually 
cooled to -80°C in an isopropanol-containing cryo-container (Nalgene, USA) before 
being transferred to liquid nitrogen.
2.3 Pseudotype Lentiviral Vector related Techniques
2.3.1 Transient transfection of HEK 293-T cells to make lentiviral 
vectors.
Lentiviral vectors were produced as described by Besnier et ah, 17 HEK 293-T cells 
were seeded so that 1 0  cm dishes were just sub-confluent on the day of transfection. 
18 pi of FuGENE- 6  (Roche) was added to 200 pi of Opti-MEM (Invitrogen). 1 pg of 
pHR-SIN-CSGW (a generous gift from Adrian Thrasher, Institute for Child Health, 
UCL, UK), 1 pg o f pMDG (a generous gift from Didier Trono, Ecole Polytechnique 
Federale de Lausanne (EPFL), Switzerland) and 1.5 pg of the Gag-Pol expression 
vector p8.91 (Not I) (generous gift from Greg Towers UCL, UK), were made up to 15 
pi volume in H20  and added to the FuGENE- 6  and Opti-MEM mixture. The 
transfection mixture was incubated at room temperature for 30 min before being 
added drop wise to the confluent HEK 293-T cells in 8  ml DMEM medium 
(Invitrogen) with 10% FCS (Biowest, France) 100 U/ml penicillin and 100 pg/ml 
streptomycin (Invitrogen).
The HEK 293-T cells and the transfection reaction were incubated overnight at 37°C 
and 10% CO2 and the following day the media was exchanged for fresh DMEM
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containing 10% FCS. The lentiviral vector containing supernatants were harvested at 
48, 72 hours post transfection and passed through a 0.45 p  m filter and stored at -80°C 
in 1 ml aliquots.
2.3.2 Lentiviral vector titration of infectious units by GFP expression
HEK 293-T or TE671 cells were seeded at 1x10s per well o f a 24-well plate and 
cultured overnight at 37°C and 10% CO2 in 500 pi of HEK 293-T medium (DMEM 
containing 10% FCS, 100 U/ml penicillin and 100 pg/ml streptomycin). 100 pi, 80 
pi, 60pl, 40 pi, 20 pi and 1 pi of lentiviral vector containing supernatant were mixed 
with HEK 293-T medium to a total volume of 100 pi. The diluted lentiviral vector 
containing supernatants were added to HEK 293-T or TE671 cells in the 24 well 
plates and incubated overnight at 37°C and 10% CO2 . The cells were washed once 
with HEK 293-T medium and incubated for a further 36 hours.
After incubation the HEK 293-T or TE671 cells were trypsinised and the percentage of 
GFP expressing cells determined by flow cytometry relative to non-infected cells. The 
percentage of GFP expressing cells was converted to infectious units by assuming a 
total of 2x l0 5 cells at the time of infection. Infectious units were plotted against pi of 
input supernatant. The absolute titre of the lentiviral vector was determined by 
extrapolating the infectious units per ml (IU/ml) using the straight-line region of the 
above plot.
2.3.3 Flow cytometry
Ten thousand events were collected using a FAC Scan flow-cytometer with Cellquest 
software (Becton Dickinson, UK). Data was analysed using Windows Multiple 
Document Interface Flow Cytometry Application (WinMDI, J. Trotter, 
http://facs.scripps.edu).
2.4 Live Virus Propagation and Harvesting
The Saquinavir resistant molecular clone virus derived from HXB2, containing G48V 
and L90M mutations in protease, was obtained from the Programme EVA, and the 
Centralised Facility for AIDS Reagents (NIBSC). Sources, J Rose, A Kohli and Dr. C 
Craig. The cell-free supernatant was used to infect 5x l0 6 MT-4 cells, which were 
incubated at 37 °C and then resuspended in a total volume o f 10ml RMPI10. The 
cultures were maintained by addition o f more RMPI10 if  the colour o f the media
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appeared too yellow and incubated further until initial signs of cytopathic effect 
(CPE) were observed. At this point the infection was supplemented with a further 
4x l0 7 MT-4 cells and the culture maintained as described above, until full CPE was 
observed.
The infections were harvested by pelleting the culture (1500 rpm at 4°C); stocks of 
virus were aliquoted and stored as cell free supernatants at -80 °C. The infected cell 
pellet was washed twice in sterile PBS, then resuspended in two 400jul aliquots and 
stored at -20°C.
2.4.1 Extraction of infected cell genomic DNA
A 200pl aliquot of the infected cell pellet DNA resuspended in PBS, was extracted 
using the QIAamp® DNA Mini Kit (Qiagen), according to manufacturers 
instructions.
2.4.2 Transfections of Infectious Recombinant Clones
2.4.3 MT-4 and SupTl Transfections
The day before transfection MT-4 cells (or SupTl) were split 1:2 to ensure an actively 
growing population. Transfection of HIV molecular clone DNA was carried out with 
2x l0 6 MT-4 cells and 8 pl DMRIE-C ((l,2-dimyristyloxypropyl-3-dimethyl-hydroxy 
ethyl ammonium bromide) and cholesterol) (Gibco) transfection reagent and 2pg 
vector DNA. Cells were incubated in 6 -well plates and media changed every 1 -2 days, 
and observed for any signs o f CPE in the culture. When CPE was observed the 
infected cells and supernatant were transferred to a 75 cm3 tissue culture flask and 
supplemented with 2 x l0 7 cells in order to create large stocks of each clone. When full 
CPE was observed in these cultures the cell free supernatant was harvested and stored 
at -80°C. This stock was used to create and sub-stock by infecting 5xl0 6 MT-4 cells 
with 500pl of cell free supernatant in a 25cm3 flask. When most of the cells in this 
culture displayed signs of CPE, a further 4x l07cells were added and the culture 
transferred to a 75cm3 flask. The cell free supernatant and infected pellet were 
harvested and treated as described in section 2.4.
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2.4.4 293T Transfections
HEK 293-T cells were seeded so that 10cm dishes were confluent on the day of 
transfection. 18 pi of FuGENE- 6  (Roche) was added to 200 jllI o f Opti-MEM 
(Invitrogen) containing 2jng of HIV molecular clone DNA and the transfections were 
continued as outlined in section 2.3.1.
2.5 Titration of Live Recombinant Virus Stocks
2.5.1 MTT Titration Assay
Virus titrations were carried out in MT-4 cells using 3-(4,5-dimethylthiazol)-2,5- 
diphenyltetrazolium bromide (MTT) to determine cell viability. Frozen cell free virus 
supernatant stocks were thawed and serially diluted (0.5 logio ) in clear RPMIjo 
(without phenol indicator) (Gibco) and plated out onto a low evaporation 96 well 
plate (Coming Costar), in a total of 50|il. MT-4 cells, 2 x 106 per assay were 
resuspended at 7.5 x 105/ml and then plated out 50jli1 per well.
After 5 days incubation 20 pi of MTT (Sigma-Aldrich) (5 mg/ml in PBS) was added 
and the plates were incubated for 2 hours before the addition of 170 pi of acidified 
isopropanol (8 6 % Isopropanol, 11% dH20 , 2.7% NP-40 and 0.3% concentrated HC1). 
The absorbance was measured at 540nm and the TCID50 (Tissue culture infectivity 
dose) determined by Spearman-Karber method 90. Each assay contains four replicates 
and the TCIDso/ml is determined from the average of all four data sets.
2.5.2 GHOST Cell Titration Assay
A day prior to titration experiments, GHOST cells (5 x 104 cells/well) cells were 
seeded in 24-well plates to obtain a sub-confluent cell layer by the time of infection. 
Infections were set-up with cell free supernatants and vims was applied in the 
presence of 20 pg/ml polybrene to enhance infection efficiency. Serial two fold 
dilutions from lOOpl of vims supernatant in 500pl total volume of non selective 
DMEM (minus Puromycin and G-418) were plated out and incubated overnight. The 
following day, the media in each well was replaced with fresh media. The plates were 
incubated for a further 24 hours, after which the cells were trypsinised and fixed with 
formaldehyde (1% final concentration) the percentage of GFP expressing cells 
determined by flow cytometry relative to non-infected cells and the IU/ml was 
determined as detailed in section 2.3.2.
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2.5.3 HIV-1 Antiviral assay
The sensitivity o f the recombinant viruses to a panel o f marketed inhibitors, was 
determined by MTT cell viability assay with MT-4 cells 250. Saquinavir, Indinavir, 
Ritonavir and Nelfinavir, were all obtained through the AIDS Research and Reference 
Reagent Program, Division o f AIDS, NIAID, NIH. Amprenavir and AZT were 
provided by GlaxoSmithkline, Stevenage, UK.
MT-4 cells, 2 x 106 per assay, were incubated with virus (MOI 0.0001) for 1 hour at 
37 °C and then resuspended at 7.5 x 105/ml in clear RPMIjo (Gibco) and plated out 
onto a low evaporation 96 well plate (Coming Costar) containing serial two fold 
dilutions of inhibitor.
After 5 days incubation the plates were processed as mentioned above and the TCID50 
determined by Spearman-Karber method 90. Each assay contains four replicates and 
the TCID5o/ml is determined from the average of all four data sets.
2.6 Growth Rate Comparison
Each infection was set-up to contain the amount of vims that would provide 10% 
infection of GHOST cells as determined by duplicate titrations on GHOST cells as 
described in section 2.5.2. A stock infection containing vims and 5.25 xlO6 SupTl 
cells in a total volume of 8 ml RPMI10 was set-up for each of the vimses. To minimise 
any variation in each o f the time points, the stock infection was aliquoted across 1 2  
wells of a 24 well plate, each well containing in 500)11 of media. The infections were 
incubated at 37°C, except for the zero time point which was harvested immediately, 
and stored at -80°C. In all 13 time points were taken at 0, 6 , 12, 24, 30, 36, 49, 57, 73, 
81, 103, 127 and 150 hours post infection and all time point were stored prior to 
parallel analysis.
Each time point was titrated on GHOST cells on three separate occasions and the 
number of infected cells per ml, as detected by FACS analysis o f GFP expressing 
cells, was calculated for each time point.
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Chapter 3 Development of a Single Cycle HIV-1 Assay to 
Study Drug resistance
3.1 Introduction
The prolonged use of antiretrovirals for treatment of HIV selects for viruses that contain 
mutations which confer reduced sensitivity to the inhibitors they have been exposed to
0 0  i o o’ ’ . The development of resistance to most antiretrovirals occurs in a step-wise
manner 2 , ’49>194’213 and the highly error prone mechanisms of HIV replication enhance this 
selection process. The detection of resistance is primarily by sequence evaluation of the 
isolated virus and the identification of known resistance mutations, which leads to a
1 'ISgenotypic estimation of resistance . These methods are quick and provide an insight 
into any potential appearance of resistance and may avert a failing therapy.
Phenotypic methods require the amplification of viral sequences from patient plasma and 
the introduction of sequences into the molecular clone, followed by culturing of the 
resulting recombinant virus. The minimum time to produce chimeric patient derived 
viruses and determine the antiviral sensitivity can be as little a 15 days in some assays 125, 
although longer culturing times are normally required and generally extend this period to 
4 to 6  weeks 257.
The need of these assay systems for virus isolation adds labour, time and cost and so has 
limited their usefulness in screening large sample cohorts. More recently the development 
of new phenotypic assays which circumvent the requirement for virus isolation by 
generating replication defective vectors that contain patient virus sequences and a reporter 
gene, such as luciferase have been described. Amplified protease and RT gene segments 
are inserted into the reporter gene viral vector, in which the luciferase gene was inserted 
into a deleted region of env. Measurement of virus replication is carried out by luciferase 
detection of pseudotyped virus particles after co-transfection of cells with an MLV env 
vector and a single round of infection in fresh target cells. Virus particles are only able to 
complete a single round of replication, due to the lack of an envelope protein and the 
entire assay including the assessment of antiviral activities is completed in 8  to 1 0  days
257 . The assay described by Petropoulos et a l,  utilises a PCR amplicon that spans the p7- 
p l-p 6  protease cleavage sites in gag and also whole of protease protein and the RT 
coding region from amino acids 1 to 313.
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Many publications have highlighted the importance of using the whole of gag in 
evaluating its contribution to resistance compensation and restoring the growth ability of 
viruses resistant to Pis 107191224 358 An attempt has been made to study replication 
capacity, a component o f fitness, by constructing recombinant viruses containing gag and 
protease sequences derived from virus infecting patients treated with antiretrovirals. A 
single cycle reporter assay was used to determine differences in replication rates o f 
recombinants with mutant gag in a wild-type background. The reporter system utilised 
was the lentiviral vector system designed by Naldini et al. ’ . This three-plasmid
expression system was used to generate HIV-derived vector particles that could mediate 
stable in vivo gene transfer into non-dividing cells. Segregation of the coding regions 
required to produce an infectious particle is carried out by a split-genome expression 
system, composed of a packaging vector, an env vector and a HIV Gag-Pol vector 78,361. 
The system is similar to that described by Petropoulos et al., in that only a single round of 
replication can occur after transfection o f the viral genomic sequences.
Specific Aims and Questions
At present no system exists to explore the pleiotropic effects of Pis, this would require a 
vector system that encompasses the whole gag region and would also allow for insertion 
of the cognate protease. The research work detailed in this chapter aims to create such a 
system with primary focus on insertion of gag, as the effects of this region from virus 
isolated from PI treated patients has not been thoroughly explored.
The overall aim of this work was to create patient derived HIV viral vectors which could 
be used to determine the effects on replication capacity of the inserted patient virus 
derived gag regions.
I. Identify patient derived virus isolates which may contain CSM or gag 
compensatory changes from a sample cohort
II. Amplify gag sequences and clone into retroviral vector
III. Determine if the gag region affects virus growth ability
IV. Is the gag from PI resistant viruses more or less efficient at replication than those 
from naive sources?
V. And to see if the system can be used for drug sensitivity assays
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3.2 Results
3.2.1 Patient Derived Virus Sample Sequencing:
Anonymised patient plasma were identified from a database search o f patients receiving 
anti-retroviral therapy which were submitted for routine resistance testing at UCLH, 
London, UK. The criteria for selection was extensive prior antiretroviral therapy, high 
viral load and the presence of multiple PI mutations, including primary, those which 
directly effect inhibitor sensitivity, and secondary which are those mutations that alone do 
not affect drug sensitivity, but, may increase the mutant enzymes ability to function. As a 
control sample a patient derived virus was also selected that had no prior therapy or no 
primary resistance mutations. Sequencing of these protease and RT regions revealed the 
presence of multiple drug resistance mutations. Only sample 2, the control sample, had no 
resistance mutations, but contained a variety of other changes compared to the HXB2 
consensus, however these are not thought to be associated with resistance to 
antiretrovirals 40. (See Table 3.1)
Stored patient viral RNA was reverse transcribed as outlined in the Materials and 
Methods section 2.1.15 using the primer F I22271. A PCR product encompassing the 
entire gag region and containing the first 60 amino acids of protease was amplified with 
primers HG/FINotl and HG/RJBclI containing N otl and Bell restriction sites using the 
Expand Long Template PCR System (Roche).
Only four out of the five samples generated a 1676bp product containing the restriction 
sites necessary for cloning into the Gag-Pol expression vector.
Sequencing was carried out on the patient virus derived 1.6 kb fragments that were cloned 
into the vector p8.91(Ao/7). The following primers were used to verify the sequence of the 
clones, the numbers in parenthesis denotes the position of the primers in vector pNL4.3. 
The sequences to the oligonucleotides used are given in Materials and Methods Table 2.1. 
AQ GAG5 (789), Gagl (790), GAG SE2 (1132), GAG SE3 (1498), GAG SE4 (2027) 
and GAG AS1 (2316).
The amino acid translations of the gag sequences derived from the 1.6kb fragments are 
shown in Figure 3.1 aligned with reference sequences, HXB2, pNL4.3 and p8.91 (Notl). 
Sequencing revealed that 5 clones derived from patient isolated virus samples 2, 4 and 5
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had in frame stop codons in one or more of the chromatograms. These were not studied 
further. One clone isolated from virus obtained from patient 5 had a premature stop in the 
protease gene and 2  others from the same patient virus isolate also had stops in gag, as 
did 2 clones from patient 4. All of the sequenced gags showed sequence differences from 
lab reference strain HXB2. Two of the sequences from virus derived from patient 2 had 
the most changes. The only CSM detected was from virus obtained from patient 5 at 
amino acid position 449. However, this was a Leucine to Proline change rather than the 
usual Phenylalanine change which is associated with drug treatment 107. The gag  isolated 
from this patients virus is also slightly extended, compared to the wild type, with an 
insertion after the PTAPP motif.
Viral clones isolated from patient 2 have a complete duplication o f the PTAPP, preceded 
by a Leucine and Glutamic acid insertion. These two virus clones from patient 2 are 
overall four amino acids shorter than wild-type gag, with a four amino acid deletion prior 
to the pl7/p24 cleavage site, a two amino acid deletion prior to the p2/p7 cleavage site 
and two separate amino acid deletions in the p6  protein (Figure 1).
Figure 2 shows an alignment of the protease genes from the patient virus derived clones. 
The sequencing of the protease gene revealed a more homogenous population than that 
found in gag. The only significant mutation observed generated a Leucine to Isoleucine 
change at amino acid position 10 in Pt5-cl7, which is a secondary resistance mutation. 
The Bell site used for cloning is located at amino acid position 60 in the protease gene; 
therefore, the recombinants contained the C-terminal 39 amino acids o f the wild-type 
protease.
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Patiert VL
(copies
/ml)
Sensitivity to 
Drug C lass
Mutations from WT
pi RTI NNRTI Protease RT
1 9'30C R R R L101,1113V, L24I, 
R41K.M46L, 154V, 
K55R, G57K/R, 62V, 
I63U, 164V, A71V, 
V82T/A
M41L, K43N, E44D, V60 , A98G, C102<, V118 , 
D123E, 1135_, K173Q,M184V, R211K.T215Y,
K219R, K223C, F227L, L228R, A272P, R277K, V29GI, 
L29/K.
2 3490C S S S K20M, L63P V35T, E36A, T39E, S43T, K82R, Q102K, K104R, 
K"22E, D123G, C'628, K173A, D177E, T2DCA 
E2.4Q, Q207D, V245Q, E248D, A272P, Q278H, 
T286A, V292I. E297K. V317A
3 251 DC R S S V3I. L10I/V. L19Q 
K20M, S37N, M46V, 
I62V, Le3P,ia4V/L, 
L90M I93.
A98S. K1C3R. E122K, Q174K. M184V, Q2C7E.R211K. 
L214F, T215S, V245E, P272A, R277K, A288S, 1203V, 
K311R.D324E, I329V
4 526DC S R R V3I. I13V.S37N 
R41K.D60E, I62V, 
L63=>, H69Y
V35T/I. V60I. S68G. R83<. F116Y. D123E. Q151M. 
I178_, V179D, Y188L, T20DA, Q207D, R211K, L214F, 
V245G, D25DE, R277K, T268A, 1293V, E297K, 
D323E. 3322A. I329V, G333D
D /31UC S R R V31.L10V, 112V, 
113V, S37N.I63P, 
I64V
D67N, K70R, V9UI, A93S, K1U2K, E122K, S162Y, 
Q174H, Y181I, M184I, T20DA, E203K, Q207E, R211K, 
L214F, L283I, 293V, E297K, I529V
Table 3.1: Viral Load and mutations in Protease and RT coding regions of viruses isolated from patient samples. See Materials and 
Methods section 2.1.16. Mutations in bold are those known to be associated with resistance to antiretrovirals 40 . Sensitivity to drug 
class (R=Resistant) (S=Sensitive) was determined using the Stanford Genotypic Resistance Interpretation Algorithm, version 4.2.6.
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Figure 3.1: Aligned gag amino acid sequences of Pseudotyped Clones (arrow indicates start
codon ► < and bold letters indicate cleavage site and shaded amino acids represent changes from
p$.9\_Notl).
Gag Start
T
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - c l 7  
W T -C 1 3  
N L 4  .3  
HXB 2
p 8 . 9 1 _ N o t 1 
C l u s t a l
M G ARASVLSG  
M G ARASVLSG  
M GARASVLRG  
M GARASVLRG  
M G ARASVLSG  
M G ARASVLSG  
M GARASVLSG  
M G ARASVLSG  
M G ARASVLSG  
M G ARASVLSG  
M G ARASVLSG  
M G ARASVLSG  
* * * * * * * *  *
1 5
G E L D R W E K IR  
G E L D R W E K IR  
G K L D A W E K IR  
G K L D T W E K IR  
G E L D R W E K IR  
G E L D R W E K IR  
G E L D R W E K IR  
G E L D K W E K IR  
G E L D K W E K IR  
G E L D K W E K IR  
G E L D R W E K IR  
G E L D R W E K IR  
* . * *  * * * * *
2 5
LR PG G K K K YK  
LR PG G K K K YK  
LR PG G K K TYM  
LRPG G KKTYM  
LR PG G K K K YK  
LR PG G K K K YK  
LR PG G K K K YK  
LR PG G K K K YK  
LRPG G KKQ YK  
LRPG G KKQ YK  
LR PG G K K K YK  
LR PG G K K K YK  
* * * * * * *  *
3 5
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S G E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
L K H IV W A S R E  
* * * * * * * *  *
4 5
L E R F A V N P G L  
L E R F A V N P G L  
L E K F A L N P G L  
L E R F A iiN P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
L E R F A V N P G L  
★ * . ★ * •
5 5
L E T S E G C R Q I  
L E T S E G C R Q I  
L E T S E G C K Q I  
L E T A E G C R Q I  
L E T S E G C R Q I  
L E T S E G C R Q I  
L E T S E G C R Q I  
L E T T E G C R Q I  
L E T S E G C R Q I  
L E T S E G C R Q I  
L E T S E G C R Q I  
L E T S E G C R Q I  
* * *  . * * *  . * *
P t 2  - 1  
P t 2 - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - c l 7  
W T -C 1 3  
N L 4  .3  
HXB 2
p 8 . 9 1 _ N o t l  
C l u s t a l
6 5
LG Q L Q P S L Q T
LG Q L Q P S L Q T
IK Q L H P A L Q T
IK Q L Q P A L Q T
LG Q LQ P S LQ T
LG Q L Q P S L Q T
LG Q L Q P S L Q T
L A Q LQ P S LQ T
LG Q L Q P S L Q T
LG Q L Q P S L Q T
LG Q L Q P S L Q T
LG Q L Q P S L Q T
k k » k » k k k
7 5
G S E E L R S L Y N
G S E E L R S L Y N
G T E E L R S L F N
G T E E L R S L F N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
G S E E L R S L Y N
• k  k  k  k  k  k  • k
8 5
T V A T L Y  CVHQ  
T V A T L Y C V H Q  
T V A T L Y C V H E  
T V A T L Y C V H A  
TV A T L Y C V H Q  
TV A T L Y C V H Q  
TV A T L Y C V H Q  
TV A T L Y C V H Q  
T JA V L Y C V H Q  
T IA V L Y C V H Q  
TV A T L Y C V H Q  
T V A T L Y C V H Q  
*  . *  * * * * *
9 5
R IE IK D T K E A
R IE IK D T K E A
G IE V R D T K E A
G IE V R D T K E A
R IE IK D T K E A
R IE IK D T K E A
R IE IK D T K E A
K IE V K D T K E A
R ID V K D T K E A
R ID V K D T K E A
R IE IK D T K E A
R IE IK D T K E A
*  . • • k  k  k  k  k
1 0 5
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K V E E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
L D K IE E E Q N K
k  k  k  • k  k  k  k  k  k
1 1 5  
SKKKAQ Q AAA  
S KKKAQQAAA  
CQQKTQQAAD  
C Q Q K IQ Q A A D  
SKKKAQ Q AAA  
SKKKAQ Q AAA  
SKKKAQ Q AAA  
SKKQAQQAAA  
SKKKAQ Q AAA  
SKKKAQ Q AAA  
SKKKAQ Q AAA  
SKKKAQQAAA  
• • • ★ * ★ ★
pi 7-MATRIX x  p24 CAPSID
1 2 5  1 3 5  1 4 5  1 5 5  1 6 5  1 7 5
P t 2 - 1  D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
P t 2 - 2  D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
P t 2 - 1 0  KGK V S  Q N Y P IV Q N IiQ  G Q M V H Q A IS P  R T L N A W V K V * E E K A F S P E V I P M F T A L S E G A
P t 2 - 1 2  KGK V S  Q N Y P IV Q N L Q  G Q M V H Q A IS P  R T L N A W V K V t E E K A F S P E V I P M F T A L S E G A
P t 3  -  9 D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
P t 3 - 1 0  D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
P t 4 - 1 3  D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
P t 5 - c l 7  N TG N N S P P V S  Q N Y P IV Q N L Q  GQMVHQALSP R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
W T -C 1 3  D T G jp $ $ Q -V S  Q N Y P IV Q N L Q  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
N L 4 .3  D T G N N S Q -V S  Q N Y P IV Q N L Q  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
HXB 2 D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
p 8 . 9 1 _ N o t l  D T G H S N Q -V S  Q N Y P IV Q N IQ  G Q M V H Q A IS P  R T L N A W V K W  E E K A F S P E V I P M F S A L S E G A
C l u s t a l  . * *  * * * * * * * * ; *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
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Figure 3.1(continued): Aligned gag amino acid sequences of Pseudotyped Clones (arrow 
indicates start codon ► m and bold letters indicate cleavage site and shaded amino acids represent 
changes from pS.91 Notl).
►CYP A BINDING^
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - C l 7  
W T -C 1 3  
N L 4  .3  
HXB 2
p 8 . 9 1 _ N o t l
C l u s t a l
1 8 5
T P Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
TP Q D LN TM LN
T P Q D LN TM LN
1 9 5
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
TVGGHQAAMQ
* * * * * * * * * *  * * * * * * * * * *
2 0 5
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN D E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
M L K E T IN E E A
* * * * * * * . * *
2 1 5
A EW D R VH P VH
A EW D R VH P VH
A EW D R liH P V H
A EW D R LH P VH
AEW DRVHPVH
AEW DRVHPVH
AEW D R VH PVH
AEW D R VH PVH
AEW D R LH P VH
AEW D R LH P VH
A EW DRVHPVH
AEW DRVHPVH
2 2 5
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P S Q L R
A G P IA P G Q L R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
A G P IA P G Q M R
2 3 5
E P R G S D IA G T
E P R G S D IA G T
E P R G S D L A G T
K P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
E P R G S D IA G T
. * * * * * . * * *
P t 2  - 1
P t 2 - 2
P t 2 - 1 0
P t 2 - 1 2
P t 3  -  9
P t 3 - 1 0
P t 4 - 1 3
P t 5 - c l 7
W T -C 1 3
N L 4  .3
HXB 2
p 8 . 9 1 _ N o t l  
C l u s t a l
2 4 5  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IA W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IA W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
T S T L Q E Q IG W  
* * * * * * * *  *
2 5 5
M T H N P P IP V G
M T H N P P IP V G
M T IP H L S P V G
M TN N P P V P V G
M T H N P P IP V G
M T H N P P IP V G
M T H N P P IP V G
M T N N P P IP V G
M T H N P P IP V G
M T H N P P IP V G
M T N N P P IP V G
M T H N P P IP V G
2 6 5
E IY K R W IIL G
E IY K R W IIL G
D IY K R W IIL G
D IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
E IY K R W IIL G
2 7 5
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
L N K IV R M Y S P
★  ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k
2 8 5
T S IL D IR Q G P
T S IL D IR Q G P
V S IL D IR Q G P
V S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
T S IL D IR Q G P
2 9 5  
K E P FR D Y V D R  
K E P F R D Y V D R  
K E P F R D Y V D R  
K N P FR D Y V D R  
K E P F R D Y V D R  
K G P FR D Y V D R  
K E P F R D Y V D R  
K E P F R D Y V D R  
K E P F R D Y V D R  
K E P F R D Y V D R  
K E P F R D Y V D R  
K E P FR D Y V D R  
*  * * * * * * * *
3 0 5  3 1 5  3 2 5  3 3 5  3 4 5  3 5 5
P t 2  - 1  F Y K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 2 - 2  FY K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 2 - 1 0  F fK T L R A E Q A  fQ EVK N W M A D  T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 2 - 1 2  FY K T LR A E Q A  JQ EVKNW M TD T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 3  -  9 FY K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 3 - 1 0  F Y K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 4 - 1 3  FY K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
P t 5 - c l 7  FY K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE D M M TA  CQGVGGPGHK
W T -C 1 3  FY K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
N L 4 . 3  F Y K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A TLE E M M TA  CQGVGGPGHK
HXB 2 F Y K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  A A T L E E M M T A  CQGVGGPGHK
p 8 . 9 1 _ N o t l  F Y K T LR A E Q A  SQEVKNW MTE T L L V Q N A N P D  C K T IL K A L G P  G A T LE E M M T A  CQGVGGPGHK
C l u s t a l  * : * * * * * * * *  . * * * * * * * .  . * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *  * * * * * * * * * *
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Figure 3.1(continued): Aligned gag amino acid sequences of Pseudotyped Clones (arrow
indicates start codon ► ^ and bold letters indicate cleavage site and shaded amino acids represent
changes from p8.91_-/Vof/).
p24 CAPSID p2 ^  p7 NUCLEOCAPSID
3 6 5 3 7 5 3 8 5 3 9 5 4 0 5 4 1 5
P t 2  - 1 AR V LAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 2 - 2 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 2 - 1 0 ARVLAEAM SQ A N S - - - - . - H I MMQRSNFKGP K R TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 2 - 1 2 ARVLAEAM SQ A N S - - - H i MMQRSNFKGP K R IV K C F N C G K E G H IA K N C R APRKKGCW KC
P t 3  -  9 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 3 - 1 0 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 4 - 1 3 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
P t 5 - c l 7 ARVLAEAM SQ V T N S A A S A A I MAQRGNFRGQ R K IIK C F N C G K E G H IA K N C R APRRKGCW KC
W T -C 1 3 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
N L 4  .3 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
HXB 2 ARVLAEAM SQ V T N - - - S A T I MMQRGNFRNQ R K TV K C FN C G K EG H TA R N C R APRKKGCW KC
p 8 . 9 1 _ N o t 1 ARVLAEAM SQ V T N - - - P A T I M IQ K G N FR N Q R K TV K C FN C G K E G H IA K N C R APRKKGCW KC
C l u s t a l * * * * * * * * * * * *  *  . *  *  . . * * * * * * * * * *  * . * * * * * * * * * * * *
p7 NUCLEOCAPSID ^  p i ^  p6
4 2 5  4 3 5  4 4 5  4 5 5  4 6 5  4 7 5
GKEGHQMKDC TE R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ----------------- PE E S FR p tG E E T T
GKEGHQMKDC TE R Q A N FLG K  IW PSHKGW PG N F L Q S R P E P T  A P ----------------- PE  E S F R F G E E T T
GKEGHQMKDC TE R Q A N FLG K  LW PSNKGRPG N F L Q N R P E P T  A P L Q P T A P P A  E S F R F *— E E T  
GKEGHQMKDC TE R Q A N FLG K  LW PSNKGRPG N F L Q N R P E P T  A P L Q P T A P P A  E S F R F - - E E T
GKEGHQMKDC TE R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ------------------PE E S F R F G E E T T
GKEGHQMKDC TE R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ------------------PE E S F R F G E E T T
GKEGHQMKDC TE R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ----------------- PE E S F R F G E E T T
GREGHRMKDC TE R Q A N FLG K  IW PS & K G R PG  N F P Q S R P E P T  A P P A --------- P P E  E S F R F G E G T T
GKEGHQMKDC TE R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ----------------- PE  E S F R F G E E T T
GKEGHQMKDC T E R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ------------------PE E S F R F G E E T T
GKEGHQMKDC T E R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ------------------PE E S F R S G V E T T
GKEGHQMKDC T E R Q A N FLG K  IW PS H K G R PG  N F L Q S R P E P T  A P ----------------- PE E S F R F G E E T T
♦  ' k 'k 'k 'k 'k 'k -k 'k 'k 'k  *  ★ *  *  ★
Gag STOP 
▼
4 8 5  4 9 5  5 0 5
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
TP A P K Q E S K D  R E - - P L I S L K  S L F G N D P L S Q *  
TP A P K Q E P K D  R E - - P L J S L K  S L F G N D P L S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G N D Q S R -*  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
T P P Q K Q E P ID  K E L Y P L T S L R  S L F G N D P S S Q *  
T P S Q K Q E P ID  K E L Y P L A S L R  S L F G S D P S S Q *  
* *  * * *  *  . *  * *  * * .  * * * * *
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - C l 7  
W T -C 1 3  
N L 4  .3  
HXB 2
p 8 . 9 1 _ N o t l  
C l u s t a l
P t 2  - 1  
P t 2 - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - c l 7  
W T -C 1 3  
N L 4  .3  
HXB2
p 8 . 9 1 _ N o t l  
C l u s t a l
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Figure 3.2: Aligned Protease amino acid sequences of Pseudotyped Clones (T  indicates start
codon and shaded amino acids represent changes from p8.91_Afo/7).
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - C 1 7  
W T -C 1 3  
p N L 4 . 3  
HXB 2
p 8 . 9 1 _ N o t l  
C l u s t a l
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - C 1 7  
W T -C 1 3  
p N L 4 . 3  
HXB 2
p 8 . 9 1 _ N o t l
C l u s t a l
Protease Start
▼-- - I  I
5 1 5  2 5
P Q IT L W Q R P L  V i l K f G G Q IK  E A L L D TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A LLD TG A D D  
P Q IT L W Q R P L  V T IK V G G Q IK  E A L L D TG A D D  
P Q IT L W Q R P L  V S IK V G G Q IK  E A LLD TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A L L D TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A L L D TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A LLD TG A D D  
P Q IT L W Q R P I V W K IG G Q L K  E A L L D TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A LLD TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A L L D TG A D D  
PQ VTLW Q RPL V T IK IG G Q L K  E A LLD TG A D D  
P Q IT L W Q R P L  V T IK IG G Q L K  E A LLD TG A D D
★ ie
Bell cloning site
3 5  4 5  5 5
T V L E D IN L P G  K W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E D M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E D M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M S L P G  R W K P K M IG G I G G F IK V R Q Y D  
T V L E E M N L P G  R W K P K M IG G I G G F IK V R Q Y D  
*  *  *  *  . . _ *  *  * * * * * * * * * *  * * * * * * * * * *
6 5
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
7 5
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
* * * * * * * * * * ' k 'k 'k 'k 'k 'k 'k 'k 'k 'k
8 5
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
9 5
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
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Figure 3.2: Aligned Protease amino acid sequences of Pseudotyped Clones (▼indicates start
codon and shaded amino acids represent changes from p8.91_Afo/7).
Protease Start
- I  I
5 1 5
P t 2 - 1  P Q IT L W Q R P L  V ^ IK $ G G Q IK
P t 2 - 2  P Q IT L W Q R P L  V T IK IG G Q L K
P t 2 - 1 0  P Q IT L W Q R P L  V T IK & G G Q fK
P t 2 - 1 2  P Q IT L W Q R P L  v | i k | g Gq | k
P t 3 - 9  P Q IT L W Q R P L  V T IK IG G Q L K
P t 3 - 1 0  P Q IT L W Q R P L  V T IK IG G Q L K
P t 4 - 1 3  P Q IT L W Q R P L  V T IK IG G Q L K
P t 5 - C 1 7  P Q IT L W Q R P | V V V K IG G Q L K
W T -C 1 3  P Q IT L W Q R P L  V T IK IG G Q L K
p N L 4 . 3  P Q IT L W Q R P L  V T IK IG G Q L K
H XB 2 P Q IT L W Q R P L  V T IK IG G Q L K
p 8 . 9 1 _ N o t l  P Q IT L W Q R P L  V T IK IG G Q L K
C lu s  t  c i l
2 5
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
E A L L D TG A D D
3 5
T V L E D IN L P G
T V L E E M N L P G
T V L E D M N L P G
T V L E D M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
T V L E E M N L P G
* * * * * * * * * *  * * * * .  . * *
B ell cloning site
4 5  5 5
K W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
R W K P K M IG G I G G F IK V R Q Y D  
* * * * * * * * * *  * * * * * * * * * *
P t 2  - 1  
P t 2  - 2  
P t 2 - 1 0  
P t 2 - 1 2  
P t 3  -  9 
P t 3 - 1 0  
P t 4 - 1 3  
P t 5 - C 1 7  
W T -C 1 3  
p N L 4 . 3  
HXB2
p 8 . 9 1 _ N o t l  
C l u s t a l
6 5
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
Q IL IE IC G H K
7 5
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
8 5
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
P V N IIG R N L L
9 5
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
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3.2.2 Cloning of Patient Derived Virus Samples
The initial and preferred cloning strategy was to clone the patient virus derived PCR 
products into the Gag-pol expression vector p8.91 (Notl) (see Figure 3.3) after first 
digesting with the relevant restriction enzymes. This approach was attempted several 
times without success and so a second cloning strategy was adopted. This was to first 
clone the patient derived virus PCR products into a TA cloning vector then to transform 
plasmid DNA into methylase negative cells, which would allow the patient virus derived 
sequences to be digested out from the un-methylated plasmid DNA for ligation into the 
Gag-Pol expression vector. (Direct cloning of the TA ligation reaction into E.coli, M- 
cells was not possible due to the low transformation efficiency of these cells 
(Transformation efficiency of SCSI 10 & JM110 competent cells to generate 
unmethylated DNA is 5 x 106 transformants/pg pUC18 DNA, compared with 5 x 109 
transformants/|ug pUC18 DNA of XL 10-Gold® Ultracompetent cells; from Stratagene 
product information sheet)). Patient viral DNA sequences were successfully cloned into 
the TA cloning vector. However, sub-cloning into the Gag-Pol expression vector failed. 
Several possible reasons were identified for the failure of the final cloning step: (a) 
general ligation conditions such as the stoichiometry of the vector to insert ratio; (b) 
incubation temperature; (c) the ligase used and alkaline phosphatase treatment o f the 
vector; (d) over digestion of the PCR product could also account for the ligation failure. 
Many optimisation experiments were carried out to determine the reasons for the failure. 
Throughout the optimisation, the problem encountered was the failure to obtain colonies 
containing the correct sized insert and not the actual failure o f the ligation to occur. The 
success of the ligations was confirmed by using PCR to amplify across the junction of the 
region ligated using an oligo specific only for the Gag-Pol expression vector, downstream 
of the Bell cloning site and another oligo located upstream of the Bell cloning site. 
Therefore, the amplicon generated could only be derived from a correctly ligated product. 
Bands were detected at the correct size in the ligation reactions, but the vector only 
control ligations remained negative. Colonies screened contained plasmids smaller than 
expected, suggesting some deletions had occurred during replication of the vector by 
E.coli. To overcome this, ligations were transformed into StBL2 cells (Invitrogen), which 
are more tolerant of DNA sequences containing repeat elements likely to cause 
recombination, such as those of HIV 92. The products for ligation were tested for
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complete digestion, by ligating the compatible ends to each other, thus forming 
heteromers if both ends were cut and dimers if only one end was digested. It was also 
proposed that UV exposure of vector DNA in the ligation caused nicks in the DNA which 
would reduce transformation efficiency. This was explored by making new vector DNA 
without exposing it to UV, thus, avoiding this possibility.
Eventually, correctly ligated clones were isolated using E. coli HB101 and the Roche 
Rapid ligation kit. HB101, like StBL2 is more tolerant o f HIV sequences and a much 
higher transformation efficiency was achieved using this strain compared to StBL2. The 
ligation kit used a “5-minute quick” protocol, that had been tried previously (NEB and 
Fastlink) without success. It is not clearly understood why the Roche ligase would 
perform any better. Correct clones were originally derived by pre-cloning into the pGEM 
vector, but as previously mentioned this method diminished heterogeneity and direct 
cloning from the PCR product was eventually successful, albeit at a much lower 
frequency i.e. ratio of clones screened to clones with insert. A total of 14 clones were 
produced from patient virus derived samples, four virus clones from patient 2 , two from 
patient 3 derived virus, three viruses derived from patient 4 and five virus clones from 
patient 5. However, five of these clones contained stops codons, resulting in truncated 
gags or protease genes. A wild-type clone derived from pNL4.3 was also constructed.
3.2.3 Modification of Gag-Pol expression vector to include RT
The initial aim of this work was to examine the role of mutations in gag associated with 
drug resistance on viral replication capacity, using the Gag-Pol expression vector p8.91 
(Notl). This was used to generate pseudotyped clones with the gag and part o f the 
protease from patient derived virus samples, enabling the analysis of gag mutations. 
However, it was not understood how the substitution of 60 amino acids of protease would 
affect the growth characteristics of the pseudotyped viruses. As Gag is the substrate for 
protease, substituting a mutant gag and combining with a part mutant protease is less 
ideal than being able to insert the whole mutant protease gene. With this in mind, it was 
decided to modify the existing expression vector to allow for the insertion of a larger 
region from the patient’s virus. Restriction analysis of the vector and HIV sequences 
identified a region that would allow the silent insertion of an Xm al restriction site 
downstream of the junction of RT and integrase, 44 amino acids into the integrase open 
reading frame (ORF). The aim was to make this vector using the cloning strategy outlined
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in Materials and Methods, however, due to the difficulties of ligating after T th l l l  
digestion, this approach was abandoned in favour of directly mutating the Gag-pol 
expression vector, p8.91 (Not/) . This approach yielded the p8.91 -Xma vector containing 
the Xm al restriction site. To verify the presence of the restriction site, the plasmid was 
digested with Xm al and EcoRl, which created two fragments 11449bp and 702bp. 
However due to time limitations this vector construct was not used as it would require 
either complete sequence analysis to verify no spurious mutations were incorporated 
during PCR muatgensis. Or further sub-cloning to reduce the fragment size that would 
require sequence verification.
3.2.4 Generation of Pseudotyped viruses.
Co-transfection of the Gag-Pol expression vector p8.91 (Notl), along with the vector 
pMDG, which expresses the VSV-G envelope and the packaging vector pHR-SIN- 
CSGW, into the 293T cell line results in the production of a VSV-G pseudotyped virus 
particle (see Figure 3.3); capable of only a single round of replication. Infection of T cells 
with the harvested viral supernatant results in GFP expression, from which viral titres can 
be calculated. Initially, experiments were carried out to determine the levels of replication 
o f clones carrying patient virus derived gag sequences. However, due to very low levels 
o f GFP expression in the patient virus clones and lower than expected levels in the 
positive controls, some DNA stocks were remade and other reagents tested. Different cell 
lines, 293T, TE671 and HeLa were tested to see if they would give better results when 
infected with the pseudo typed retroviral vectors. With new 293T cells and new pMDG 
DNA, very high GFP levels were observed with the positive controls. However, patient 
virus clone 5c-17 was the only patient-derived viral clone in which any detectable levels 
of GFP were recorded. The only other clone constructed to give measurable values was 
the wild-type clone 13, which was amplified from pNL4.3 and cloned into the Gag-Pol 
expression vector. Data obtained from FACS analysis o f pseudotypes is shown in Figure 
3.4; Figure 3.5 shows the titration curves used to calculate the number of infectious units 
per ml. Production of recombinant pseudotypes from patient derived virus was eventually 
successful. However, due to the low titres obtained and the low level of the wild type 
pNL4.3 recombinant pseudotype, it was thought that the differences between fit and unfit 
viruses would be difficult to measure accurately in this single cycle system. It was also 
hoped to use this system to determine ICso’s of the recombinant pseudotypes to
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antiretrovirals, but due to the low titres, the dynamic range of the assay would be too 
small to measure inhibition by antivirals accurately.
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Figure 3.3: Schematic of the generation of lentiviral vector. Depicted are the relevant 
portions of the three plasmids cotransfected into 293T cells. The packaging construct, 
pCMVDR8.2 shown in the diagram was replaced by p8.91(Notl), which has additional 
HIV accessory genes removed, indicated by (X). The major 5’ splice donor site (SD) has 
been conserved in both p8.91(Notl) and in pHR’, which represents the transducing vector 
pHR-SIN-CSGW, this provides the vector genome. The viral LTRs are indicated, the gag 
gene is truncated after 350 bp and is out of frame, and it follows the RRE and a splice 
acceptor site (SA).
pMD.G encodes the heterologous hCMV promoter driven, VSV envelope that 
pseudotypes the vector. Figure adapted from Naldini et al. 225.
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Figure 3.4: Level of GFP expression of Pseudotypes detected by using FACS. Table 
below lists the percentage cells expressing GFP in the right bottom quadrant.
io° 10’ io2 v
Pt5-cl7
10° 1 0 ' io2 io’
10 ' 10= 10’ 10'
WT-cl3
1 0 ' 10- 10*
Pt2-2
Pt2-1 p8.91
^---- ior'
Mock-293T
GFP
% Cells Expressing GFP
Pt5-cl7 3.4
WT-C3 26.9
Pt2-2 0.3
p8.91 92.6
Pt2-1 0.4
Mock-293T 0 . 6
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Figure 3.5: T itration curves of Pseudotypes viruses. Below are listed the calculated 
Infectious units per ml. (pMDGmnp and p8.91-SG were new reagent controls made and 
tested alongside positive control p8.91 ).
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3.3 Discussion
The appearance of resistance mutations is one of the main causes of treatment failure 
in HIV infected individuals on antiretroviral therapy. The acquisition o f these 
mutations has been shown to be detrimental to the growth o f HIV. The genotype of 
HIV from individuals failing therapy often reveals the presence o f resistance and 
compensatory mutations, which restore viral fitness and permit higher replication 
rates even in the presence of antiretrovirals. The mechanism of action of these 
compensatory mutations is not yet clearly understood and their appearance in HIV 
infected individuals can make predicting therapy outcome more difficult. Therefore a 
clearer understanding of the effects and the role these mutations play would 
potentially benefit patients by allowing better treatment regimens.
The approach adopted was to study the effects of substituting the gag  gene, derived 
from HIV infected individuals into a wild-type background replication defective clone 
that upon co-transfection with an envelope and packaging vector produced a 
pseudotyped virus capable of only a single round of infection. This approach would 
allow for a rapid and direct comparison of the growth rates or replication capacity of 
the generated viruses using GFP as a marker for the number of viral particles. A total 
of eight recombinant virus clones were generated from the patient derived material 
and only one of these lead to expression of detectable levels of GFP. A wild-type 
recombinant virus was also constructed from the molecular clone pNL4.3, this also 
had very low GFP expression levels. Cloning into the Gag-pol expression vector 
p8.91 (Notl), proved to be problematic and several cloning strategies were employed. 
The initial strategy adopted was to clone the patient derived viral PCR products into 
the expression vector p8.91 {Notl) after first digesting with the appropriate restriction 
enzymes. This strategy had the advantages of generating a heterogeneous population 
i.e. direct from the population PCR, and also the methylase sensitive Bell enzyme was 
able to digest the PCR product. The problems encountered with cloning into the Gag- 
pol expression vector, p8.91 (Notl), could have been due to the instability of the HIV 
sequence, although fewer problems were encountered during the cloning and 
construction of the cassette vector pNL4.3-PSX; subject of the next chapter. The 
problems associated with the expression vector p8.91 {Notl), could be attributed to
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the fact that it has the HIV sequence under the control of a CMV promoter, this may 
have caused expression of HIV sequences that caused the observed difficulties. This 
problem can arise when the gene product itself can interfere with metabolism in E. 
coli. Expression of HCV proteins by E.coli has been shown to occur by Foms et al. 
They demonstrated that spurious translation was initiated within the HCV sequence 
and that the sequence upstream of the initiating AUG codon o f HCV might 
conceivably function as an initiation complex and allow translation of the HCV 
sequences in E. coli. They also showed that the introduction o f a frameshift mutation 
upstream of the HCV translation-initiation codon dramatically increased the
09proportion of translationally competent clones isolated .
The reasons for the very low levels of infection detected by the recombinant virus 
pseudotypes, could be an effect of substituting in ‘unfit’ genes; however, this would 
not explain the disappointing reduction in titres seen by substituting the gag  from 
another wild-type molecular clone. This reduction could be due to combining the gags 
from two HIV molecular clones, HXB2 and NL4.3. The gag gene o f the expression 
vector p8.91 is a combination of the first 239 amino acids from HXB2 and the 
remainder of the gag comes from pNL4.3, as does the whole Pol gene 225. The wild- 
type clone constructed in this study has sequences solely derived from pNL4.3, so the 
main differences are the MA and nearly half of CA sequences. This amounts to 11 
changes in the 239 N-terminal amino acids of gag in the constructed wild-type clone 
compared to the p8.91 (Notl) vector. Four of these changes are grouped close to the 
pl7/p24 cleavage site, although their proximity to the scissile bond may undermine 
their relevance. It is thought these differences alone could not possibly account for the 
substantial loss seen in infectivity, as the newly formed gag o f the wild-type clone is 
less chimeric. It should also be noted that during previous construction of the vector 
within this triple transfection system many of the sequences encoding critical 
virulence factors, such as V if , Vpr, Vpu and Nef were removed from this expression 
system, in order to optimise the safe in vivo delivery of genes 225. Therefore, 
substituting the whole Gag-Pol region with that derived from another source is likely 
to adversely affect virus production. What is also unclear is the effect o f having only 
half of the protease from the donor inserted into the newly formed clone. It may be 
that the less efficient processing of Gag by the chimeric protease contributed to the 
titre reductions observed in the patient virus clones compared to the wild-type clones.
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Cloning difficulties with the vector p8.91(7Vo/7) limited the manipulation of this vector 
as did the lack of suitable, unique cloning sites. Therefore, this required either 
extensive modification o f this clone, or a new HIV Gag-Pol vector. Modifying the 
molecular clone, pNL4.3 to insert gag, protease and RT separately would create a 
live virus system that could be made into a complementary single cycle system by 
deletion or truncation of env. The use of the live virus was in part due to the 
availability of Class III facilities and as adaptation of a virus to a new environment is 
a key component of fitness, it requires multiple replication cycles and so infectious 
progeny must be produced.
The sequencing of the cloned patient-derived virus gags revealed the presence of 
cleavage and non-cleavage site mutations. Viral clones isolated from patient 5 and 
two viral clones from patient 2  demonstrated the most variation and both had 
duplications of the PTAPP motif, which is thought to be necessary for efficient 
budding from the cell surface 241. Patient 2 was PI naive and patient 5 PI experienced. 
Insertion mutations in gag, such as those described in this report have previously been 
detected at a moderately low frequency in therapy naive subjects. However, all 
patients who had mixed PTAPP sequences, comprising of wild type and insertion 
mutants reverted to complete PTAPP insertion during therapy, suggesting a selective 
advantage for this genotype in the presence of antiretrovirals 241. Lastere et al. 171 also 
reported that the presence of a duplicated PTAPP motif correlated with a poorer 
virological response to a Pi-containing salvage regimen. The recombinant virus clone 
from patient 5 was the only patient derived isolate to produce any detectable levels of 
virus. It also was the only sample with known PI resistance associated mutations 
(Table 3.1). Therefore, it may have had the most time to evolve in a drug resistant 
selecting environment. This clone also has a single proline insertion near the pl7/p24 
cleavage site, which is also preceded by a Glutamine to Proline change. It is thought 
that the introduction of prolines can introduce flexibility or a turn in the polyprotein 
perhaps aiding cleavage by the less efficient drug resistant protease 343. This clone 
also has three amino acid duplications near the p2/p7 cleavage site and a single 
deletion truncating the C-terminal amino acid of p6 . With such a highly evolved or 
divergent genotype it could be expected that this gag and its associated protease 
would have a level of complementarity as this has been shown with the V82A and 
15OV mutations in protease 171. The mutations in gag alone did not confer any level
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of resistance. However, when present with substitutions in the protease, they not only
had an impact on the in vitro replication capacity of the viruses but also increased
188their resistance to Amprenavir
Patient 2 derived virus clones, 2-10 and 2-12 are very different from the other two 
clones isolated from the same patient derived viral RNA. From Table 3.1 it can be 
seen that this patient’s viral genotype was PI sensitive. It is possible that these 
mutations could have evolved without any drug selection or that, the virus at 
seroconversion was PI resistant and the ‘unfit’ resistance mutations in protease were 
lost. This patients virus does have an M361 mutation in the protease, which has been 
observed in PI treated individuals, but this mutation is also present in wild-type 
viruses in most non-B clades 40 176. It is also possible that the errors seen are PCR 
induced errors or that this is sample contamination, although no other samples 
amplified resemble this genotype.
The adaptation of this infection system to produce a safe means of delivering genes 
into non-dividing target cells required extensive modification. Even though the 
system has been shown to operate successfully without the accessory genes, the data 
presented by Zufferey et al., shows an additive effect i.e. an increase in the number of
t r  i
transduced cells, when Vpr was included in the expression construct . So it is 
possible that Vpr has a function in this system albeit at a reduced level. HIV infection 
and virus production is a complex mechanism that involves an intricate relationship 
with virus and host. Therefore it is possible that other interactions may play a role in 
the development of high titre pseudotyped particles, such as, NC interacting with 
integrase and stimulating DNA integration in vitro 34.
The production of these pseudotypes was essentially to explore the effects of the 
variation in patients virus gags on viral replication. It was also hoped this system 
could be used to determine the phenotypic sensitivity to antiretrovirals of the 
pseudotyped viruses. These viruses could also have been used to look at the effects of 
drug resistant patient derived virus gags on cyclophilin binding, as two of the virus 
clones both from Patient 2 had changes in the cyclophilin binding loop. However, one 
of these mutations has been reported to appear through in vitro passage o f HIV-NL4.3 
in the absence of any Pis I07. Patient 5 was the only patient derived virus to produce
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any detectable infectious units, although it contained only a secondary mutation as 
detected in the resistance test sequence data, see Table 3.1 and in the clone used to 
create the psuedotyped virus, figure 3.2. Patient 5 derived virus was also used in a 
later chapter of this thesis to construct a live virus, this also had the same PI mutation, 
see figure 5.1a. Further evaluation of the gag derived from this virus may be worthy 
as the patient derived virus has had prior exposure to NRTIs which can induce 
duplications, as is seen with the insertion near the PTAP motif see figure 3.1. It 
would have also been interesting to see if the PTAPP duplicated clones have a better
256replication capacity in the presence of NRTIs
The approach chosen made use of a transfection system that segregated the coding 
regions required to produce an infectious particle over three separate plasmids. This 
also negated the need for class III virus handling facilitates, which were unavailable at 
the time of this work. Had class III facilities been available for completion o f this 
work then a slightly different approach would have been adopted.
(i) Completion of the additional cloning sites would have allowed separate addition of 
gag, protease and RT coding regions. This chapter includes the cloning strategy for 
the addition of an Xm al restriction site at the end of RT. Had this been completed it 
would have only required the addition of another site in protease to facilitate the 
desired single and multiple gene cloning system which would be required to dissect 
the effects of mutations in the patient derived viruses.
(ii) The lack of class III virus handling laboratory required the use o f a replication 
incompetent system. Had these facilities been available then this work would have 
been superseded by the live virus work, which is the subject of the next chapter. This 
is because the effects of continued virus replication may help to determine the 
importance or function of the mutations seen in the patient derived viruses e.g. loss of 
mutations in a drug-free environment would implicate their involvement in resistance 
or compensation to antiretrovirals.
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Chapter 4 Construction of a Live Virus Vector System to 
Study Drug Resistance
4.1 Introduction
The single-cycle pseudotyped virus assays have proved to be a valuable tool in predicting 
the resistance of patient derived viruses to antiretrovirals and have also been adapted to
1 9 T 1 1 98  9 7 0study replication capacity of such recombinants ’ ’ ’ . However, in order to study
replication capacity and evolution in the presence of antiretrovirals, a system which 
allows infection and re-infection to occur is likely to be more relevant. The initial RVA 
system developed by Kellam et al.. requires homologous recombination to occur to form 
a replication competent virus 153. This event is a normal cellular event and is similar to 
that which occurs during meiosis and mitosis and was also shown to occur in tissue 
culture 286. Homologous recombination requires a double cross-over event to occur in 
order to generate a viable viral genome. This was first described by Upcroft et al., where
321an SV40 genome was recombined to produce viable progeny
The limitation of this system is the need to have identical sequences in the recombination 
or overlap region, although this is not a requirement for the system to function. However, 
if the sequences are not completely homogeneous across the overlap regions, then this 
will result in the generation of a heterogeneous virus population. The population derived 
from such a transfection experiment will result in a virus pool that differs in the base 
sequence in the recombination region.
RVA systems that generate replication competent patient derived viruses utilise the 
heterogeneity present within the patient virus pool to allow growth of the majority species 
present. 272. This does not preclude the presence of quasispecies which may exist at a 
lower frequency and play little part in the generation of resistance or differential growth 
capacity. However, it is possible for these viruses to contribute a genetic diversity which 
could alter the genetic make up of the majority virus and so lead to the generation an 
artificial predominant virus population, especially under the in vitro conditions of 
transfection systems 88.
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The development of replication competent virus vectors which allow for the insertion of 
clonal genomes have been previously reported 19,296? but these systems do not incorporate 
the gag gene and therefore, cannot be used to determine its effects on replication and
resistance of the recombinant viruses. RVA systems have been developed that include the
281regions coding for the p7/pl and p l/p 6  cleavage sites of the gag gene . As do the 
majority of single cycle phenotypic assays employed for the routine demonstration of
0 ^ 7  '7QAresistance in patient derived virus isolates ’ . However, the inclusion of only the C-
terminal portion of the gene precludes monitoring the effects of the whole of gag, which 
has been shown to effect drug susceptibilities and replication capacity of viruses 107.
Specific Aims
This chapter details the production of a replication competent HIV vector system in 
which restriction sites were introduced at the termini of the gag, protease and RT coding 
regions. The overall aim was to develop a system that encompasses the whole gag region 
and would also allow for insertion of the cognate protease and RT from virus isolated 
from patients who had prior exposure to antiretrovirals. The system would allow the 
relationship of mutations seen in regions more distal from the protein targeted by the 
antivirals used in the patients regimen to be studied. The use of a clonal genome input 
may also help to clarify the phenotype of the derived viruses sequence i.e. with no 
contribution from undetectable populations, as routinely measured by the relatively 
insensitive method of sequence analysis of a patient derived virus. The vector, based on 
the subtype B molecular clone pNL4.3 was shown to generate virus which was able to 
grow to comparable levels of the parental virus. Several different methods were 
employed to determine the amount of virus present within the harvested virus stocks.
I. Introduce unique restriction sites into an existing vector system, so as to facilitate 
the removal of the gag, Protease and RT genes.
II. Confirm that no other changes were introduced into the HIV coding regions.
III. Determine if the introduced mutations impact on the phenotypic characteristics of 
the virus.
IV. Check if the inserted restriction site mutations are stable in the virion.
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4.2 Results
The initial steps in the production of the molecular live virus clone involved the 
production of a plasmid containing a fragment from the HIV-1 live virus vector pNL4.3 
encompassing the protease and RT genes, pGEM-Spe-EcoR. A 5.8kb fragment from 
pNL4.3 was amplified using the primer pair 5’GagNarl and 3'p8.91£'coi?-down and the 
Expand Long Template PCR System (Roche). After conformation of correct PCR 
amplification of the product by agarose gel electrophoresis and EtBr visualisation, the 
whole PCR product was purified through PCR product purification columns (Stratagene). 
In order to clone the cleaned PCR product into the TA vector cloning vector, 
pGEMTEasy (Promega), the addition of Adenosine overhangs was first required, see 
Materials and Methods section 2.1.8. The pGEM ligation reaction was incubated 
overnight at 4 °C, and then an aliquot was transformed into chemically competent E. coli 
cells. The confirmation of colonies containing the correct Narl to EcoRI insert was 
carried out by plasmid DNA digestion of the pGEM clones using the Narl and Spel 
restriction enzymes.
This vector containing the pNL4.3 PCR derived fragment in the TA vector provided the 
backbone sequence for the introduction of restriction sites to facilitate the removal of the 
protease and RT genes.
4.2.1 Insertion of restriction sites in gag, Protease and RT
Analysis of the HIV sequence was carried out using Vector NTi (Invitrogen) to identify 
potential restriction sites that could be added at the junction of the protease and RT 
sequences, as native restriction sites that flanked these genes were not present. A Narl 
restriction site located 15 lbp from the ATG start of gag was to be utilised for the 
restriction endonuclease removal at the N-terminus of gag. The criteria for the selection 
of suitable restriction sites were primarily their absence in the HIV coding sequence of 
the vector pNL4.3. Also required was the ability to incorporate the site without changing 
the subsequent amino acid sequence i.e. silent or synomonous changes 
Once suitable sites were identified their introduction in the HIV sequence contained 
within pGEM-Spe-EcoR was carried out using the Quick-Change mutagenesis kit
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(Stratagene). The addition of each restriction site required was carried out sequentially 
and involved: (see Table 4.1)
(i) Quick Change mutagenesis
(ii) transformation in E.coli and growth of selected clones
(iii) preparation of plasmid DNA from the picked clones
(iv) restriction enzyme digestion with the mutationally inserted restriction 
endonuclease and EcoRI; which is only present once in the pNL4.3 vector and 
thus, confirms the presence of mutation by production a double band upon 
EtBr visualisation.
The pGEM clone containing HIV Narl to EcoRI fragment with the Pvul, SexAI and Xmal 
restriction site was called pGEM(P+S+X).
The mutagenesis protocol utilises a high fidelity polymerase. Although these enzymes 
have demonstrated very low error rates compared to other polymerases, it was still 
thought necessary to adopt a cloning strategy that minimised the regions exposed to the 
mutagenesis system. This was overcome by transferring the smallest sized fragments 
possible through use of native restriction sites, into vectors that had not undergone 
mutagenesis. Thus, only the fragments that were cloned into the vector had been created 
by mutagenesis and were the only regions that required DNA sequencing.
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Figure 4.1(a): Construction of pNL4.3+PSX (a) mutagenesis required for insertion of 
restriction sites..
£ 4 7 7  p 4 7 8 j4 7 9 j- j4 8 0 j^ 4 8 l£ 4 8 2
A46 D47 R48 Q49 G50 (p6  POL)
WT gaacagggacttgaaagc WT gag ccg ata gac aag gaa
i  i  i
MT gaacagggtctagaaagc MT gag ccg ate gac aag gaa
Xbal Pvul
L12 K 13 P 14G 15M 16D 17 (RT) C56 S57 P58 G59 I60 W61 (INT)
WT tta aag cca gga atg gat WT tgt age cca gga ata tgg
i  I  i  1
MT tta aaa cca ggt atg gat MT tgt age ccc ggg ata tgg
SexAl Xmal
Figure 4.1(b): Construction of pNL4.3+PSX, exploded view of restriction sites around 
the ampicillin gene in pNL4.3. Numbers in parenthesis indicate base pair position in the 
molecular clone pNL4.3.
Pvul (12722) Zra I  (13274)
Narl (13575)
B gll (13590)
3’LTR
Nef B gll (12472)
Pvul I  (13618)
cellular genomic sequence Amp-r
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Table 4.1: Oligos used for mutagenesis
Mutagenesis
site
Oligo Name Oligo Sequence (5'—>3')
Xbal GAG-Xfo-FWD GCCCGAACAGGGTCTAGAAAGCGAAAGTAA
GAG-Xba-KEV TTACTTTCGCTTTCTAGACCCTGTTCGGGC
Pvul Pvu- 1-FWD GAAGCAGGAGCCGATCGACAAGGAACTGTA
Pvu-1 -Rev TACAGTTCCTTGTCGATCGGCTCCTGCTTC
Sex AI &x4-FWD CCAGTAAAATTAAAACCAGGTATGGATGGC
SexA-REV GCCATCCATACCTGGTTTTAATTTTACTGG
Xmal S.9\Xma-EWD GACTGTAGCCCCGGGATATGGCAGCTAGATTG
S.9\Xma-REV CAATCTAGCTGCCATATCCCGGGGCTACAGTC
(■-)PvuI 
AmpR
Blac-Pvw-FWD CTCCTTCGGTCCTCCTATCGTTGTCAGAAGTA
Blac-Pvw-REV TACTTCTGACAACGATAGGAGGACCGAAGGAG
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4.2.2 Removal of Inherent Restriction Sites N arl and Pvul from pNL4.3
As previously mentioned the existence of sites in the wild-type pNL4.3 HIV coding 
sequence was of primary concern, however, their presence in the coding or non-coding 
regions outside the HIV sequence did not exclude their selection.
The restriction site for Pvul was to be utilised for the excision of the C-terminal region 
gag. This site was also found to be present in the ampicillin resistance gene located in the 
pNL4.3 vector (see Figure 4.1b). To remove this site required the insertion of a silent 
change that would abolish the Pvul site, but retain the amino acid sequence. This was 
carried out with the Blac primer pair, see Table 4.1. Analysis of transformed E.coli 
colonies by Pvul and EcoRI digestion in correct clones produced a double band upon 
EtBr visualisation in the Pvul abolished clones. In those clones where the Pvul site 
remained, a triplet was produced, as another Pvul site is present in a non-coding region, 
located at base position 13618. A second single-cutter, Bgll was also used in conjunction 
with EcoRI to confirm the removal of the Pvul site in the ampicillin gene. To ensure no 
spurious mutations were introduced after PCR mutagenesis, a Bgll fragment from a clone 
containing the removed Pvul site was cloned back into pNL4.3 to create the plasmid 
pNL4.3-Pvw. This plasmid was then subjected to restriction digest with the enzymes Zral 
and Pvul to remove a 346 bp fragment, which also contained a Narl restriction site. After 
gel purification the correctly digested plasmid molecules now contain protruding 3 ’ 
overhangs from Pvul digestion and blunt ends from Zral endonuclease action. The 3’ 
overhangs were removed by treatment with Pyrococcus furiosus (Pfu) DNA polymerase, 
(Stratagene), which possesses 3 '—>5' exonuclease activity. Thus, leaving a molecule with 
two blunt ends which were ligated together, creating the plasmid pNL4.3 (-Pvu+Nar).
Sub-cloning of the 4.2kb Spel and EcoRI fragment which contained the inserted 
restriction sites Pvul, SexAI and Xmal from the pGEM-Spe-EcoR vector into pNL4.3(- 
Pvu+Nar) produced the molecular clone pNL4.3-PSX.
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4.2.3 DNA sequencing of pNL4.3-PSX
DNA sequencing was carried out on the 4.2kb Spel and EcoRI fragment which had 
undergone mutagenesis, to confirm the presence of the Pvul, SexAI and Xm al restriction 
sites and to verify no other errors were present. DNA sequencing was also carried out on 
the Bgll fragment inserted from pNL4.3-Pvu to eliminate the Pvul site in the ampicillin 
resistance gene.
The following primers were used to verify the sequence of the clone pNL4.3+PSX.
3' pos: 13985; and 5Amp-r were used for sequencing the ampicillin gene. 5'5g/.seq and 
yBgl.stq  were used for sequencing the Bgll fragment cloned back into pNL4.3. The 
following primers were used for sequencing the Spel and EcoRI fragment that contained 
the three inserted restriction sites. The positions on the primers names are reference to 
their respective positions in the parental vector pNL4.3; pos: 1104, pos: 1620, pos: 2122, 
pos: 2619, pos: 3102, pos: 3687, pos: 4150, pos: 4644, pos: 5071 and pos: 1104(rev), see 
Materials and Methods Table 2.1.
4.2.4 Addition of Xbal site to produce pNL4.3X-PSX
In order to generate viruses with the gag region derived from alternative sources required 
the utilisation of the N-terminal Narl site. Several approaches were tired to overcome the 
problem of cloning with this restriction enzyme. Although fragments could be correctly 
digested through the use of a modified enzyme, Turbo Narl (Promega), the major 
obstacle proved to be the ligation into the recombinant vector pNL4.3-PSX.
After several attempts with the modified enzyme and the use of an alternative enzyme 
KasI, which recognised the same restriction enzyme sequence, it was decided to 
introduce a new restriction site at the N-terminus of gag. Sequence analysis identified a 
possible Xbal site located upstream of the Narl site, 137 bp from the ATG start of gag. 
Mutagenesis on the pNL4.3-PSX vector and subsequent selection of Xbal containing 
clones was carried as described in Materials and Methods section 2.1.8. The oligos used 
for the mutagenesis are shown in Table 4.1.
Once a correct clone was identified, both this and the pNL4.3-PSX vector were digested 
with BstTAlX releasing a 3.8kb blunt-ended fragment. This fragment from the Xbal
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containing clone was blunt-ended ligated into the BstZXIX cut pNL4.3-PSX vector and 
transformed into E.coli. The identification of clones containing the required Xbal site was 
achieved through Xbal and EcoRI restriction digest analysis and the clone displaying the 
correct restriction digest pattern was called pNL4.3X-PSX.
4.2.5 DNA sequencing of pNL4.3X-PSX
To confirm the presence of the site and also to ensure that no other mutations were 
inadvertently incorporated, the whole BstZXIX fragment in pNL4.3X-PSX vector was 
sequenced. In addition to the primers previously mentioned in section 4.2.3, the following 
primers were used for sequencing the BstZXIX fragment that contained the Xbal 
restriction site; AS3LTR, AS GAG 5A, Gag 3, Gag SE3, 5'Amp-r, 5'Z?g/.seq and 
3'Rg/.seq, see Materials and Methods Table 2.1.
Alignments for sequences after the removal of Narl and Pvul sites are shown in Figure 
4.2.
The construction of the pNL4.3X-PSX vector produced a molecular clone in which the 
individual gene products gag, protease and RT could be removed by restriction enzyme 
digestion. Removal of the gag gene was accomplished by Xbal and Pvul digestion; the 
protease was excised by Pvul and SexAI digestion and removal of RT utilised the SexAI 
and Xmal sites. Combinations of genes could also be removed through correct restriction 
enzyme digest, allowing the insertion of linked gag, protease and RT genes from an 
alternative source. (See Figure 4.3)
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Figure 4.2: Sequence alignment of pNL4.3+PSX clones 8 (C8 ) and 15(C 15) against 
pNL4.3; removal of 346bp fragment containing Narl and Pvul sites.
Zra 1 
▼
C8 -  p N L + P S X  T A TT TA G  AAAAATAAAC AAATAGGGGTT C CG CGC A C A T T T  C C C CGAAAAGTG C CAC CTG A
C 1 5 -p N L + P S X  TATTTAG AAA A A TA A A C A A A TA G G G G TTC C G C G C A C A TTTC C C C G A A A A G TG C C A C C TG A
p N L 4  . 3 TA TTTAG AAAA ATAAA CAAATA G G G G TTC CG CG C A C A T TT C  CC CGAAAAGTG C CACCTGA
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
C 8 -p N L + P S X  C --------------------------------------------------------------------------------------------------------------------------------------------------------
C 1 5 -p N L + P S X  C --------------------------------------------------------------------------------------------------------------------------------------------------------
p N L 4  . 3 C G TC TA A G A A A C C A TTA TTA TC A TG A C A TTA A C C TA TA A A A A TA G G C G TA TC A C G A G G C C
*
C 8 -p N L + P S X  ---------------------------------------------------------------------------------------------------------------------------------------------------------
C 1 5 -p N L + P S X  ---------------------------------------------------------------------------------------------------------------------------------------------------------
p N L 4  . 3 C TTTC G TCTCG CG CG TTTCG G TG ATG ACG G TG AAAACCTCTG ACA CATG CAG CTCCCG G A
C 8 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
C 1 5 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
p N L 4  . 3 GACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTC
C 8 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
C 1 5 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
p N L 4  . 3 AGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACT
C 8 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
C 1 5 -p N L + P S X  --------------------------------------------------------------------------------------------------------------------------------------------------------
p N L 4  . 3 GAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCAT
Nar 1 Pvu 1
T T
C8 -p N L + P S X  ------------------------------------------------------------------------------------------------------------------------CGGTGCGGGCCTC
C 1 5 -p N L + P S X  ----------------------------------------------------------------------------------------------------------------------- CGGTGCGGGCCTC
p N L 4 . 3  CAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTC
★ ★★★★★★★★★★★■A-
C 8 -p N L + P S X  TTCGCTATTACGCCAGGGGAGGCAGAGATTGCAGTAAGCTGAGATCGCA
C 1 5 -p N L + P S X  TTCGCTATTACGCCAGGGGAGGCAGAGATTGCAGTAAGCTGAGATCGCA
p N L 4 . 3  TTCGCTATTACGCCAGGGGAGGCAGAGATTGCAGTAAGCTGAGATCGCA
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
147
Gag
X bal (653)
5'-LTR
N arl (639)
Gag
B stZ iyl (13551) 
Amp-r
Bgtl (12481) ✓
X b a l (653)
Spel (1508)
pNL4.3-XPSX
14487 bp
3'-LTR
PvuI (2226)
P rotease
SexAI (2589) 
SsfZ i7l (2930) 
RT 
Pol
Xm al (4402)
\ IntegraseEco RI (5744)
ENV
X b a  I (653)
1670 bp
Gag+Protease
Gag
1943  b p
Gag+Protease+RT
P ro tease
Gag P vu  1 (2226) Sear Al (2589)
P v u l (2226)
Pvul (2226)
Protease
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Figure 4.3: Schematic of the vector pNL4.3X-PSX. Restriction sites used to excise regions and size of fragments generated are also 
illustrated.
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4.2.6 Production of Virus stocks
Large DNA stock preparations (maxi preps, Materials and Methods section 2.1.6) were 
made of the constructed molecular clones, pNL4.3-PSX and pNL4.3X-PSX along with 
the parental pNL4.3 clone and HIV molecular clone pHXB2D. These DNA stocks were 
used to transfect MT-4 and HEK 293T cells as outlined in Materials and Methods section 
2.4.2 and transfected viruses were maintained and cultured to produce transfected virus 
stocks; see Materials and Methods section 2.4.
All the molecular clones that were transfected produced detectable virus as determined by 
the presence of cytopathic effect (CPE), between 7-10 days post-transfection. After the 
full CPE was observed the virus was harvested (Materials and Methods section 2.4) and 
the infected cell pellet DNA was extracted (Materials and Methods section 2.4.1). A 
region covering the gag and Pol domains was PCR amplified from the infected cell pellet 
and DNA sequencing was carried out. The sequence data confirmed the presence of the 
inserted restriction sites and homogenous nucleotide peaks were seen at these locations. 
The details of these techniques are given in the Materials and Methods section 2.1.13.
4.2.7 Virus Titre and Antiviral Sensitivity Determinations
The amount of infectious virus present in the prepared MT-4 virus stocks, NL4.3-PSX, 
NL4.3X-PSX, NL4.3 and HXB2 was determined using the MTT Titration Assay as 
described in Materials and Methods section 2.5.1.
Figure 4.4 shows the titration curves for the transfected virus stocks from a minimum of 
six independent assays and each assay contains four replicates. All the harvested 
molecular clone stocks produced similar amounts of infectious virus in the range of 9000 
to 20000 TCID5o/m l of cell free supernatant. The calculated T C ID so/m l was used to 
determine the virus input for the MTT Antiviral Assay which was used to measure the 
sensitivity of the virus stocks to antiviral inhibitors. The details of the assay are outlined 
in the Materials and Methods section 2.5.3.
In order to ensure both pNL4.3X-PSX and pNL4.3-PSX vectors did not show altered 
sensitivity to antiretroviral drugs, MTT antiviral assays were carried out, see Materials
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and Methods section 2.5.3. Figure 4.5 shows the IC50 values obtained for both viruses 
derived from pNL4.3X-PSX and the parental vector pNL4.3, in four Pis that are currently 
licensed. Several other stocks o f different antiretrovirals were ordered from NIH, but 
failed to show any antiviral activity. Two different stocks of 3TC were ordered from the 
NIH, neither of these lots demonstrated any antiviral activity in several MTT assay 
determinations. The antiviral assays for the Pis SQV, APV and NLF were repeated on 
five separate occasions and demonstrate almost identical IC50 values in three out of the 
five assays. The two other assays in this data set show a less than 2-fold difference in the 
ICso’s over the three Pis tested and also appear to have elevated ICso’s compared to the 
other three assays. A less than 2-fold variation was seen in three out of the five assays 
with SQV, IDV and APV.
The fourth chart in Figure 4.5 represents the IC50 values obtained for three independent 
IDV antiviral assays. The NL4.3X-PSX virus stock demonstrates a 2-fold increase in IC50 
compared to the parental virus NL4.3 and variation across the 3 assays also shows a 2- 
fold deviation.
The sensitivity of the virus stocks to the RT inhibitor AZT was also investigated and the 
percentage protection afforded by increasing AZT concentration is shown in Figure 4.6. 
Two separate assays were performed and X-PSX virus demonstrates slightly lower IC50 
values in both assays compared to the NL4.3 virus stock. A difference of 19nM and 8nM 
was seen between the two virus stocks over the two assays and the overall variation 
between assays was less than 2-fold.
The double amino acid SQV resistance mutant, G48V+L90M virus stock was used as a 
control for the antiviral assay, to demonstrate an increase in IC50 to SQV. The growth of 
this virus stock was carried out as outlined in the Materials and Methods section 2.4. This 
mutant contains a double mutation which has previously been reported to confer 
approximately 40-fold resistance to SQV 20,144. The assay demonstrates a >30-fold 
increase in resistance to SQV of the double mutant compared to wild-type, with ICso’s of 
200nM and 6nM respectively. The ICso’s to the other two compounds AZT and APV 
were much more similar for the mutant and wild-type viruses; 33nM and 36nM for AZT 
and 80nM and 57nM for APV. A slight decrease in sensitivity to APV can be seen with
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the SQV mutant, but this is less than 1-fold and so is within the error rate for the assay 
(Figure 4.7).
4.2.8 GHOST assays
An alternative assay system was also employed to determine the amount of virus present 
in the harvested viral supernatant stocks. This method involved the use of a reporter cell 
line, containing the green fluorescent protein (GFP). The GFP gene is under the control 
of a HIV-2 LTR; infection with HIV results in the production of the Tat protein’ which in
217turn induces GFP expression . The correct plating density was represented by the 
plating density that resulted in a confluent layer of cells in each well o f the 24 well plate 
on the day of FACS analysis, see Table 4.2 below. After 24 hours incubation only the 
highest cell density plate showed a full confluency level, further 24 hours incubation 
resulted in the next highest cell density also displaying 100% confluency. The two lowest 
cell densities remained sub-confluent even after 48 hours incubation.
Table 4.2: Plating density and confluency as visualised by light microscopy.
Cell Density 
per Well
Percentage Confluency
24Hr 48Hr
1.25xl04 30% 50%
2.5x104 50% 75%
5xl04 80% 100%
lxlO5 100% 100%
The infectivity of the virus stocks was measured using FACS to detect for the expression 
of the GFP by infected cells. The amount of green fluorescent events detected was used 
to measure the number of infected cells. At 24 hours post infection the highest number of 
infected cells was detected in the 50,000 cells per well plate, at the highest concentration 
of virus (see Figure 4.8). This was one of the intermediate plating densities used and also 
produced the highest percentage of infected cells at 48 hours. The lower plating densities 
suffered from increased cell death due to the virus killing at high virus concentrations, as
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a consequence not enough events were counted during FACS and this skewed the data in 
the 48hrs experiment.
To determine the amount of virus present in the harvested cell-free supernatant stock the 
number of infected units per ml was calculated as described in Chapter 2 Materials and 
Methods section 2.5.2. Two independent experiments were used to calculate the titre of 
the NL4.3 virus stock are shown in Figure 4.9. The bars represent the number of infected 
cells as determined from the percentage infectivity, the line represents the calculated 
number of infected cells per ml or the titre/ml. Both the two highest virus dilutions were 
used to calculate the titre of the virus stock as these gave the most consistent percentage 
infections over the two experiments. The calculated titre and the standard error of the 
calculation are shown in Figure 4.9 in the inset. The titres calculated by both MTT assay 
and GHOST cell titration are almost identical and suggest a TCIDso/ml of 2000 ±287 or 
number of infectious particles per ml of 2330 ±373.
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Figure 4.4: Titration curves of virus stocks of vector constructs and molecular 
clones. Error bars indicate Standard error over a range of values obtained from a 
minimum of 6 independent experiments.
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Figure 4.5: Repeat IC50 values for X-PSX and NL4.3. X-PSX (blue) and NL4.3 (red), shown are results for asays against four 
separate Pis. n=5 (SQV, AMP, and NLF); n=3 for IDV.
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Figure 4.6: AZT Drug Sensitivity Assays. Assays carried out on two separate occasions 
with X-PSX and NL4.3. Error bars indicate the ranges of values obtained from 
quadruplicate data points in a single experiment.
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Figure 4.7: Comparison of IC50’s for HXB2 and SQV resistant virus G48V+L90M 
in SQV, AZT and APV.
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4.3 Discussion
The use of recombinant virus systems to establish the phenotype of viruses isolated 
from patients on therapy has become a valuable tool in deciding the effectiveness of 
antiviral regimens and to decide if  a switch in inhibitor is required. ’ ’ . The
generation of recombinant viruses containing patient virus derived protease and RT 
regions has been the primary focus o f research to date, as these proteins are the direct 
targets of all but one o f the FDA approved inhibitors 55’249’329. As the protease 
interacts with its substrate Gag, through stenc processes and both open reading 
frames are produced by the highly error prone HIV RT, the potential for the substrate 
to acquire and select for mutations in response to environmental pressures is highly 
likely. Thus, this necessitates a requirement to include the gag region in RVAs. Such 
a need has also been demonstrated by several research groups, which have shown that 
the Gag protein plays an essential role in the restoration o f replication in PI resistant 
viruses ,60’281’327. The C-terminal peptide o f the Gag polyprotein, p6 may also play a 
role in the resistance to NNRTIs 256.
The examination o f patient derived virus phenotype through RVA has also used the 
virus genotypic pool present in the patient plasma, to derive the recombinant virus 
from. While this approach represents the viral heterogeneity present in individuals 
with an infection post-seroconversion, the majority sequence derived genotype, may 
not accurately represent the phenotype due to contributions from minority 
quasispecies. Such effects may lead to the generation o f recombinants and could 
result in the appearance o f low level quasispecies which contribute to the growth 
characteristics or antiviral resistance o f the virus pool, possibly leading to inaccurate 
phenotype-genotype correlations. These systems are also limited in relating the 
significance of linkage between gene products, again due to the heterogeneity and 
recombination potential.
The previous chapter detailed the use of a pseudotyped transfection system that was 
able to incorporate the gag gene from an alternative source and produce a 
recombinant virus capable only of a single round of replication. This system was only 
able to detect infectious virus in only one recombinant constructed from a patient-
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derived virus isolate and also produced a low level wild-type recombinant and was 
therefore considered o f limited use. A further limitation o f this system was that only 
the first 60 amino acids o f protease could be cloned into the Gag-Pol expression 
vector along with the associated gag, as the only available restriction site was located 
within the protease coding region. Therefore, it was decided to develop a replication 
competent virus vector in which single or multiple gene products could be replaced 
and used to generate replication competent virus, with aims o f replacing the gag, 
protease and RT with those from HIV positive, antiviral treated patients.
In order to construct this vector and to minimise the amount o f sequencing required 
for confirmation o f the vector construction, a cloning strategy was implemented as 
opposed to direct mutagenesis o f an existing vector. If  direct mutagenesis were 
carried out to insert restriction sites, the whole vector would require sequencing to 
confirm that no other errors had been inadvertently acquired through polymerase error 
during the mutagenesis reactions. Using the cloning approach would only require 
sequence confirmation of the gag and polymerase regions, (3.8 kb) instead of the 
entire viral genome.
Production of the molecular clone involved several cloning steps in which the whole 
14.8kb vector was manipulated. Each of the cloning steps required meticulous 
optimization o f ligation and transformation conditions in order to construct each of 
the vectors used in the construction of the molecular clone pNL4.3-PSX. In order to 
utilise this vector ‘entirely’ required cloning into the Narl site, located 15 lbp from the
11 f tgag start and present in most HIV clades, except for clade F . Another advantage of 
using the Narl site was that it included the Gag packaging loops, this region of HIV 
sequence; which in NL4.3 is the 107bp upstream of the gag start, may play an 
important role in evaluating replication capacity of any recombinants, as this region 
interacts with NC to effectively package the HIV genome 63131. However, removing a 
Narl fragment and ligating it back into the pNL4.3-PSX vector was very inefficient, 
with only two correctly ligated clones selected from >500 colonies screened. Several 
different approaches were adopted to try and overcome the problem of Narl cloning 
such as different ligation kits, restriction enzyme reaction components, BSA, enzymes 
suppliers and reaction buffers. An alternative enzyme KasI, which is an isoschizomer 
of Narl was also utilised, but proved to be just as inefficient. The addition of the Xbal
160
site 14 bp upstream o f the Narl site, was positioned such that it included the Gag 
packing loops. It was hoped this would be easier to clone into, as Narl has been 
shown to demonstrate marked site preferences. For example on pBR322, the Narl site 
at 548 bp is cut very slowly (New England Biolabs product information sheet).
The DNA stocks that were made o f the completed cloning vectors were used to 
produce replication competent virus stocks, by transfecting into the HTLV-I 
transformed T-cell line, MT-4. The virus stocks were made primarily to test for any 
deleterious effects o f the synonymous mutations inserted during the production of the 
restriction sites. All the DNA stocks transfected produced CPE, detected by light 
microscopy, within similar time periods from transfection initiation. The viral 
infectivity was determined by titration o f the cell free supernatant, which showed that 
all stocks produced similar levels o f infectious virus. This would suggest that the 
mutations inserted do not affect the growth and replication ability of the viruses. This 
is to be expected, as all the changes introduced were non-coding and would not cause 
any structural or functional changes to the enzyme. However, it has been recently 
demonstrated that even synonymous changes can have a substantial impact on virion 
production. Such an effect has been reported with an A —>G change in the gag NC 
coding sequence 128, resulting in a virus that produced normal protein and DNA levels 
compared to a virus without the A—>G change. The drastic effect of the synonymous 
change was only evident by the lack of any detectable virion production and viral 
RNA in the cell-free supernatant.
The comparable growth rates seen during production of the viral stocks and their 
equivalent titres obtained after serial dilution o f the stocks, suggests that productive 
infection rate i.e. the rate o f infection, virion production and re-infection, is similar. 
As each viral clone was transfected with the same number o f cells and these were 
maintained with equivalent amounts o f cells and fresh media and the virus stocks 
were harvested in the same overall volume. Each assay was conducted a minimum of 
six times and produced TCID50 values all within 2-fold of each other (Figure 4.4). 
This level of variation is to be expected from a cell based assay, especially 
considering there is a five day incubation period in which any differences in cell 
plating number between assays can be amplified. The titration value obtained from 
this assay is primarily used to equalise the amount o f virus supernatant used to infect 
cells for the antiviral assay. This assay system utilises the same cells and plate format
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as the titration assay and thus provides a complementary system for the analysis of 
inhibitor sensitivity. This complementarity was seen in the similar IC50 values 
obtained from the antiviral assays against Pis and AZT (Figures 5 and 6 ). Although 
most of the assays with the same virus stock were within a 2 -fold range, two sets of 
assays displayed higher IC5 0S. This was consistent for all the Pis, as the assays 
numbered three and four with SQV, NLF and APV were carried out with the IDV 
assays numbered one and two. This increase in IC5 0 , means that more antiviral was 
required to inhibit the viruses and could be possible if  the antiviral stocks were too 
dilute e.g. through pipetting error. However this is unlikely as it occurred in all the Pis 
and over two separate assays, during which fresh stocks were made from the 
concentrated stock solutions. Another, more likely possibility, is that because the end­
point measurement in this system is cell viability; as measured by the conversion of
251the tetrazolium compound to a formazan compound by viable cells , any increased 
IC50 could represent poor cell growth over the course o f the assays this may occur 
after cells have been cultured for long periods. This would be detected as less 
formazan conversion, which has the same effect as increased cell death. Elevated 
ICso’s could also be attributed to a low initial cell number in the assays, through 
inaccurate cell count or through too much virus added initially.
The X-PSX virus appears to show a consistent increase in resistance to IDV, as is 
shown in Figure 4.5. It is possible that these differences in IC50 values may reflect 
possible errors in the titration at the time o f these assays. The increase is nearly two­
fold, which is within the limits o f error expected for such cell based, replication
. . 257,272competent assays
The SexAI site was introduced in the N-terminal region o f RT and involved the 
insertion o f synonymous changes in codons 14 and 15 of this protein. Although 
neither o f these sites have been reported as being involved in resistance to RTFs 40, 
the activity of this class o f antiviral was also checked using AZT. The X-PSX virus 
and the control virus NL4.3 displayed similar sensitivity to this RTI. Figure 4.6 shows 
typical sigmoid curves generated when titrating the virus in escalating inhibitor 
concentrations. Again, the two separate assays are all within a two-fold range of each 
other, with a less than two-fold difference between the viruses in each assay. Some of 
the points within these assays appear to display greater than 100% values in terms of 
cell viability. This occurs in the wells o f the assay plates that contain high drug
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concentrations; the cells are initially incubated with the virus prior to plating out, the 
infected cells that are added to high drug concentration wells are afforded complete 
protection by the compound. The presence o f virus has previously been shown to 
induce growth proliferation in cells 135. In this system the high drug concentrations 
prevent further virus growth but do not affect the growth of the cells, which are in a 
more activated state due to the initial presence o f the virus and so, outgrow the 
uninfected cells in the cell-control, which is used as the 100% cell viability value.
To demonstrate the expected shift in drug sensitivity with a resistant virus genotype, 
the SQV double mutant, G48V+L90M was grown, titrated and assayed in MT-4 cells. 
The assays were carried out using the molecular clone HXB2 as the wild-type control, 
as the mutant virus was constructed by the RVA method, using a protease deleted 
HXB2 vector 202. Both viruses showed similar ICso’s for AZT, however in this assay 
the mutant also seemed to require a greater concentration of APV to inhibit growth of 
the virus by 50%. Neither o f the mutations G48 or L90M is thought to be involved 
with resistance to APV either in vitro or in vivo 40 135. This increase in IC50 of 23nM is 
more likely to reflect variation within the titration values calculated for viruses and 
results in altered M OI’s. The very low MOI o f this assay also means that virus input 
volumes can be low in this system especially with high titre viruses and thus, any 
errors could mean vastly different virus amounts. However, this error is still below the 
2-fold error o f such assay systems and was primarily carried out to demonstrate the 
shift in IC50 associated with resistance to SQV.
The MTT assay system determines the titre o f virus in the virus stock as the 
percentage o f cell viability i.e. the amount of supernatant required to kill 50% of the 
cells is the TCID50. The MTT assay is a cell based assay that relies on virus induced 
cell death as means to quantify virus content. In order to maintain consistency 
between assays, cells are routinely grown to similar cell densities and passaged. A day 
before assay use, the cell are split again in order to ensure actively dividing cells, 
which would reduce errors due to cell growth phase differences and ensure that cells 
are similarly infectable. Each MT-4 cell line is passaged a maximum of 25 times 
before a new line from frozen cell stocks is used to replace the old cells. As with all 
cell based assays other variability may occur such cell number between assays, slight 
volume differences and differing evaporation rates, which could be significant in an
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assay incubated for 5 days. This particular problem is reduced through the use o f low 
evaporation plates, which showed no significant difference in cell number in edge 
wells when plated at the same density and counted one week after plating (data not 
shown). Each virus grown is titred by serially diluting the virus on a 96 well plate, 
each well containing a constant number o f MT-4 cells. After the 5 day incubation 
period the cells are treated with MTT, which is metabolised by viable cells and causes 
a colour change which is measured using a spectrophotometer. The measurement of 
drug sensitivity is carried out in exactly the same format, with only two differences 
the first being the incubation o f the virus with the cells for 2 hours and ensure the 
virus amount is constant between wells, the infection is set-up in bulk and aliquoted 
into each well. The second difference is the addition o f the antiviral, which is serially 
diluted across the 96 well plate. This similarity between the determination of the 
amount o f virus in the stock and the drug sensitivity assay also help to ensure that 
variability due to assay format differences are reduced.
Each assay, both titration and IC50, are performed with a NL4.3 control, which over 
time accumulates several separate data determinations. To ensure assay 
reproducibility, all assays in which the determined values for the NL4.3 control show 
a greater than two-fold variation, are disregarded. However, it is an indirect measure 
of the amount o f virus present as no viral protein or target is used as the end-point 
measurement. For this reason an alternative method was explored for virus 
quantification. The GHOST cell-line contains the GFP gene linked to the HIV-2 LTR 
which is driven by Tat activation upon HIV infection and thus, is a direct measure of 
virus production. These cells are derived from Human Osteosarcoma (HOS) cells 
stably expressing CD4+ receptor and both CXCR4 or CCR5 coreceptor and are 
therefore able to support infection by HIV. The initial experiments in the development 
of a titration assay using this cell-line were designed to evaluate the best cell plating 
density and incubation periods to produce a reproducible infection, proportional to the 
amount o f virus added. The use o f this cell-line to measure infectivity and replication 
capacity o f drug-resistant HIV has been previously reported by several groups 19,299. 
These studies used this system to quantify the single-cycle infectivity o f viruses by 
measuring the amount o f GFP detected after 24hours infection, as the HIV generation 
time is thought to be between one to two days 5’254. The single-cycle infectivity of the
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NL43 virus was highest with the cell that density that showed approximately 80% 
confluency on the day o f FACS analysis.
The reproducibility o f the assay in measuring the amount o f infectious particles in the 
NL4.3 virus stock is shown in Figure 4.9. The two highest virus dilutions were used 
to calculate the number o f infectious units per ml as these values gave more 
significant percentage infection values than the lower virus dilutions. The NL4.3 virus 
stock was previously used in the MTT assay system for TCID50 determination and 
this system gave a titre o f 2 x l0 4 TCIDso/ml. The GHOST assay also gave a very 
similar titre for the same virus stock o f 2 .33xl04 infectious units/ml.
Stability o f mutations was confirmed by sequence analysis o f the areas covering the 
restriction sites; the presence o f the mutations after two to three weeks in cell culture 
confirmed the stability o f these mutations. If  these mutations had a detrimental effect 
on the virus population, then it would be expected that these would be lost overtime 
and a heterogeneous population would be seen in the chromatogram peaks associated 
with the restriction sites, however, this was not the case.
The development o f this restriction site cloning system has the disadvantage of 
requiring cloning o f the patient derived virus fragment into the vector; this has proved 
to be difficult and the construction o f virus isolated from patients is the subject of the 
next chapter. The advantage o f this system is that the subsequent transfection 
experiments involve a homogeneous population, ideal for looking at primary 
infection. Any difference seen from the input genotype must therefore be as a result of 
evolutionary selection and not due to the presence o f any other pre-existing species 
that is present as a minority. Increasing the diversity o f the input genome e.g. to allow 
for the examination o f growth o f a more complex heterogeneous system, would 
simply require the transfection o f several different clones. Recombinant clones 
generated using this system incorporate the whole gag region and the packaging 
signal from the sample source. It is hoped that the development of this vector will 
allow for the examination o f the effects o f mutations associated with HAART not 
only in the protease and RT coding regions but also in the gag gene and also any 
variation that occurs in the packaging loops.
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Although the aims o f this chapter were achieved, if  circumstances were ideal several 
other approaches would have been explored.
(i) Use o f restriction site other than Xbal that is less likely to occur in the HIV regions 
to be studied, although this had previously been used by other researchers as a 
cloning site in construction o f sim ilar replication competent vectors.
(ii) The cloning vector contained the wild-type genes which were to be substituted by 
the patient virus derived regions o f  interest, thus gel-purification o f the digested X- 
PSX vector was required in order to remove the wild-type region. The use of small 
oligonucleotide linkers which could have been ligated into the cut vector would 
abolish the need for an inefficient and time consuming approach as gel-purification, 
which also resulted in loss o f  30%-50% o f  vector DNA, (referenced from-Stratgene 
product insert).
(iii) Had more time been available a pseudotyped vector would have been developed, 
this approach, similar to that used in Chapter 2 would have been developed to 
complementary to the live vector used in the remainder o f the research. By this it is 
meant that, the X-PSX vector would have been used as a single cycle vector by either 
the deletion o f the envelope region or insertion o f a stop codon to truncate it. This 
could then be used with either a VSV-G envelope, such as the pMDG vector used in 
chapter 2, or the patient virus derived envelope could have been used to explore the 
effects o f envelope variation on phenotype. This would also expand the use of this 
system in that it could be used to determine sensitivity o f mutated envelopes to entry 
inhibitors.
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Chapter 5 Use of Live virus vector system for clinical 
isolates
5.1 Introduction
The assessment o f antiviral sensitivity o f patient derived viruses through the use of 
phenotypic assays provides a direct approach and enables a more accurate estimation 
o f the effect o f the genotype on antivirals, than genotypic assays. Phenotypic 
resistance testing using prim ary isolates has been previously reported and requires the 
co-cultivation o f HIV infected PB M C ’s with freshly isolated PBM C’s 145. These 
systems have the advantage o f culturing the whole viral genome, but involve long 
culture times and are labour intensive and so not suitable for routine assay use.
Phenotypic testing is now regularly performed using plasma derived virus PCR 
products that encompass the protease and RT coding regions. Systems which are 
based on using homologous recombination to construct the virus genome 136 or more
9 S7recently single cycle assay systems have been described
The use of Pis results in the appearance o f morphologically aberrant forms of HIV 
particles, which represent the blockage o f  cleavage o f the Gag polyprotein as
52determined through EM and analysis o f Gag cleavage patterns . The restoration of 
protease function has been shown to occur thorough the accumulation of resistance 
and compensatory mutations in both the protease and at the gag cleavage sites
84,223,230.292
The phenotypic sy stems that have been developed to date are unable to investigate the 
effects o f mutations in patient derived viruses across all three regions, gag, protease 
and RT, although some include the C-terminal portion o f gag 257,281.
Previously, a live virus vector was constructed which contained restriction sites that 
could be used to facilitate the introduction o f either single or multiple coding regions 
for gag, protease and RT. This chapter details the construction o f chimeric constructs 
which contain the aforem entioned coding regions derived from patient virus that had 
prior exposure to antiretroviral therapy. Several constructs were made and used to 
generate recombinant virus stocks, which were tested for resistance to a panel of FDA
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approved compounds. The ability o f some o f the clonal HIV recombinant genomes to 
maintain the introduced sequence in the absence o f drug pressure was also studied.
Specific Aims and Questions
The specific aim o f this chapter was to demonstrate that the addition o f gag along 
with the highly resistant protease, affects phenotypic drug sensitivity determinations 
and therefore, should be routinely considered when such assays are undertaken to 
determine the effectiveness o f a particular drug regimen, especially when there has 
been extensive prior exposure to Pis . The chosen approach utilises a single genotype, 
which demonstrates that the mutations shown in the gag and protease regions are 
linked on a single genome and so are more likely to co-exist.
I. Demonstrate the use o f the cloning system in the development of 
recombinants clones, containing single and multiple inserts o f gag, protease 
and RT, derived from patient isolated virus.
II. Production o f high titre virus stocks from patient virus clones 
III. Assessment o f phenotypic resistance
5.2 Results
5.2.1 Amplification of gag , protease and RT coding regions from 
Patient isolated virus
Patient samples that were previously identified in Chapter 3 were used to construct 
the recombinant virus clones. The previous antiviral exposure history, mutations in 
protease and RT and viral loadof the isolates are also shown in Chapter 3 Table 3.1. 
Two approaches were used to generate the replication competent recombinant HIV 
clones from the patient derived viral RNA. The first was to amplify PCR products 
with primers that contained the appropriate restriction sites from the patient derived 
viral cDNA and directly clone into the pNL4.3-PSX vector. The PCR primers 
conditions were optimised for subtype B, pNL4.3, as most o f the samples were of this 
subtype. However, patient virus 2 was classified as subtype C based on protease and 
RT sequence and the protease region o f patient virus 1, which was classified as 
subtype D. Also the position o f the oligo’s was determined by the position of the 
restriction enzyme sites at the junction o f the coding regions o f gag, protease and RT,
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therefore there was very little possibility for variation, with respect to position. The 
only variables that could be modified and may have resulted in an increased number 
of samples being PCR positive were M g2+ concentration and the annealing 
temperature o f the oligos. The use o f longer and thus more stringent oligo was not 
undertaken as amplicons had already been generated in order to demonstrate the 
cloning required to produce chimeras o f  the gag, protease and RT coding regions, 
either separately or in combination.
To generate the gag  only fragment the prim er set 5 ’Gag-Afar7 and 3 ’Gag-Pvw/ was 
used, which produced a PCR product o f 1612 bp. The gag and protease fragment 
required the prim er set 5 ’Gag-Atar7 and W ro -S exA l  and generated a 1976 bp 
amplicon. The protease only amplicon o f 390 bp was produced with the primer set 
5 ’Gag-Pvul and 3 ’ Pro SexAl. The protease and RT region was amplified with 
5’Gag-/Vw7 and 3 ’Integrase-Xma7, which produced a 2202 bp amplicon.
As mentioned previously, the lack o f success in cloning the gag fragment into 
pNL4.3-PSX was attributable to the N arl restriction site and the inability to 
successfully ligate into it. This obstacle prevented the construction o f clones contain 
the gag region derived from alternative sources. Despite this, several clones were 
produced from ligating into the first molecular construct, pNL4.3-PSX. The eventual 
production o f the pNL4.3X-PSX cloning vector allowed the incorporation o f gag 
through the introduction o f an X bal site at its N-terminus. To amplify any fragment 
for cloning the gag  region was now carried out with the primer 5’Gag-XZ?a/, resulting 
in amplicons lObp shorter than those produced with 5 ’Gag-7Var7.
5.2.2 Production of Recombinant Clones
After production o f the patient derived virus recombinants, the sequences o f clones 
and the HIV coding region was analyzed by DNA sequencing. The details of these 
techniques are given in the M aterials and Methods section 2.1.13. Clones that 
contained the desired m utational patterns were assigned the following nomenclature, 
Pt (Patient) num ber (1-5), followed by the region (P) protease; (PR) protease and RT), 
then follwed by the clone number.
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5.2.2a Protease and RT clones
Production o f these clones was by direct amplification from cDNA the details are 
given in the M aterials and M ethods sections 2.1.15 and 2.1.10, using the high fidelity 
Phusion Polymerase (Finnzymes) and then ligation into the Pvul and Xmal digested 
pNL4.3-PSX. Only two patient derived virus samples produced an amplicon with 
these PCR conditions, virus derived from patients 1 and 5. These two samples that 
were also those with the highest viral loads, which implies that the PCR with these 
oligos was inefficient and required further optimisation. Several pNL4.3-PSX patient 
virus clones were isolated that upon PCR amplification with gag and RT primers, 
located within the vector pNL4.3-PSX produced amplicons. These were gel purified 
and the protease coding region sequenced as outlined in the Materials and Methods 
section 2.1.13.
A total o f six clones containing the protease and RT coding regions derived from 
patient virus samples 1 and 5 were produced ; 4 from patient 1 derived virus 
(Ptl(PR)-C4, C6, C7, C l2) and 2 from patient 5 derived virus (Pt5(PR)-C25 and 
C23). Figure 5.1a shows the protease alignment o f the clones from both patient 
derived virus samples aligned with pNL4.3-PSX. Both virus clones from patient 5 
were identical in amino acid sequence and showed 5 changes from pNL4.3-PSX, 
these were a L10V, T12V, I I 3V, L63P and 164V.
A total o f four recom binant clones were produced from virus derived from patient 
sample 1 with all but one o f the clones showing identical amino acid sequence across 
the protease region. The only diverse clone contained an additional K20R mutation, 
but was otherwise identical to the other clones generated. The proteases from patient 1 
derived virus all contained a two amino acid insertion at codon 35, composed of a 
Glutamine and an Asparagine. In all fourteen amino acid changes were seen in these 
clones compared to the parental clone pNL4.3-PSX. The changes detected were 
L10V, I I 3V L24I, L33F, M36L, M46I, I54V, K55R, R57K, I62V, L63P, I64V, L76V 
and V82A.
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5.2.2b Patient Derived Virus Protease clones
As with the protease and RT clones the amplicons for cloning directly into pNL4.3- 
PSX were generated from the cDNA and cloned into the Pvul and SexAI digested 
vector. These ligations proved to be the most efficient, with a 95% of clones selected 
(19 out o f 20) containing the protease region as determined by PCR amplification 
across the cloning junction, with primers that annealed in gag and RT regions (see 
Materials and M ethods section 2.1.9 and Table 2.1). A total of six clones were 
analysed by DNA sequence analysis and the alignment o f the amino acid sequence of 
the protease is shown in Figure 5.1b. All clones selected except one demonstrated 
complete sequence hom ology with each other, as they did with the protease and RT 
clones, clone 6 o f this latter group, contained the K20R mutation.
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Figure 5.1a: Alignment of the protease region from protease and RT clones. Clones obtained 
from both patient derived virus samples 1 and 5, the shaded codons represent changes from 
pNL4.3-PSX
P t l ( P R ) - C 4  
P t l ( P R ) - C 6  
P t l ( P R ) - C 7  
P t l ( P R ) - C 1 2  
P t 5 ( P R ) - C 2 3  
P t 5 ( P R ) - C 2 5  
p N L -P S X  
C l u s t a l  C o
P Q IT L W Q R P V  
P Q IT L W Q R P V  
P Q IT L W Q R P V  
P Q IT L W Q R P V  
P Q IT L W Q R P V  
P Q IT L W Q R P V  
P Q IT L W Q R P L  
* * * * * * * * *  .
1 5
V T V K IG G Q L K  
V T V K IG G Q L R  
V T V K IG G Q L K  
V T V K IG G Q L K  
W V K IG G Q L K  
W V K IG G Q L K  
V T IK IG G Q L K  
*  • . * * ★ * * * .
2 5
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L L D T G A D D
E A L L D T G A D D
E A L L D T G A D D
3 5
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V L E E - - M N LPG  
T V L E E - -M N L P G  
T V L E E - -M N L P G
4 5
R W K P K IIG G I
R W K P K J IG G I
R W K P K IIG G I
R W K P K IIG G I
R W K P K M IG G I
R W K P K M IG G I
R W K P K M IG G I
5 5
GGFVRVKQ
GGFVRVKQ
GGFVRVKQ
GGFVRVKQ
G G F IK V R Q
G G F IK V R Q
G G F IK V R Q
* * * * * * * * * *  * * . * * * * * *  * * * * * * * * * *  * * * . . * . *
P t l ( P R ) - C 4  
P t l ( P R ) - C 6  
P t l ( P R ) - C l  
P t l ( P R ) - C 1 2  
P t 5 ( P R ) - C 2 3  
P t 5 ( P R ) - C 2 5  
p N L -P S X  
C l u s t a l  C o
6 5
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q V ^ V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q IP ^ E IC G H K  
Y D  Q IP V E IC G H K  
Y D  Q I L I E I C G H K
7 5
A IG T W V G P T
A IG T V W G P T
A IG T W V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
A IG T V L V G P T
8 5
P A N I IG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P V N I IG R N L L  
P V N I IG R N L L  
P V N I IG R N L L
9 5
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
★ * ★ * ★ * * *  * * * * * * * * *
Figure 5.1b: Alignm ent o f the protease region from protease only clones. Clones obtained 
from patient derived virus sample 1, the shaded codons represent changes from pNL4.3-PSX
P t l ( P ) - C 3  
P t l ( P ) - C 8  
P t l ( P ) - C l  
P t l ( P ) - C 1 5  
P t l ( P ) - C 1 8  
P t l ( P ) - C 2 0  
p N L -P S X  
C l u s t a l  C o
P Q IT L W Q R P V
P Q IT L W Q R P V
P Q IT L W Q R P V
P Q IT L W Q R P V
P Q IT L W Q R P V
P Q IT L W Q R P V
P Q IT L W Q R P L
1 5
V T V K IG G Q L K
V T V K IG G Q L K
V T V K IG G Q L K
V T V K IG G Q L K
V T V K IG G Q L K
V T V K IG G Q L K
V T IK IG G Q L K
2 5
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L ID T G A D D
E A L L D T G A D D
3 5
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V F E E Q N L N L P G  
T V L E E - -M N L P G
4 5
R W K P K IIG G I
R W K P K IIG G I
R W K P K IIG G I
R W K P K IIG G I
R W K P K IIG G I
R W K P K IIG G I
R W K P K M IG G I
5 5
GGFVRVKQ
GGFVRVKQ
GGFVRVKQ
GGFVRVKQ
G G FVRVKQ
GGFVRVKQ
G G F IK V R Q
* * * * * * * * * *  * * * * * * * * * *  * * * ; * * * * * *  * * * * * . * * * ★  * * * * * . * ★ * *  ★ * * .
P t l ( P ) - C 3  
P t l ( P ) - C 8  
P t l ( P ) - C I O  
P t l ( P ) - C 1 5  
P t l ( P ) - C 1 8  
P t l ( P ) - C 2 0  
p N L -P S X  
C l u s t a l  C o
6 5
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q V P V E IC G H K  
Y D  Q I L I E I C G H K
7 5
A IG T V W G P T
A IG T V W G P T
A IG T V W G P T
A IG T V W G P T
A IG T V W G P T
A IG T V W G P T
A IG T V L V G P T
8 5
P A N IIG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P A N IIG R N L L  
P V N I IG R N L L
9 5
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
T Q IG C T L N F
* * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
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The second approach was used to produce gag, protease and RT fragment templates 
for the virus genomes derived from the patients, as this would show linkage of the 
separate coding regions on a single genome. To carry this out the stored patient viral 
RNA was reverse transcribed as mentioned in Chapter 3 and the gag, protease and RT 
encoding regions from were amplified by PCR using the primer set 5’Gag-Afar/ and 
3Tntegrase-Ama/. The resulting 3788 bp amplicons were visualized by EtBr stained 
agarose gel electrophoresis and were then cloned into the pGEM cloning vector 
(Promega) as outlined in the M aterials and M ethods section 2.1.12. The resulting 
clones were screened by PCR screening o f the colonies generated after transformation 
of the pGEM ligation reaction into E.coli H B lO l’s. The screening was performed 
with oligo’s T7 and SP6, resulting in a product o f 3.8 kb upon visualization by 
agarose gel electrophoresis.
Only three samples; virus derived from patient 1, 2 and 5 produced full-length 
amplicons from the pGEM  clones, which contained the whole coding regions for gag, 
protease and RT. Although full-length amplicons were generated from all patient 
virus derived RNA, suggesting that the 5’Gag-Narl oligo is more efficient, which is 
to be expected as it was designed to utilise a region which contained an inherent Narl 
site present in m ost sub-types.
To minimise sequencing and as the scope o f this project was to demonstrate the 
ability to clone virus derived sequences from alternative sources into the restriction 
sites, only virus derived from patient samples 1 and 5 were sequenced. The gag amino 
acid sequence data for pGEM  clones PtlpG EM -C2, and Pt5pGEM-C20 is shown in 
Figure 5.2 and the changes from pNL4.3-PSX for the protease and RT regions are 
listed in Table 5.1.
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Table 5.1: Mutations identified in pGEM clones containing the HIV protease and 
RT regions isolated from 2 patient derived virus isolates. The mutations in bold 
are associated with resistance.
Protease RT
Patient 1 L10V, I13V, L24I, 
L33F, 35QNins, 
M36L, M46I,
I54V, K55R,
R57K, I62V, L63P, 
I64V, L76V, V82A
M41L, K43N, E44D, L74V, A98G, K103N, V I 181, 
D123E, I135L, S162C, Y181C, M184V, Q207E, 
R211K, T215Y, A272P, 1293V, E297R, S322T, 
Q334D, F346Y, G359S, F389S, K390R, E399D, 
A400T, D460N, S468P, D471N, K476Q, H483R, 
L491, A554N
Patient 5 L10V, T12V, I13V, 
L63P, I64V
D67N, K70R, V90I, A98S, K102N, Y181I, S162Y, 
Q174H, M184I, T200A, E203K, Q207E, R21 IK, 
F227L, A272P, L283I, I293V, L295I, E297K, I329V, 
R356K, K366R, K390R, E399D, K431T, V467I, 
L491S, K527N, V531I, A554N
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Figure 5.2: Alignment of the gag region contained in the pGEM clones derived
from both patient virus samples 1 and 5. The shaded codons represent changes
from pNL4.3-PSX
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Figure 5.2(continued): A lignm ent of the gag region contained in the pGEM  
clones derived from  both  pa tien t v irus sam ples 1 and 5. The shaded codons 
represent changes from pNL4.3-PSX
P t l p G E M - C 2  
P t 5 p G E M - C 2  0 
N L 4  .3
C l u s t a l  C o
4 7 5  4 8 5  4 9 5
P P Q K Q E P ID K  E L Y P L A S L jK S  L F G N D P S S Q
P S Q K Q E P ID K  E L Y P L A S L R S  L F G N D Q ------
P S Q K Q E P ID K  E L Y P L A S L R S  L F G S D P S S Q
5.2.2c Patient 1 Derived Virus Gag clones
As the template for this recom binant was the pGEM clone there was only one possible 
gag genome that could have been extracted, therefore only a single clone was 
constructed, which m atched the sequence obtained from the pGEM clone PtlpGEM - 
C2. The pGEM  clone was used to amplify from, as this was previously shown to have 
a SaS  that was linked to the protease containing the two amino acid insertion.
5.2.2d Patient 1 Derived Virus Gag and protease clones
The Ptl-(G ag+Pro) clones were constructed from two sources, the first was through 
PCR from the cDNA and the second was by PCR from the pGEM clone PtlpGEM- 
C2. Both gel purified amplicons were ligated into the digested pNL4.3X-PSX vector 
and a single clone containing the desired coding regions from each ligation was 
produced. Both clones were sequenced with an oligo that covered the p7/pl and pl/p6 
cleavage sites o f  gag, the whole o f protease and up to codon 187 of RT, a fragment 
length o f approxim ately lkb. Sequence analysis revealed that both clones contained 
the A431V and L449V gag  CSMs and were homogenous in protease with respect to 
amino acid sequence. The only non-synonymous changes seen between the two 
clones in this fragment were in the p6Gag. The first occurred at codon 453 and was the 
result o f a single base change. Clone 7 contained a Leucine and clone 27 a Proline. 
The second coding change, also attributed to a single base change was at codon 492. 
Clone 7 contained a Proline and clone 27 harboured a Leucine.
Two other non-coding changes were also seen between the two Gag+Pro clones; 
clone 7 contained the AAA at codon 475 in gag, while a AAG coded for Lysine in 
clone 27. The other synonymous change seen occurred in protease at codon 62, where 
a GTA and a GTG coding for Valine were detected in clones 7 and 27 respectively.
The production o f the gag, protease RT products was hampered by the presence of 
existing Xbal restriction sites in the pGEM  clones from both patients virus. Virus 
derived from patient 1 contained an Xbal site in the RT and virus from patient sample 
5 had an Xbal site in gag. A num ber o f approaches were used to try and generate this 
gag, protease and RT fragment (i) X bal and Xm al restriction digest and subsequent 
ligation o f multiple restriction fragments and (ii) production o f a new pGEM gag to
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RT clone o f  P tl , in which the Xbal site was removed by SDM. (iii) cloning RT 
fragment o f patient 1 derived virus into the gag  and protease clone.
5.2.3 Production of Virus stocks
Clones that contained the desired mutational patterns were used for production of 
recombinant viruses. The viruses that were generated contained the HIV Protease 
(termed patient-Pro), gag  (termed patient-GAG), Protease and Gag (termed patient- 
Gag+Pro) and protease and RT (termed patient-Pro-RT) from patient derived virus 
samples in a w ild-type HIV-1 m olecular clone background.
5.2.3a MT-4 transfections
Large DNA stock preparations (maxi preps, Materials and Methods section 2.1.6) 
were made o f  the patient derived virus recombinant molecular clones. These DNA 
stocks were used to transfect M T-4 cells using DMRIE-C, as outlined in Materials 
and Methods section 2.4.3 and the resulting viruses were maintained and cultured to 
produce transfected virus stocks; see Materials and Methods section 2.4.
The transfected m olecular clones were monitored for signs o f virus production as 
determined by the presence o f CPE in the infected cultures. The first patient virus 
recombinants to display CPE were the Pt5(PR) clones c23 and c25, after 6 days in 
culture. This was followed by the P tl(P)-c8 clone, which showed signs o f infection 7 
days post-transfection. The P tl-(PR ) clones c6, c7 and c l 2 all displayed CPE after 10 
days in culture. All the recom binant viruses that contained the gag region i.e. P tl- 
c3(Gag) and the P tl-(G ag+Pro) clones c7 and c27, required the longest culture times 
before CPE was visible by light microscopy. Several transfection attempts with the 
gag containing clones were unsuccessful at producing any indication that productive 
infection was occurring. These viruses required culture periods of 15-21 days before 
CPE was evident in the cultures.
In order to create high titre stocks, a 500ul aliquot o f cell-free supernatant was used to 
infect 5 x l0 6 M T4 cells, infections were cultured until full CPE was observed, see 
Materials and M ethods section 2.4.
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5.2.3b 293T transient transfections
Due to the prolonged culture times required for production o f the recombinant stocks 
through transfection in MT-4 cells, an alternative approach was attempted. This 
involved transfection o f  the recombinant virus DNA stocks into the human embryonic 
kidney (HER) 293T cell-line. This cell-line has been shown to produce high viral 
titres, due to the high transfection efficiencies 105. Use o f the transfection reagent 
Fugene (Roche) has been optim ized for 293T cells, the details of these techniques are 
given in the M aterials and M ethods section 2.4.4. As before, a 500ul aliquot o f cell- 
free supernatants generated from the 293T transfections was used to infect 5x l0 6 MT4 
cells, these infections were cultured further until full CPE was observed.
5.2.4 Comparison of Transfection Methods
Viruses generated by both transfection methods were titred using the MTT assay 
system along with the re-infection stocks, termed ‘sub’ (sub-master). A comparison of 
the titres attained by transfecting the viral DNA in either MT-4 or 293T cells is shown 
in Figure 5.3. Three patient virus derived clones, which included the protease and RT 
regions were transfected along with the pNL4.3X-PSX and the parental molecular 
clone pNL4.3. The 293T transient transfections were the least productive method in 
terms o f generating detectable virus. The initial transfection only permits a single 
round o f virus production as the 293T cells lack the receptors to allow infection. The 
use o f these 293T generated viral supernatants for the infection o f MT-4 cells, which 
permitted m ultiple virus replication cycles, also failed to produce any measurable 
virus levels in the recom binants derived from the patient 1 virus. Creation of virus 
stocks with high enough titres that could be used in the assays, required the 
transfection and a single passage in MT-4 cells to create the patient 1-sub virus 
stocks.
Both m olecular clones pNL4.3X-PSX and pNL4.3, produced high titres when used to 
transfect either M T-4 or 293T cells and the infection o f MT-4 cells to produce the sub 
stocks, produced the highest recorded titres. The virus clone derived from patient 5 
produced lower TC lD 50/ml compared to the wild-type molecular clone produced by 
the same method.
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The highest titres in all the viruses was achieved by MT-4 sub infections, with this 
method producing 2-fold more virus than through the 293T and MT-4 infection in all 
the recombinants tested.
5.2.5 Titrations and Antiviral Assays in MT-4
The amount o f  infectious virus present in the prepared MT-4 virus stock was 
determined using the M TT Titration Assay as described in Materials and Methods 
section 2.5.1. A table o f TCIDso/ml values derived from the titration assays is shown 
in Table 5.2 and examples o f  the titration curves used to calculate the titres are shown 
in Figure 5.4.
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TC
ID
so
/m
l
100000
9 0 0 0 0
8 0 0 0 0
7 0 0 0 0
6 0 0 0 0
5 0 0 0 0
4 0 0 0 0
3 0 0 0 0
20000
10000
□ 293T
□ 293T-sub
□ MT-4 
■ MT-4-sub
pt1(PR)-c4 pt1(PR)-c7 pt5(PR)-c25
Virus S tock
X-PSX N L 4 -3
Figure 5.3: A co m p ariso n  o f th e  titres  ob ta ined  by transfecting  the viral DNA in 
e ither M T -4 o r  293T  cells.
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f ig u r e  5 .4: M I I A ssay  d e riv ed  titra tio n  curves, e r ro r  bars  rep resen t the 
s ta n d a rd  e r r o r  fro m  a t least tw o in d ep en d en t experim ents.
100
X-PSX
Pt1-C3(GAG)
Pt1-C8(Pro)
Pt1-c27(GAG-Pro)
Pt1-c6(-Pro-RT)
Pt5-C25(Pro-RT)
NL4.3
0)o<DO)ro
50
c<UO
k_<D
CL
0 •2 •31 -4 •65 •7
Log10 virus Dilution
T ab le  5.2: T C ID 5o/ml va lues d e riv ed  fro m  the  titra tio n  curves used to calculate 
the  titre s  o f th e  re c o m b in a n t v iru s  clones show n in F igu re  5.4.
Virus Stock TCID50/ml
X-PSX 3.20 x 103
Pt1-C3(GAG) 8.27 x 104
Pt1 (P)-C8 2.34 x 103
Pt1-c27(GAG+Pro) 9.43 x 103
Pt1(PR)-c6 9.23 x 104
Pt5(PR)-C25 1.80 x104
NL4.3 3.23 x 104
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The TCID 5o/ml values were used to determine the input for the MTT antiviral assay 
which was used to m easure the sensitivity o f the recombinant viruses to a panel 
antiretrovirals. Figure 5.5 shows the comparison o f ICso’s obtained for the 
recombinant viruses. In m ost cases a minim um  o f  two assays each with four replicates 
per assay was used to obtain the IC50 . The results for the PI RTV are not shown as no 
IC 50 value could be determ ined for this compound when tested for the patient 1 
derived viruses containing the protease coding region. In all determinations the P tl- 
Gag virus showed no resistance to RTV and both the P tl-(P ) and Ptl-Gag+Pro viruses 
had ICso’s greater than 20|lIM, which was the highest concentration o f compound 
tested and greater than 200 times the wild-type IC50. This concentration o f RTV 
showed only slight levels o f protection in the MTT viability assay. The aim was to 
demonstrate that these viruses were significantly more resistant than wild-type virus, 
which showed an IC50 o f lOOnM. Increasing the concentration to obtain a significant 
level o f protection would have resulted in cellular cytotoxicity, confounding any 
result.
Figure 5.6 shows the fold changes in ICso’s for the Pis tested o f the patient 1 
recombinant virus clones com pared to NL4.3, the X-PSX virus clone is also included 
in the comparison.
Both figures show that recom binants which contained the protease derived from 
patient 1 isolated virus were the only resistant viruses to the Pis tested, an additional 
increase in IC 50 was seen w ith the inclusion o f the gag  region from the patient 1 
derived virus. The P tl-G A G  alone virus showed only a slight increase in IC 5 0  against 
SQV and IDV. This approxim ately 2-fold increase; 1.90 and 2.03 respectively, was 
less than seen in the X-PSX  m olecular clone virus for the same Pis; 1.35 and 1.32 
respectively, so not considered significantly different.
Pt5(PR)-C25 shows w ild-type sensitivity to all the Pis used in the antiviral assays, it 
was also tested with AZT and was shown to be as susceptible as wild-type as 
expected as it contains no PI or AZT resistance mutations.
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5.3 Discussion
The prolonged use o f  antiretrovirals results in the development of resistance 
mutations to the protein targeted by the compounds. It has been shown that resistance 
mutations to Pis accum ulate in the protease and its substrate, the gag polyprotein 
12,77,191,358 ^ ost genotypjc ancj phenotypic monitoring o f patients with HIV is carried 
out by analysis o f the two main targeted regions, protease and the RT 292>347. These 
interpretations are then used to decide which therapies are most likely to offer the 
greatest clinical benefit.
The exact nature o f the contribution o f gag  mutations that arise during antiviral 
therapy on the virus phenotype still remains essentially unknown.
In order to dem onstrate the utility o f the live virus vector, a series o f recombinant 
viruses were constructed, in which all the restriction sites introduced at the termini of 
the coding regions were utilized. This resulted in the production o f chimeric clones 
which contained gag, protease and RT derived from patient vims isolates receiving 
antiretroviral therapy.
As previously m entioned in Chapter 3, the manipulation o f a large DNA vector 
created several problem s during cloning, one o f  which was the removal o f any vector 
DNA that had not been com pletely digested before addition into the ligation reaction. 
To prevent the contam ination o f  digested vector DNA with uncut/partially cut DNA, 
the restriction digests were resolved on low percentage agarose gels and subjected to 
very low voltage electrophoresis for in excess o f two days, as to prevent any uncut 
vector which existed in these gel purified DNA preparations would also be 
transformed into the host E.coli. As the fragment from the source sample replaces a 
fragment o f  the same size from the original, the presence of wild-type contamination 
could only be detected after sequence analysis revealed its’ existence.
Another problem  that occurred was the production o f chimeric clones containing the 
gag, protease and RT coding regions. This was hampered in both the patient vims 
samples chosen, as both contained native X b a l  restriction sites. In patient 1 derived 
vims the intrinsic X b a l  site was located in RT and in patient 5 derived vims, it was 
located in the gag  region. Prior to the selection o f X b a l  as the gag, N-terminal cloning 
site, an analysis o f several databases was carried to determine the frequency of its
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occurrence. The use o f  this restriction enzyme was also based on its selection by 
another group which produced a similar cassette system 19, although in this case the 
X bal site was used at the 5 ’ junction o f protease. The X b a l  site was also used in the 
construction o f  the m olecular clone pHXB2D; HIV sequence containing segment o f 
this vector is inserted into the backbone vector using X ba l sites 91. The Xba I  site was 
only a problem  if  the gag cloning site were to be utilised on the fragment being cloned 
in. This only occurred with the Gag to RT fragment from patient 1 and any Gag 
containing fragm ent from patient 5. The Xba I site was chosen as it was thought to be 
easier to clone with compared to the original choice o f the intrinsic Nar I  site and a 
suitable site for its silent insertion was available which also allowed the inclusion of 
the gag packaging loops. I f  this vector system were to be used for future high 
throughput use then it would require modification, as there would likely be a problem 
with viruses that contained an X ba I  site in the Gag-Pol coding region; see Table 5.3. 
M odification o f  this vector would require a more extensive survey o f available sites 
either to incorporate a less frequently occurring restriction site or to add one further 
downstream o f the packing loops possibly in the 5 ’LTR.
Table 5.3 The proportion o f HIV sequences in the Los Alamos HIV database that 
contain Xba I  restriction site in the Gag-Pol region.
Sub-type Totalnum ber
Num ber containing Xba 
I  restriction site
Percentage of 
total with Xba I
C R F’s 324 251 11.41
A 80 65 81.25
B 464 131 28.23
C 415 351 84.58
D 2 1 9 42.86
F 15 1 2 80.00
G 18 16 88.89
H 3 3 1 0 0 . 0 0
J 2 2 1 0 0 . 0 0
K 2 2 1 0 0 . 0 0
N 5 5 1 0 0 . 0 0
O 2 2 18 81.82
U 7 6 85.71
X 13 2 15.38
Total 1391 873 62.76
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As mentioned in the results section o f this chapter, in order to create the Gag-RT 
clone, the pGEM  clone PtlpG E M -C 2 was mutated to remove the X bal site, to then 
allow it to be PCR amplified, digested and cloned in to the X bal and Xm al cut vector. 
This step was also ham pered by incomplete digestion o f the pNL4.3X-PSX vector, 
using the X b a l  and X m a l restriction enzymes, resulting in partially cut vector 
contam ination as m entioned above. The production o f this patient virus derived Gag- 
RT clone rem ained unfinished due to time restrictions. However, as all the clones 
constructed required the use o f all the restriction sites at some point, the need to 
demonstrate any further utilisation was thought less important than continued analysis 
o f the viruses so far generated.
In order to generate stocks o f  sufficient titre, different methods o f transfection were 
attempted. The highest titres in all the viruses was achieved through MT-4 
transfection and culturing followed by further infection using the harvested cell-free 
supernatant i.e. the M T-4 sub infections. However, this method requires several days 
in culture before any visible signs o f infection are seen, even with a wild-type 
molecular clone. The alternative method attempted was transient transfection of the 
patient-derived virus vector constructs into HEK 293T cells, which would then 
produce virus into the culture m edium after 2-3 days. This method was successful for 
the molecular clones and also for the effectively wild-type virus clone derived from 
patient 5 isolated virus. The resistant viral constructs derived from patient 1 virus all 
produced undetectable levels o f virus through this transfection method, which would 
suggest that the differences in virus production are attributable to the protease and RT 
sequences. Both these enzymes in the patient 1 viruses were heavily mutated, the RT 
contains several m utations thought to be non-synergistic , such as the AZT resistance 
mutations M 41L and T215Y, along with the NNRTI mutation Y181C 29 and M l84V 
23, which partially reverse AZT resistance and also are detrimental to RT function no. 
The deficient virus production could also be an effect o f the mutant protease. The 
protease from patient 5  virus contains far fewer mutations which are thought to be 
detrimental to enzyme function, than are present in virus derived from patient 1 99,224. 
M utations detrimental to enzyme function are more likely to require additional 
compensatory changes to restore replication competence 31 \  thus, gag  polyprotein 
would require additional mutations to compensate for the less efficient protease. In 
Chapter 3, the only isolate to provide a pseudotyped virus was that obtained from
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patient 5 derived virus, which also implies it is relatively growth unimpaired. 
Although the gag  from patient 1 derived virus failed to amplify with the primers 
required for construction o f  the single cycle recombinant, so a direct comparison is 
not possible.
When transfected into M T-4 cells the two viral clones from patient 1 (Pro-RT) clones 
c4 and c7 produced different TCIDso/ml even though they have identical sequences in 
the protease. Therefore, it would be expected that these viruses would produce similar 
levels o f  infectious virus when transfected into the same cells. The differences that 
were seen in TCID 50 could reflect the inherent errors in such live virus and cell 
culture work i.e. the lower TCIDso/ml detected in the virus stock after the Ptl-c4 
transfection could be due to a lower transfection efficiency as a result o f experimental 
variation. This stock was then used to infect more MT-4 cells; unlike the first stocks 
that were generated by transfection with equal DNA quantities, this infection is 
equalized by supernatant volume. The differences in the TCIDso/ml of the input 
supernatants is then extrapolated further by the multiple rounds of infection and re­
infection that occur during the days in culture prior to harvesting. The opposite effect 
is seen in the X-PSX stock, which produced almost 2-fold higher TCIDso/ml in the 
transfection than was seen after the 293T derived virus was used to infect MT-4 cells. 
This is most likely due to there being too much virus present in the initial inoculum 
used to infect the M T-4 cells, which could have caused massive cell death and in turn 
loss o f virus titre as there are no cells left to infect.
As expected the patient viruses containing the protease showed resistance to Pis. The 
highest fold changes were seen in the Pis the patient virus had most exposure to. P tl- 
GAG possibly contributes some resistance to SQV and IDV, although less than 2- 
fold, but it appears to be consistent. However, a similar, increase in fold resistance 
profile is seen for the X-PSX vector with IDV (Figure 5.6), although the actual 
difference in IC50’s compared to NL4.3 is much lower than for the Ptl-GAG virus.
The most resistant viruses to the Pis were those that contained the protease isolated 
from patient 1 derived virus, except for the Pro-RT clones. The lack of any resistance 
to Pis and RTIs in the P tl (Pro-RT) clones infers that the genotype does not match the 
phenotype (Data not shown)e.
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To determine if  the genotype had reverted, clonal analysis o f the RT region amplified 
from the infected cell pellet was carried out which showed the majority (7 /8 ) clones 
were carrying the drug resistant mutation at codon 215. This codon position was 
chosen to determine if  reversion had occurred in the RT o f  the recombinants, as it has 
been previously demonstrated that this mutation is unstable when transmitted to drug 
naive seroconverters l8. The transfection o f a clonal population could be seen as 
representative o f an in vitro transmission event, which is also thought to involve a
71 | 81homogeneous population ’ . The exact reason for the lack o f phenotypic resistance
in the P t-1 (Pro-RT) clones is not clearly understood. The Pt-5(Pro-RT) which was 
cloned and transfected at the same time shows wild-type sensitivity to the antivirals 
tested, namely, SQV, APV, NFV and AZT. However this should be expected from the 
sequence data obtained for this sample. Although it would have been expected to 
show high level resistance to 3TC due to the presence o f the M l841 mutation, 
unfortunately no stocks o f 3TC were available at the time these assays were carried 
out.
The sequences derived from the pGEM clones was subjected to the Stanford 
Genotypic Resistance Interpretation Algorithm, Version 4.2.6 for a predicted 
phenotype interpretation. As expected the patient 5 virus scored susceptible to all the 
Pis and showed high level resistance to the NN RTI’s DLV and NVP, due the 
mutation at Y181I and also to 3TC, due to M l84V  mutation. This patients virus had 
prior exposure to the 3TC and NVP, therefore the prior treatment explains the 
genotype and the predicted phenotype. The virus derived from patient 1 scored high 
level resistance to NFV, IDV, APV, primarily due to the M46I, I54V and V82A 
mutations. This was also detected in the phenotypic evaluation o f the protease 
containing viruses. The predicted and actual phenotype also correlated with regard to 
Saquinavir, with low level resistance detected and predicted. The interpretation 
algorithm also predicted that this virus isolate would show low level resistance only to 
Tenofovir, due to the absence o f K65R, leaving this and SQV as the sole treatment 
options for this patient.
To evaluate the level o f  heterogeneity within the patient 1 viral RNA sample, several 
different clones which contained the protease and RT regions were produced. These 
clones contained almost identical protease regions, with only one clone from four
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displaying a single amino acid variation at codon 20 (K20R). The production o f the 
protease only containing clones failed to generate a single clone with the K20R 
mutation, from the six clones which were produced by direct PCR from the 
heterogeneous cDNA, as were the protease and RT clones. This K20R variant may be 
either required, in which case the virus is evolving to acquire it, or it could be in the 
process o f being discarded. The pGEM clone which contained the Gag-RT region, 
also derived by the amplification from the cDNA, contained the resistant protease and 
RT, but not the K20R, further supporting its’ low level proportion within the virus 
quasispecies. The requirement for the K20R could be established by sequencing o f  the 
Ptl-(Pro-RT) virus populations, from both the c6  and c7 passage stocks. It would 
seem that the patient 1 protease only virus does not require the K20R as this was not 
detected by population sequencing o f the infected passage cell pellet. This may 
suggest that at a low level, the protease containing the K20R, which is thought to be a 
compensatory mutation 4 0 1 5 4 ’2305 is or was linked to the mutant RT. Bleiber et al. 
noted that the cloning o f the cognate RT improved the replication capacity o f some 
protease mutant clones 19.
The hom ogeneity within the protease region overall would suggest that the major 
genotype w ithin the sample population contains the highly resistant protease, which 
also includes a double amino acid insertion at codon position 35. The presence o f 
insertions in the protease coding sequence have previously been reported 
2 4 ,1 5 6 ,3 0 9 , 3 1 4 ,3 4 1  Y k e s e  insertions are generally duplications o f neighbouring sequences 
caused by slippage o f  the RT during reverse transcription and have been shown to 
confer only a m odest growth advantage compared to the viruses in which the insertion 
had been deleted 156. The growth abilities o f the viruses generated is the subject o f the 
next chapter.
The genotypes generated from the patient 2 and 5 viral cDNA used for the cloning 
into the PSX vector shows almost identical sequence data to that shown in Chapter 3 
for the same samples, across the protease and in the case o f the virus derived from 
patient sample 5, also the gag  region. These results confirm that the PCR 
amplification selects for the majority genotype. To test that the amplified viral 
product is representative o f the viral population could be done by comparison of 
sequence data o f  the whole protease region from that obtained by routine resistance
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testing (see Table 3.1) and that o f the clones identified in Figure 5.1a and b. This 
shows only 3 changes with respect to the patient 1 derived virus at L I01, L33Fand 
L63P from a total o f 13. The insertion was also identified in all cases. The pGEM 
clone sequence (see Table 5.1) for this sample was also identical to the protease 
clones identified in Figure 5.1a and b. The sequence for the Patient 5 derived virus 
clones identified in Figure 5.1a, was also almost identical to the routine resistance test 
sequence in table 3.1, only changes at V3I and S37N were absent from any o f the 
protease clones in Figure 5.1a and in table 5.1.
The RT showed more variation when comparing the sequence obtained by routine 
resistance testing, and that o f the pGEM clone in both patient 1 and 5 derived virus 
clones. This is prim arily due to the larger RT fragment sequenced; 333 and 99 amino 
acids for RT and protease respectively. Routine resistance testing is also population 
based and unlike clonal analysis, shows no linkage o f mutations. Patient one RT 
sequence in table 3.1 has 8  additional changes from that o f the pGEM clone in table 
5.1, from a total o f 21 mutations. The variation between the two sequences in RT may 
also reflect the extensive previous NRTI and NNRTI treatment history, in all this 
patient had been exposed to 7 different RT inhibitors. The pGEM clone contains more 
NNRTI resistance associated mutations than the sequence identified in resistance 
testing and the L74V m ay be in response to ddl 306.
Patient 5 RT sequence in table 5.1 has 3 additional changes from that o f the pGEM 
clone in table 3.1, from a total o f  20 mutations. No further sequence analysis o f clones 
was carried out with RT as this was not prim arily involved in the study.
The increased diversity in the RT region could also be attributable to PCR 
recombination, this could occur in both PCR reactions and during the production of 
high titre stocks, as the PCR was only optimised for production o f good yield 
amplicons and not to m inim ise possible recombination events. As all infections 
originated from a clonal stock any recombination that occurred would represent the 
out growth o f a dom inant species.
An alternative, but more labour intensive approach would be limiting dilution PCR, 
where multiple PCR reactions are set up so that only 30% o f the total reactions 
produce an amplicon. This technique is more likely to result in the production o f an
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amplicon that is derived from a single template molecule and so is less likely to suffer 
from recombination.
Real-time PCR may be utilised for the detection o f  minority species o f HIV, 
sensitivity o f such assays are approximately 1 % in some studies and quantification o f 
the total viral population was possible as low as 4% 74. Although another group has 
shown even greater sensitivity, detecting proportions as low as 0 . 1  to 2 1 % o f total 
virus population 13°. However this technique does not isolate a product that can be 
utilised to produce a virus. The only patient virus derived material available was the 
viral RNA, had PBMCs been available the patient cells could be cultured with 
stimulated donor cells to derive a population o f virus from the infected patient cells. 
Although, co-culturing may lead to the selection o f a minority population that grows 
well in co-culture in the absence o f drug and may not be representative o f the starting 
population. The quasispecies from this population would represent virus produced 
from integrated proviral DNA in the infected cells. This population may exhibit a 
different heterogeneity to that derived from plasma viral RNA. The latter is more 
likely to display less heterogeneity due to the oligo-specific selection during cDNA 
production i.e. only sequences which hybridise to the oligo used for cDNA production 
will be selected. To minimise this effect, the oligo used for cDNA synthesis should be 
located in a highly conserved region.
The interplay between resistance and compensatory mutations is an incredibly 
complex one, it would require the understanding o f the association o f each mutation 
with its effect on several phenotypic markers, such as resistance and replication 
capacity. W hat is clear is that the exclusion o f the protease substrate gag , from 
phenotypic evaluations o f  resistance, leads to a underestimation o f the level o f drug 
sensitivity, especially to Pis and possibly also to NRTIs 256. This report demonstrates 
that inclusion o f  the gag  region from a highly PI experienced individual can result in 
an approximate 2 -fold increase in ICso’s.
With more time available this work would have been completed by the production of 
more patient derived viruses, such as from patient sample 1, the gag, protease and RT 
clone would have created a ‘full-set’ o f clones from this patient sample. Other patient 
samples were also selected and viral cDNA from these were amplified, but as
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mentioned in the discussion earlier, as all the clones constructed required the use o f 
all the restriction sites, any further utilisation was thought less important than the 
continued analysis o f the viruses generated so far. One further avenue that could 
also be explored is a greater dissection o f  the regions o f gag involved in PI resistance 
or compensation o f  resistance .i.e. are both N and C terminal regions required to bring 
about an increase in resistance to Pis?
Infected individuals from countries with a healthcare system that provides virological 
monitoring and access to several classes o f antiretrovirals allowing a change o f any 
failing compounds in the regimen, are more likely to be able to control virus load and 
resistance, which in turn would have an effect on transmission rates 175324348  
However, in those countries where limited classes o f antivirals are available and little 
or no virological monitoring exists, such as the poorer and more AIDS burdened 
countries, the re-cycling o f  same class compounds is more likely to occur. The 
standard first line therapy in developing countries consists o f two N R TI’s plus an 
NNRTI, or three N R TI’s. Second line therapy is likely to be the Pis with at least one 
NRTI 122. Research data suggests that RT genotypic diversity in HIV clade C may 
influence the em ergence o f drug resistance, especially to NNRTIs, NVP, DLV and 
EFV and also to the NRTI AZT 182. The effects o f Pis may also be abrogated by 
naturally occurring m utations in subtype A and C backgrounds, which may exhibit a
326higher biochem ical fitness in the presence o f commonly prescribed Pis . Therefore, 
in order to successfully control viremia and resistance with such a limited supply of 
antiretrovirals in these developing countries, may require a greater understanding of 
the com plexities o f resistance and the associated effects on viral fitness.
The next chapter aims to study the effects o f the gag  region on the growth and 
replication ability o f  the recom binant viruses in the context o f wild-type and mutant 
proteases.
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Chapter 6 Growth characteristics of Pt1-derived virus 
constructs
6.1 Introduction
The emergence o f  highly resistant viruses in individuals on HAART has, in the 
majority o f patients, resulted in the appearance o f a less pathogenic strain, which 
achieves lower viral loads and causes less depletion o f CD4+ T-cells ,17. The 
selection o f a particular genotype can result in the fixation o f certain mutations 322 327? 
resulting in the selection o f an evolutionary pathway, which in a previous 
environment, such as under a particular drug selection pressure, produced the most fit 
species. However, a change in environment, such as the introduction o f a new 
antiviral into a regimen, may require the addition o f new mutations for successful 
viral adaptation. Primary to virus growth, is the requirement for replication, which in 
this setting necessitates the acquisition o f resistance mutations. These new resistance 
mutations must also maintain functionality o f the targeted protein and must also 
provide synergy with other existing resistance mutations. The first publication relating
10
to this possible lack o f synergy was by Chow et ah using the combinations o f AZT, 
ddl and NVP. Due to the perceived potential o f this regimen to cause HIV to mutate 
in a stepwise m anner to an unviable state, it was termed, convergent combination 
therapy 278. A lthough now it is apparent that the myriad o f genomes which make up 
the quasispecies, especially within a pre-treated individual, are likely to negate the 
effectiveness o f  such an approach.
A main factor to be determ ined is how to measure viral fitness and in what context i.e. 
which cell line; m acrophages vs. T-cells or PBM C’s, which virus source; primary 
isolates vs. cell adapted or recom binant clones. Many caveats exist to each method 
and a clear consensus on how to determine fitness o f different viruses is yet to be 
achieved.
An understanding o f  how to use virus fitness information would have several practical 
applications in designing current regimens, such as, the control o f HIV with a reduced 
number o f com pounds. This would lead to less toxic and complicated regimens, 
costing less to maintain. This may also facilitate the design o f lifelong antiviral
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therapies for HIV infected individuals, in poorer countries. Several studies have 
compared a single boosted PI with standard triple HAART in patients as a 
maintenance therapy and found no significant difference in the two treatment arms
108,214
Previously, a virus had been isolated from a highly antiretroviral experienced 
individual, which contained multiple resistance mutations in protease and RT coding 
regions. This virus also contained a novel two amino acid insertion in protease and 
also displayed mutations in gag  associated with PI treatment. To investigate the 
potential effects o f the m utated protein coding region on virus growth a series o f 
recombinants were made. The protease containing virus clones demonstrated high 
levels o f resistance to those Pis which the patient had previously been exposed to. The 
inclusion o f the resistant virus gag , increased PI resistance, although, gag  alone 
afforded no decrease in sensitivity to any o f the Pis tested.
The overall aim o f this chapter was to determine if  the inclusion o f the gag  region 
results in the modulation o f growth characteristics o f the recombinant viruses and to 
see if  this was compensated for by the inclusion o f the cognate protease. As this 
vector system includes the region involved in packaging o f the viral RNA in new 
progeny virions, the effects o f mutations in this region are also investigated. This 
region is not included in any recombinant virus systems that have previously been 
developed to explore the effects o f mutations associated with PI therapy and so would 
provide the first evidence that this region is also under selective pressure from Pis.
The specific aims o f this chapter were to:
(a) evaluate different methods to determine replication capacity, this was carried out 
by
(i) Com parison o f  growth rates o f the recombinant viruses
(ii) Dual Infections with a wild-type virus
(b) determine the difference in reversion o f gag  and protease sequences after culturing 
in the absence or presence o f  different antivirals.
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6.2Results
6.2.1 Comparison of Virus Titration Methods
To determ ine which assay system could best be used for the comparison o f growth 
abilities, two infections using MTT titrated stocks were set-up. This involved the 
growth o f  a w ild-type molecular clone, HXB2 and a Saquinavir resistant double 
mutant, G48V+L90M . Both infections were set-up at an equivalent MOI o f 0.0001, 
determ ined by M TT titration, which is the same input used for the antiviral assay 
determ inations. Stock infections were set-up and then aliquoted in equal volumes in a 
6 -well plate. A single sample time point was collected each day and the cell-free 
supernatant stored at -80°C, until all time points had been collected. Analysis o f all 
the time points was carried out using either MTT titration or GHOST GFP reporter 
cell assay, as described in Materials and Methods 2.5. All the time points were titred 
simultaneously, to reduce any possible inter-assay variation, such as different cell 
growth rates.
The results obtained for plotting the TCID50/ml, as determined by the MTT assay and 
the num ber o f infectious units per ml, obtained from the GHOST assay, over the 
period o f the growth curve are shown in Figure 6.1. Both methods demonstrate a 
sim ilar pattern for the level o f virus detection across the time points, even though the 
end-point detection is different in both assay systems. However, the suggested fold 
difference betw een the two viruses after six days is greater in the MTT assay than 
detected by the GHOST assay. A 5-fold difference in TCID50/ml was seen by using 
the M TT assay and a 1.6 fold difference using the GHOST assay.
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Figure 6.1: Com parison of growth rates of two virus isolates, HXB and 
Saquinavir double m utant (G48V+L90M), using M TT and GHOST assay 
systems.
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6.2.2 Growth Comparison of Patient 1 Derived Viruses
6.2.2a Titration of Recombinant Viral stocks
As only one representative recombinant virus clone was to be utilised for growth 
characteristic analysis the nomenclature o f the virus stocks was simplified to represent 
which coding region was derived from the patient isolated virus. The TCID5o/ml 
values for the recombinant viruses are shown in Table 5.2 along with the original 
clone number.
As both the methods for determining amount of virus in the samples appeared to 
produce similar values, it was decided to continue with the GHOST cell reporter 
assay. This method had the advantages of quantifying the actual number of infected 
cells as apposed to the more indirect measure of cell viability in the MTT assay. Also, 
the GHOST method involved only a 48 hour incubation period, compared to the five 
days required for the MTT assay system.
The titrations are indicated in Table 6.1
Table 6.1 Titres of Patient 1 derived Recombinant viruses determined from 
GHOST GFP indicator cell titration.
Virus Stock Infectious units/ml
XPSX 1.92E+05
Ptl-GAG 3.18E+05
Pt1-Pro 1.56E+05
Pt1-GAG+Pro 1.46E+05
Pt1-Pro+RT 5.61 E+05
NL4.3 1.39E+05
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Figure 6.2: Comparison of titres as determined by GHOST assays, erro r bars 
indicate standard error over two independent assays.
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6.2.2b Comparison of Recombinant Viruses Growth Rates
To asses the rate of growth of the recombinant viruses, each of the virus stocks, 
previously titred on GHOST cells, was used to infect 5.25 xlO6 SupTl cells. The 
amount of cell-free virus supernatant used in the initial infection was that amount 
which produced 10% infection in the GHOST assay titrations. To minimise any 
variation in each infection across the time points, the stock infection was aliquoted 
across 12 wells of a 24-well plate, each well containing 3.75 x 105 SupTl cells in 
500pl of media. In all 13 time points were taken at 0, 6 , 12, 24, 30, 36, 49, 57, 73, 81, 
103, 127 and 150 hours post infection. Each time point was titrated on GHOST cells 
and the number o f infectious units per ml, as detected by FACS analysis of GFP 
expressing cells, was calculated for each time point. The titration of each time point 
was carried out on three separate occasions and the average of the three 
determinations is shown in Figure 6.3.
The highest titres were recorded in both the NL4.3 and the Ptl-Pro vims stocks at the 
103 hour time point, which is approximately after four days. This could possibly be 
due to the higher input, as demonstrated at the zero hour time point, which shows an 
approximately 1 and 0.5 logio variation in start titres for the NL4.3 and Ptl-Pro 
vimses, respectively.
All the vimses showed a continued reduction from the calculated input titres over the 
first 24 hour period, followed by a gradual increase in detected infection in all but two 
o f  the vims stocks. The slowest increase in the number of GFP positive infected cells 
was observed for both of the vimses derived from patient 1 gag  containing vimses, 
with all other vimses demonstrating a similar increase in rate of infection. This slow 
rate o f reproduction for the vimses containing the patient derived gag sequences 
would suggest that these vimses are growth impaired and that this phenotypic trait is 
related to the gag  region.
The Ptl-(Pro-RT) vims produced the lowest number of infected cells at peak 
infection, which occurred approximately 24 hours before the other vimses with 
similar replication rates.
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As the input amount in the growth curve varied and would affect the amount of virus 
produced, another method of analysis is shown in Table 6.2. This shows a comparison 
o f the amount o f virus produced at peak titre over the course o f the growth curve for 
each virus after correction for the start input. Using this method of determination 
suggests that the X-PSX viral construct replicates best, this is followed by the 
protease only virus, then by the NL4.3 virus stock. The remaining three virus 
constructs are ordered Ptl-GAG virus, Ptl-Gag+Pro and finally the virus that 
replicated most poorly, the protease and RT virus. Using this method o f analysis also 
suggests that there is very little difference between the top 2  viruses.
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F igu re  6.3: Com parison of growth rates of the recom binant viruses and NL4.3 
over a 150 hour growth period.
Error bars indicate standard error derived from 3 independent titrations.
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Table 6.2 Comparison of the amount of virus produced at peak titre over the 
course of the growth curve for each of the viruses after adjustment of start input.
Virus Construct Peak change in titre
X-PSX 2.16E+05
Pt1-Pro 2.14E+05
NL4.3 1.86E+05
Pt1 -GAG 1.56E+05
Pt1-(Gag+Pro) 8.04E+04
Pt1-(Pro+RT) 6.71E+04
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6.2.2c Competition Growth Study
The aim of this experiment was to assess the growth abilities of the virus stocks using 
dual infections. Each of the patient 1 derived recombinant viruses was competed 
against the NL4.3 molecular clone and a comparison of the rate at which each was 
outgrown by NL4.3, after serial passaging, was to be used as a measure of replication 
capacity. Initially, two different percentage ratios of recombinant vs. NL4.3 were set­
up (50% vs. 50%) for X-PSX vector as it was thought to compete equally with NL4.3 
and (80% vs. 20%) for the less fit recombinants, The MOI of each dual infection was 
0.001 and the input amounts were derived from the TCID5o/ml values obtained from a 
minimum of two MTT titration assays. Each of the infections was harvested after full 
CPE had been observed and the infected pellets were used for analysis o f mixture 
ratios.
To determine the ratio of NL4.3 and recombinant in the infected cell pellet, two 
methods of analysis were carried out. As all the recombinants were derived from the 
X-PSX or PSX vector, but, due to the fact that different sized products were cloned 
they did not contain all the same restriction sites e.g. the Gag+Pro clones were 
produced using the X bal and SexAl sites and patient derived Gag+Pro sequence, 
therefore they would not contain the gag C-terminal Pvul cloning site. The only 
common restriction site amongst all the clones was the C-terminal RT cloning site, 
X m a l , which was absent in the parental vector, pNL4.3. Therefore, analysis of 
mixture ratios in the dual infections was carried out by sequence analysis of a PCR 
amplicon that encompassed this site. This same amplicon was also used to clone into 
the pGEM cloning vector and the resulting clones were again PCR amplified across 
the X m al site. By digesting these PCR products with X m a l, the proportion of NL4.3 
was determined by the number of clones that did not contain the Xm al restriction site. 
An example of the comparison of the results obtained for one of the dual infections 
using this approach is shown in Figure 6.4 and the overall results comparison is 
shown in Table 6.2.
Each o f the PCR’s were set-up along side positive and negative controls, which were 
also digested. The 100% Xm al represents the PCR amplicon of the X-PSX vector 
DNA and should only contain products that are sensitive to X m al digestion,
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producing fragments of 673bp and 273bp. The 0% Xm al amplicon is derived from the 
PCR of NL4.3, which does not contain the RT cloning site and therefore would 
remain uncut.
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F igure  6.4: Example of a com parison of the clonal analysis and peak height 
determ ination . Example shown is for the Ptl-Pro+RT amplicon derived from the 
NL4.3 vs.Ptl-Pro+RT dual infection, passage 1 infected cell pellet.
(a) A total of 21 amplicons were analysed, 3 clones were uncut, 15 were digested and 
3 clones generated negative amplicons. The PCR negative control lane is denoted by 
the (-ve) symbol.
100% X m a
0% X m a
V 1 - v e
(b)Chromatogram of bases around the Xmal restriction site
C C C C G G G  A
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Table 6.2: Comparison of percentage mixtures in competition cultures.
Determined by sequence analysis (peak height comparison at the Xm al restriction 
site) and by clonal restriction enzyme digest analysis after the first passage in the 
competition growth study.
NL.3 vs.
Sequence Analysis Clonal Analysis
%WT %MT
(%) or No. 
of clones 
WT
(%) or No. 
of clones 
MT
Total no of 
clones
X-PSX 40 60 (42%) 8 (58%) 11 19
Ptl-G A G 2 0 80 (5%) 1 (95%) 19 2 0
Ptl-Pro 1 0 90 ( 1 0 %) 2 (90%) 18 2 0
Ptl-Gag+Pro 0 1 0 0 (0 %) 0 ( 1 0 0 %) 19 19
Ptl-Pro+RT 2 0 80 (17%) 3 (83%) 15 18
The analysis o f the first passage data by both sequence and clonal methods produced 
very similar results, except for the Ptl-GAG dual infection, which showed the 
predicated ratio by sequence analysis, but a much greater ratio of recombinant virus 
was seen using the clonal system. Overall, the input ratios were reflected in the 
determined virus proportions after a single passage, with the exception of the Pt 1 - 
Gag+Pro virus, in which no wild-type was detected by either method. Further passing 
and analysis is needed in this experiment, however, the competition experiment was 
stopped due to the reversions seen in the high titre stocks. The appearance of 
reversions meant that the experiment no longer contained two clonal populations 
competing against each other. This would mean that any subsequent analysis would 
be need to be carried out on clones to show linkage of mutations and this would 
require the sequence analysis of the whole of the gag region. It was primarily for this 
reason that further evaluation of the competition experiments was not carried out.
6.2.3 Sequence data after passage
The stability of the gag, protease and RT sequences was assessed by passage of the 
viruses in the absence of drug pressure. This was carried out by PCR amplification 
and DNA sequencing of a region covering the gag and Pol domains from the infected 
cell pellet, after harvesting of the cell-free viral supernatant for subsequent passage.
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The details o f the techniques used to carry out the PCR and DNA sequencing are in 
the Materials and Methods section 2.1.13.
6.2.3a Patient 1 and 5 viral isolate derived (Pro-RT) Recombinant 
Virus Sequence Data After Passage
As the Ptl-C6, C l  and Pt5-C25 (Pro-RT) clones contained the protease and RT 
regions from the patient derived viruses, the sequence data was primarily focused on 
the stability of the mutations in this fragment. The sequence contig that was 
assembled and analysed from the infected cell pellet sequence data, spanned the 
region from the p l/p7 gag  cleavage site to codon 345 of RT, a region of 1.5kb.
In the Pt5-C25 virus isolate the protease mutations remained stable, the RT region 
maintained most of the RT mutations that were introduced from the patient derived 
virus. The sequence after passage showed a reversion of the NNRTI mutation F227L. 
Two other changes in the RT region from the infected pellet PCR product were also 
noted. These occurred at codons 277 and 295, which altered the original patient virus 
amino acid sequence to one that occurs in NL4.3; both of these sites are polymorphic 
within sub-type B 176.
The PI mutations in Ptl-C6 and C l  remained stable over the growth period and from 
the infected pellet sequencing, it appeared that the RT mutations were also stable to. 
The only differences that were observed in the passaged stock from the transfected 
clone in the RT region were a novel T107I change not seen in other subtypes 40,176? a 
reversion o f the Q207E to the NL4.3 amino acid and a V293I change, also thought to 
be a consensus B change
Both viruses derived from patient samples 1 and 5,Pro-RT clones contained the 
m ajority o f the wild-type gag region derived from NL4.3. However, the 20 N- 
terminal amino acids are from the patient virus source, due to the position of the C- 
terminal cloning site used for the introduction of protease. Therefore, the only 
changes in the patient 1 and 5 derived virus gag fragments from NL4.3 in this region, 
are due to being introduced during the cloning.
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To further investigate the lack of resistance in the Ptl-(Pro-RT) clones, a clonal 
analysis o f the RT region containing the T215 Y mutation was carried out to determine 
the percentage of clones which were still carrying this mutation. A 1.5kb PCR product 
spanning the RT region was amplified and ligated into the pGEM cloning vector, 
transformed into E.coli and the DNA isolated from eight clones was sequenced across 
the region of interest. With the exception of one clone, which reverted to wild-type, 
all the remaining clones were mutant at codon 215, with a tyrosine at this position.
6.2.3b Patient 1 Derived Virus Protease Recombinant Sequence Data 
After Passage
The Ptl-(Pro) virus stock showed the least variation from input genotype o f any o f the 
recombinant viruses. The genotype derived from the infected cell pellet o f the 
passaged virus stock showed no changes from the wild-type gag sequence, or the 
mutant protease coding regions.
6.2.3c Patient 1 Derived Virus Gag containing Recombinant Viruses 
Sequence Data after Passage
The Ptl-G A G  and the Ptl-(Gag+Pro) virus stocks showed no deviation in the 
protease sequence from the genotype of the molecular clones used to produce the 
virus stocks. However, the gag regions from the same virus stocks showed an 
extensive reversion pattern. Figure 6.5 shows the alignment o f the gag region from 
the passaged Ptl-GAG and the Ptl-(Gag+Pro) viruses. Also shown in the alignment is 
the sequence of the gag region from the pGEM clone PtlpGEM-C2, along with 
NL4.3 reference sequence.
P tl-G A G  virus showed a more extensive loss of mutations from its clonal input DNA 
stock than the Ptl-(Gag+Pro) virus. This pattern was seen most clearly in the MA and 
p6 Gag proteins, analysis of which showed that the Ptl-(Gag+Pro) virus maintained 
all the mutations from the input molecular clone in both these proteins. By contrast 
the Ptl-GAG virus lost all the analogous mutations in p6 and only four amino acid 
changes were preserved in p i7, three of which are thought to be polymorphic; K15R, 
K30R and R76K 176. The Q28K change occurs at a position conserved amongst the
311different clades, but has been previously shown to appear . The MA insertion
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present in the original patient 1 derived virus gag was lost by the gag  only virus, but 
maintained in the Gag+Pro virus.
The MA of the Ptl-GAG virus was also shown to contain two mutations that occurred 
at amino acids positions which were originally NL4.3 sequence, namely Q59H and 
E74V. A database search revealed that these positions are highly conserved amongst 
different HIV clades, this was also the case for the T81P, which appeared in the gag 
only passage virus. The A82L/V also in p i 7 occurred in both the Ptl-GAG and the 
Ptl-(Gag+Pro) viruses respectively. This codon is normally associated with an 
Isoleucine or Threonine 176.
Both virus clones derived from patient 1 which contained gag maintained all the 
mutations in the CA protein, most of which are polymorphic with the exception of the
1247V 176
The p2 protein showed the highest number of reversions in proportion to its size; 14 
amino acids long and four reversions within the space o f six amino acids, potentially a 
‘hot-spot’ for adaptation. These occurred in both the Ptl-GAG and the Ptl-(Gag+Pro) 
viruses and included the mutation at P I ’ in the p2/p7 cleavage site. The only p7 
change that persisted when the gag and the corresponding protease were included in 
the recombinant virus, was the M423I change, which also occurs at a conserved
11fiamino acid position across the HIV clades
The A431V change at position P2 in the p7/pl cleavage site in the original clonal 
isolate was lost by both the gag containing viruses, however the adjacent cleavage 
site, p l/p6  retained the P I ’ mutation in the Ptl-Gag+Pro virus.
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Figure 6.5: Alignment of gag regions derived from Ptl-GAG and Ptl-Gag+Pro
viruses after passage.
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Figure 6.5(continued): Alignment of gag regions derived from Ptl-GAG and Ptl
Gag+Pro viruses after passage.
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6.2.4 Genotype Stability Determination
In the previous results section it was reported that reversions were occurring at some 
o f the amino acid positions in gag, after sequence analysis o f the infected cell pellets, 
derived from the patient 1 derived virus recombinant stocks. In an effort to maintain 
the original genotype introduced at transfection, it was decided to re-transfect in the 
presence of antiviral selection pressure. Also, previously demonstrated, was the need 
for multiple rounds of virus replication to generate significantly measurable levels of 
infection. Therefore, in order to fulfil these two requirements, the former being of 
most importance, a protocol was devised that would first transfect 293T cells, which 
have been shown to be produce high amounts of virus when transfected transiently 105.
n
These transfections were then supplemented with 1x10 MT-4 cells, one day after 
initial introduction of cloned vector DNA, which, it was hoped would facilitate 
productive infection of the virus produced through 293T transfection. The infection
o
was allowed to proceed a further 5 days, approximately 2 replication cycles , at 
which point the cell-free supernatant was harvested and used to infect 3x l06 SupTl 
cells in the presence of 8nM SQV, 40nM IDV, lOOnM RTV, lOOnM AZT or no 
inhibitor. The concentrations of antivirals used represents the NL4.3 IC50 values 
determined using the MTT assay system. All infections were allowed to proceed until 
full CPE was observed, or it was decided that no observable replication was ongoing, 
by virtue of no visible CPE, throughout the course of infection. 500 j l l 1 of cell-free 
supernatant was used to infect a further 2xl06 SupTl cells, this was carried out in the 
presence or absence of the aforementioned concentrations o f antivirals and also 
constituted the next passage.
The recombinant clone containing the gag derived from patient 1 isolated virus, 
showed no signs of CPE in any of the cultures which contained antivirals, only the ‘no 
drug’ infection produced visible CPE. Overall, all the viruses grew poorly, especially 
during the initial passage in SupTl cells, with no visible signs of CPE after 8 days in 
culture.
At passage two, the only virus to display production of CPE was the Ptl-Pro passaged 
in the absence of any antivirals. During this passage both the protease only clones 
exposed to RTV and IDV also produced CPE in the SupTl cultures, before the
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cessation of the passaging step. The Ptl-Gag+Pro infections required an additional 
passage step before CPE was detected in any of these infections, this virus was the 
only recombinant to produce any visible CPE in the SQV infection.
Only at the end of passage three, after a total amount of time in culture of 
approximately 30 days, was CPE d.etected in all the Ptl-Pro and the Ptl-Gag+Pro 
infections. The Ptl-GAG virus only produced detectable infection in the ‘no drug’ 
infections. All the infected cell pellets were harvested and amplified as detailed in the 
Materials and Methods sections 2.4 and 2.1.9.
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Figure 6.6: Alignment of gag sequence data generated from the Passage 3 of the
P tl-G ag virus in the absence of inhibitor.
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Figure 6.6(continued): Alignment of gag sequence data generated from the
Passage 3 o f the Ptl-G ag virus in the absence of inhibitor.
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The stability of the genomes was assessed by DNA sequencing of the infected cell 
pellet; this was carried out as detailed in the Materials and Methods section 2.1.13. To 
investigate the potential of carry-over o f the input vector after transfection, a control 
PCR was set-up which utilised oligonuleotides that annealed to the ampicillin 
resistance gene located in the recombinant virus vector. Any infected pellets that 
produced an amplicon from the ampicillin PCR were therefore, likely to contain 
contaminating input plasmid. All the infected pellet DNA samples were negative for 
this PCR, therefore, the sequence data obtained from these samples was deemed to be 
derived from the integrated infectious virus and not as a result of input plasmid 
contamination.
Analysis o f gag  region sequence data showed that less reversions occurred in the Ptl - 
GAG virus, than had been previously demonstrated during production and sequencing 
o f  the high titre stocks, see Figure 6.6. The main differences occurred in MA, where 
the all the original mutations in the pGEM clone were maintained by the Ptl-GAG 
virus. A differential mutational pattern was also observed for CA from the first 
passage result, with 3 reversions from 5 seen in this experiment, as opposed to 
complete conservation of the pGEM sequence, demonstrated in the previous passage 
data set.
The C-terminal region of gag reverted to NL4.3 sequence, as was seen previously, 
although the data obtained from this experiment showed much more heterogeneity in 
the sequence chromatograms at all the positions where reversions had occurred. 
A nother disparity from the previous sequence data was seen in the Ptl-Pro virus, here 
changes were seen in three of the infections; those under the selection pressure of 
AZT, IDV and SQV, no changes were seen in the ‘no drug’ infection derived 
infectious pellet. An identical change was seen for the AZT and IDV infections, an 
L75R, which was present as a mixture in the IDV infection and as a homogenous 
codon in the AZT infection. Two other changes were detected in the Ptl-Pro, SQV 
infection, a synonymous change in MA at codon 10, GGG to GGA, both coding for 
Glycine and a non-synonymous change, K415I, in NC. Both these non-synonymous 
changes K75R and K415I, occur at positions which are somewhat polymorphic, 
although neither of these amino acid substitutions are present in any of the HIV clades
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The sequence data obtained for the Ptl-Gag+Pro virus, demonstrated an unchanged 
genotype from the input sequence in all of the infections.
Overall and in concordance with the previous sequence data, changes were seen 
primarily in the gag regions, no changes were detected in protease or RT in any of the 
infections.
6.2.4a Analysis of Packaging Sequence
The packaging of viral genomic RNA is aided by the packaging sequence (\|/), located 
in the 5 ’UTR 42’215’303’356> The sequence analysis of the 5’UTR of the study patient 
derived virus showed several changes in the 'P, which upon passage showed some 
reversions, indicating possible selection in this region. These included a ‘T ’ to ‘G ’ 
change in stem loop 1 (SL1), which may result in mis-pairing of bases in this loop and 
causing an additional bulge structure, see Figure 6.7. A similar bulge may also occur 
in SL2, as a result of ‘C’ to ’A ’ change, which also causes mis-pairing of nucleotides. 
Both NL4.3 and the patient virus contained the same nucleotides at these two 
positions and the mutations acquired after passage are changes from both these 
viruses. Most of the remaining changes that were detected were reversions back to 
NL4.3 sequence including the addition of a missing nucleotide at the base of SL3. 
However, no reversion was detected in the apical loop of SL3, where a ‘G ’ to ‘A ’ 
change had removed a purine-rich region at the apex of this loop, which others have 
demonstrated, is a primary site for interaction with Gag 244,356. This may be as a result 
o f lack o f reversion or it may reflect redundancy in the packaging complex.
Perhaps the most important change seen in the original virus genotype was a two bp 
deletion in the palindromic, ‘kissing-hairpin loop’ region. Abolishment of this 
palindromic sequence has been shown to cause dramatic loss in virus infectivity
1 O 1 A
’ . In this study it was shown that after passage this sequence showed partial
reversion, with the insertion of a ‘GG’ sequence. Although this did not restore the 
palindromic sequence it did result in the appearance of a double guanine motif at the 
loop apex, which is thought to increase affinity to NC 198,244.
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F ig u re  6.7:Amino acid and nucleotide sequences for HIV-1 NL4.3 NC and 'P.
A) Amino acid sequence o f the NL4.3 NC protein showing the zinc-binding 
knuckles. Residues that contact the RNA in the NC-SL3 complex are denoted 
by open letters. Asterisks denotes residues that contained mutations in the Pt 1 - 
GAG recombinant that reverted after passage.
B) Nucleotide sequence and secondary structure o f the NL4.3 4* sequence. The 
dimer initiation (DIS), major splice donor sites (SD) and the gag  initiation 
codon (AUG) shown in open letters.
C) Alignment o f 4* of Ptl-GAG virus after passage, compared against original 
pGEM and NL4.3. The colour shaded boxes represent the stem loops (SL1-4).
Figures A and B adapted from De Guzman et al. 63.
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6.3 Discussion
The development of resistance to Pis has been shown to reduce the activity of the 
viral protease, requiring restoration of enzyme function through the accumulation of 
compensatory mutations 230’358. These mutations have been identified in both the 
protease and the gag coding regions of viruses isolated from highly antiretroviral 
experienced individuals. One such isolate was identified in this study and the highly 
mutated protease was also shown to contain a two amino acid insertion. To assess the 
impact o f the gag and protease regions, derived from the patient isolate on virus 
growth ability, synchronous infections using the recombinants were set-up. All 
viruses were titred on GHOST indicator cells, as prior to this growth curve, a smaller 
scale experiment was used to determine which method would be used for the 
determination of vims quantity.
Both the MT-4 and GHOST titrations gave very similar results for the amount of vims 
at each time point in the growth curve for HXB2 molecular clone and the SQV double 
m utant G48V+L90M (see Figure 6.1). The HXB2 vims achieved higher titres than the 
m utant G48V+L90M, which has previously been demonstrated to show reduced 
replication in comparison to wild-type vims 283. A greater difference in replication 
rate was seen using the MTT assay, this is probably due to the low percentage 
infections detected using the GHOST assay system. An equivalent amount of vims 
was added to the GHOST titration as was added to the MTT assay, the latter system 
had several more days in culture, during which any differences in replication rate 
could be magnified. The selection of the GHOST assay to determine vims quantity 
was due to the reduced incubation time and the more direct end-point measurement. 
Other methods of determining titres of cell free supernatant could also have been 
investigated, such as, p24 ELISA assays assess the amount of protein present, 
therefore this must have been produced by viral replication and so is a measure of 
active replication. However, it relies on binding of anti-p24 antibody to the capsid 
region o f Gag. As this was one of the regions that might vary in clinical isolates due 
to drug induced or replication restoration required mutations, this could result in 
variable binding to antibody and therefore under estimates. Assays to measure p24
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also only measure protein levels and may not distinguish between uncleaved proteins 
which could accumulate due to gag and protease mutations in the virus clones. The 
chosen method of analysis required infection of GHOST cells in order to produce a 
GFP signal. Analysis of infections where only 30% of cells are infected reduced the 
possibility of underestimation of virus quantity due to re-infection of an already 
infected cell. Viral load measurements determine the amount o f viral RNA in a 
sample and do not elude to the amount o f live/infectious virus present. All assays 
show some level of variability when assaying for the amount of p24/RNA viral load 
and TCID50. The latter is a measure of virus induced death in the MTT assay and a 
measure of the number of infectious particles produced in the GHOST cell assay. 
Both these measures were compared to each other using the same virus stock and 
gave similar results (see Figure 4.9).
In the growth rate comparison experiments the recombinants were used to infect T- 
cells and the amount of virus produced over the course of infection was monitored at 
15 time points. The variation in the start titres may have been caused by inaccuracies 
in the titre determinations, as the Ptl-Pro virus demonstrated a larger variation in the 
GHOST cell titration curves shown in Figure 6.2. These two viruses, NL4.3 and P tl- 
Pro also represent the viruses with the lowest and highest titres, so it is possible that 
the growth curve inputs are subject to more variation, as it is more likely to under or 
over estimate the amount of virus added. Therefore, any inaccuracies in the titre 
determinations are more likely to affect the samples at the extremes, when calculating 
the input for the growth curve. For example, with low titre viruses, it is conceivable 
that an under estimation of titre can occur as not enough virus infection occurs 
through cell to cell spreading infection. Thus, when larger volumes are used, this 
effect is reduced, leading to an under estimation of the titre. With high titre viruses, a 
similar under estimation of titre can be achieved if cell killing occurs too quickly, 
causing a reduction in the overall amount of virus produced.
All the recombinant viruses gradually reduced in titre from the input amount over the 
first 24hr period, the reduction reflecting the entry of viruses during the replication 
cycle (eclipse phase). The subsequent increases from this nadir level, which suggest 
the production of new virions were seen in most viruses at the next time point at 30 
hours. In the case of both Ptl-GAG viruses a recovery in titre to that of the initial
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input amount, took over 80 hours. Recovery of the Ptl-GAG appears to be better than 
that o f the Ptl-(Gag+Pro) virus, this would suggest that protease compromises the 
virus which contains it; however, the Ptl-Pro virus grew to similar rates to NL4.3. 
This anomaly could be explained by the sequence data generated from the infected 
pellets of the high titre stocks, used as the input viruses in this growth rate comparison 
study. As reported in Results section 6.2.3c of this chapter, the reversion pattern 
observed for the Ptl-GAG was greater than that seen in the Ptl-Gag+Pro, this was 
especially true for the p6 protein in gag, from both passage data sets. Sequences 
within this region are thought to be involved with the late stages of the viral Life 
cycle, such as budding, through interactions of the PTAPP motif and host proteins 
3 0 ,9 4 ,334 ,335 sequence data also showed the retention of the PTAPP to PSAPP by 
the gag and protease virus, but reversion in the gag only, even though this difference 
is thought to be polymorphic 241. This co-evolution with the mutant protease would 
appear to force gag to maintain the mutation(s) which may account for the slower 
replication seen compared to the virus that originally contained only the same gag 
region. Another point to note is that the level of reversion in the gag only clone was 
not apparent at the start of this growth curve and to what extent further reversions 
have occurred during the course of the experiment is also unknown.
The protease only virus replicated to high levels despite containing multiple mutations 
known to reduce enzyme efficiency . This high replication also occurred without 
the acquisition of any gag mutations, as demonstrated by the passage sequence data. 
Although any changes may have been undetectable by population sequencing, the 
majority of the virus genotype would appear to be the same as was introduced by 
transfection. The presence of the two amino acid insertion, which occurs in the flap
'Jf.O ^QO
region, encompassing residues 33-62 ’ of the protease protein, may play a role in
maintaining the replication capacity of the drug resistant phenotype. Molecular 
modelling experiments on SIV proteases have shown that the insertions in the 
protease gene between codons 34 to 37 cause conformational changes in the geometry 
o f the flap region and contribute to structural alterations in more distant regions of the 
molecule 156. The appearance of insertions at this position in protease have been 
previously reported in PI naive, although RT inhibitor experienced and PI treated 
individuals 245’309. The emergence of such duplications in PI naive, but RT inhibitor 
treated individuals, suggests that these insertions, which have been shown to represent
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duplications of the preceding sequence 156, may be associated with RT inhibitors and 
the inhibition of RT processivity. It is has also been demonstrated that these insertions 
do not decrease sensitivity to Pis, but do normally confer a growth advantage in the 
presence of other PI resistance mutations ,56>245’309. Thus their emergence in PI naive 
individuals, without other PI mutations, also implies that these proteases confer a 
selective advantage even in the absence of PI therapy.
The Ptl-(Pro-RT) virus, produced the lowest amount of infection in the growth curve, 
this may imply that the cloning of the cognate highly resistant RT has a detrimental 
effect on virus growth. As the protease only virus grew to high levels, the production 
o f  an RT-only clone would help to clarify this, however due to time constraints this 
was not completed.
The lack of growth associated with the gag containing virus clones, would appear to 
be solely attributable to the gag coding region, as the Ptl-GAG and the Ptl-Gag+Pro 
viruses displayed poorer growth kinetics compared to the protease only virus stock. 
One method of interpretation of the data generated from the growth rate comparison is 
to compare the start titre with the peak titre detected over the course of the growth 
curve for each of the viruses; shown in table 6.2. This method of evaluation removes 
the error associated with the differences in the start input for each of the viruses and 
orders the virus constructs based on the amount of virus produced in the ‘static’ 
conditions of the experiment i.e. no new cells were added to the assay. The molecular 
clone NL4.3 had the largest input and this may explain the lower peak change in titre. 
The Ptl-GAG construct also would seem to out perform the Ptl-Gag+Pro virus using 
this method of analysis. This may be explained by the more extensive reversion seen 
in the sequence analysis of this virus, i.e. the reversions that occurred during the 
production of this virus stock may have made the virus more adapted to the culture 
conditions.
The large error bars represent the difficulties in using a replication competent system 
to asses growth rates, as variation in titres, not only in the determination of the input 
amounts, but also in the final determination of virus quantity, undoubtedly affect the 
values at each time point. Other factors such as different plating densities and growth 
rates of the reporter cells also affect the final result. However, the overall positions of
224
the recombinants, relative to each other remained almost constant throughout the three 
separate determinations.
A more direct measure of virus growth comparisons is achieved by competing two 
viruses in dual culture experiments. To assess the growth rates o f the patient derived 
virus recombinants, each was added in excess to a mixed infection containing NL4.3. 
The amount of mutant to wild-type virus was measured as the percentage of clones 
that were isolated which contained the X m al restriction site, present only in the 
mutants. This experiment was only continued for a single passage, although variation 
was detected from the assumed input, this is more likely to reflect errors in the 
determined titres, rather than any immediate outgrowth by the presumed less fit 
recombinants.
The assessment of the vims proportions was shown to be almost identical when using 
a clonal analysis versus a population sequence analysis. Only one dual infection 
produced disparate results; NL4.3 vs. Ptl-GAG. This could be due to the sequence 
analysis being less sensitive than the clonal method, which by analysing 20 clones per 
infection, allows a sensitivity of 5%. The sensitivity of population sequencing has 
been shown to be much higher than this 151. It is also possible that an underestimation 
o f  wild-type clones occurred, due to the low frequency at which they would be 
distributed, therefore, selection of these colonies would be less likely to occur.
The similar results obtained for determination of ratios would imply that further 
analysis using just the sequence method of determination, which is a much less labour 
intensive approach, would provide an adequate interpretation of the vims proportions 
within the dual infections, after further passaging.
Continued culturing of the vims clones in the absence of dmg pressure is thought to 
select for the fittest vims in the quasispecies produced by the error prone RT, even in 
the low passage numbers used here. Those mutations which are present purely to 
prevent the antiviral compound from interfering/binding, are no longer required and 
so will be lost. This is because these mutations have been shown to be detrimental to 
the activity of the enzyme targeted by the antivirals 20’230’253. it is also assumed that the 
original wild-type vims before any exposure to antivirals and before the acquisition of 
resistance was the most genetically fit species. The persistence of the resistance
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mutations in both the protease and RT sequences of the patient 1 viruses would seem 
to suggest that they may not be detrimental to virus replication capacity, or reversion 
m ay require an intermediate that is even less fit. However, as this system was clonal, 
the acquisition of mutations or reversions could only be due to their appearance 
following an error during replication, followed by their selection as a fitter variant. 
Thus, the persistence of these mutations is solely due to the time taken for virus to 
acquire and select them. Such a similar delay in reversions was seen after longitudinal 
analysis of plasma virus from an individual who acquired HIV-1 that contained
99 rx-»1multiple RT and protease mutations . The resistance mutations m protease were 
maintained for longer than 300 days after diagnosis of HIV-1 infection. Another 
hypothesis could be that the mutational pathway required to select for these reversions 
necessitates a reduction in overall replication capacity levels and thus, this pathway 
would initially be selected against, until other reversions or mutations which work co­
operatively, allow for their selection 88,355. The only reversion of a resistance mutation 
amongst the recombinant viruses generated in this study, was the AZT, T215Y 
mutation, resulting in a heterogeneous population similar to that seen by Bezemer et 
a l  ,8.
The viruses which displayed the highest level of variability in sequence were those 
recombinants which contained the patient 1 derived virus gag region. The gag region 
also proved to be the most variable after transfection and subsequent passage. Such a 
high level o f heterogeneity in gag, after recent transmissions, was shown to occur by 
Zhang et al., the MA also demonstrated greater selection pressure than the V3 loop 
region of the env gene . The selection pressure on gag has also been shown to occur 
in vitro, after serial bottle-neck experiments starting from a clonal population 353.
The reversion pattern seen in both the viruses derived from patient 1 containing gag 
from the first passage data set, also suggests that there is a sizeable selection pressure 
placed on this polyprotein. However, the inclusion of the mutant protease seems to 
have applied another form of selection on the complementary cloned gag, this is most 
evident in the MA and p6 gag regions. As both gag  containing vimses initially 
contained the same mutant gag sequences, with the exception of the terminal 21 
amino acids of p6; here the only differences were due to the position of the Pvul 
cloning site. Therefore, any sequence differences detected between the two mutant 
gag  clones after passage, could be attributable to their associated protease.
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The changes in blue shown in Figure 6.5, represent those changes which occur only in 
the Ptl-GAG virus after passage, all of these mutations appear in MA. Two of these 
changes also occur at amino acid positions where originally the sequence in the 
pGEM clone was that of NL4.3, at codons 59 and 74. Both o f these changes are 
thought to be non-polymorphic 176, the Q59H change occurs in a region in which 
mutations have been shown to cause a reduction in the efficiency of particle 
production 98 and this codon has also been shown to be involved in the formation of 
MA tetramers 137. Mutations in MA, at codons 79, 81 and 82, which are seen in the 
pGEM clone, reverted when the wild-type protease was included, mutations at these 
positions have been shown to cause virus assembly defects 94,97. Although, changes at 
these positions occurred in the gag only clone, the resulting amino acid sequence was 
different to that of NL4.3.
The TQ insertion which also occurs in MA is similar in position to an insertion 
previously reported by Tamiya et al., where it was demonstrated that an AQQA 
insertion restored the replication capacity of the recombinant virus containing a 
mutant protease 31 The Gag cleavage pattern of the vims containing both the mutant 
gag  and protease was also shown to be comparable to that of the wild-type control in 
both the infected cell and cell-free virion preparations. It was also shown that the 
corresponding mutations in the p6 protein were required in order for optimum Gag 
polyprotein processing. The Ptl-(Gag+Pro) vims generated in this report, like that 
described by Tamiya et al., co-evolved with the insertion and also maintained the p6 
mutations, including those mutations around the PTAP, late domain budding motif. 
Whereas, the gag only vims did not retain the insertion and p6 mutations, this would 
agree with the findings of Tamiya et al..
Muller et al. have described the constmction of a vims containing a 12 amino acid 
epitope tag at the C-terminus of MA. The insert did not interfere with viral replication 
in tissue culture, and the inserted sequence could be detected after multiple rounds of
219infection . This insert was located in a region that forms a random coil 
conformation and was therefore thought not to interfere with the overall functional 
arrangement of Gag. The insert described in this report and that by Tamiya et al., 
occurs in an extended a-helix region of MA projecting away from the globular
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domain of the protein 137,219 and may serve to connect MA and CA domains in Pr55Gag 
29. Therefore, as these inserts were generated by evolution and not through in vitro 
introduction, they are more likely to be involved in one of the many roles of MA or 
Pr55Gag. The multifunctional role played by MA in the HIV Life cycle, may be the 
reason that this protein is under such selection pressure from the onset. It plays a key 
role in regulation of the early and late steps of viral morphogenesis and is required to 
interact with cellular proteins such as, nuclear import of the PIC by interactions with 
cellular importins 29,94,96
Both the viruses derived from patient 1 containing gag maintained all the p24 
mutations from the original input clones. This is thought to be because this region is 
more dependant on the conservation of overall protein structure, as opposed to
3 5 0preservation of nucleotide or amino acid sequence
The first Gag cleavage site to be processed by the viral protease, p2/NC 60’261,262? 
reverted to NL4.3 sequence in both Ptl-GAG and Ptl-(Gag+Pro) viruses. These 
changes included all the mutations at the p2/p7 cleavage site, which have previously 
been shown to be highly polymorphic, both in vitro and in vivo 191’194’299’299’350 
Interestingly, the P5 position of the original patient 1 derived virus pGEM clone, 
contains the same amino acid found in the HIV subtype B clone HXB2, however, this 
mutation also reverted back to the analogous amino acid found in the NL4.3 subtype 
B clone. This suggests that this codon position is highly restricted even within HIV B 
sub-type.
The K403R change seen in the original pGEM clone also reverts in both viruses, this 
mutation occurs in one of the zinc finger domains located in NC 94 and retains the 
basic charge of the amino acid. Basic residues within NC have been shown to be 
required to interact electrostatically with the phosphate backbone in nucleic acid, 
which is thought to be required to promote the assembly of the mature virions 29,94,114. 
This Arginine to Lysine reversion, retained the basic nature of the amino group and 
may be better at performing the RNA/DNA binding function of this region, through 
the acquisition of a less bulky side chain, which could lead to less steric hindrance.
The A431V mutation occurs at the P2 position of the NC/pl cleavage site and is 
therefore likely to be in direct contact with the enzyme substrate-binding pocket 268. It
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has previously been demonstrated that changing the Alanine to a Valine, results in 
enhanced cleavage at the NC/pl cleavage site by both the wild-type protease 231 and 
also by mutant proteases 85’188’224’311’327. Viruses carrying protease only mutations 
showed reduced infectivity which correlated significantly with reduced processing at 
the NC/pl cleavage site 211. The reversion of the A431V codon in the Ptl-(Gag+Pro) 
virus, suggests that there is selection against this mutation, in the absence of PI 
pressure and in the context of cloning with the associated mutant protease. The 
A431V mutation has also been associated with proteases containing multiple PI 
resistance mutations, therefore, its loss after sequential passage in the Ptl-(Gag+Pro) 
virus is contradictory to the evidence presented by some research groups 51191’327. . 
However all these references refer to viruses found within patients who maintained PI 
therapy and thus continued the pressure to maintain the A431V mutation. The A431 
mutation may also have a role as primary PI mutation and thus be dependant on PI 
pressure to maintain its presence. The introduction of the A431into a wild-type 
reference strain was shown to confer 3.8-fold reduced susceptibility to ritonavir 23’. 
This same research group also found that 1% of samples from a cohort of 28,241 HIV 
patients harbored the A431V change without any primary PI mutations. Peptide 
cleavage analysis has demonstrated that Valine at this position provides a better 
substrate 60, however, Alanine is present as the wild-type amino acid at this codon. 
This is thought to be because this cleavage site is among the slowest processing 
events in Gag ’ . The inclusion of the less efficient Alanine as the P2 residue
maintains the order of Gag cleavage and functions as a rate-limiting site. This 
prevents the premature cleavage of this site, which is thought to be detrimental to
260 262 340virion maturation ’ ’ . However, since resistance mutations contained within
protease are thought to be detrimental to cleavage, replacement of the Alanine with 
Valine increases the processivity at this site and compensates for reduced enzymatic 
activity of the mutant protease 191224 231. The lack of linkage of the A431V with the 
mutant protease demonstrated in this study could be attributable to these viruses not 
being produced in the presence of selective pressure i.e. Pis. Also the association of 
this A431V CSM and PI mutations has only been demonstrated for clinical isolates 
derived from heterogeneous populations, which do not show direct linkage on the 
same genome. Therefore, it is possible that these mutations do not co-exist on the 
same genome, which would explain its removal after transfection of the clone as seen 
in the Ptl-(Gag+Pro) viruses. Maguire et al., demonstrated that population
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sequencing can potentially over emphasise the linkage seen with gag and protease. 
Population sequencing of passage experiments with APV, suggested the appearance 
o f a double mutant, L449F and I50V. Clonal sequence data from the same selection
experiment showed that only one out of three 15 OV containing sequences actually
188showed linkage with the L449F mutation
The only NC mutation to be retained by either of the viruses derived from patient 1 
which contained gag, was the M423I change seen in the Ptl-(Gag+Pro) virus. This 
change is rarely seen across the different sub-types and other variations at this codon 
are also seen, usually a Leucine. The retention of this mutation implies it may also co- 
evolve with the mutant protease.
The results also show that the pl/p6 cleavage site mutation, L449V appears to co- 
evolve with the mutant protease, this association has also been shown to occur in vivo 
327. This codon change normally associated with protease resistance at this site is 
usually an L449F, it has been proposed that the L-F change develops a sequence that 
may facilitate the ribosomal frame-shifting required to produce the Gag-Pol encoded 
proteins, protease, RT and integrase. As this mutation generates a more 
homopolymeric or ‘slippery’ sequence at the nucleotide sequence level l09, thus 
compensating for reduced Gag processing by the inefficient mutant protease by 
increasing the amount of protease 60’79’109’295 The L449F mutation would change the 
F448 and L449F sequence to UUUUUU from UUUCUU, the L449V change seen at 
this codon in Ptl-(Gag+Pro) virus contains the less slippery UUUGUU sequence. The 
loss of this mutation in the Ptl-GAG vims suggests that there is selection pressure for 
co-evolution at this site with other gag mutations or with the co-expressed protease. 
However, the less slippery ribosomal frame-shifting sequence is maintained by 
mutation to the NL4.3 codon, Leucine at 449. In many of the circulating recombinant 
forms that are seen today such as AE, AG and AB, this codon is L449P 176, which is 
also a less slippery sequence motif. These viruses are produced in vivo by 
recombination with different sub-types and are thought more likely to generate the 
fittest phenotype from a heterogeneous population 234. As yet most research which has 
examined viruses that contain the homopolymeric ‘U ’ stretch have been unable to 
demonstrate that this results in an increase in viral protease production, through 
increased ribosomal shifting 109,231.
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Cleavage at the NC/pl and pl/p6 sites appear to be rate limiting steps in polyprotein 
processing 77,358 and these sites also show a high level of polymorphism, in virus 
isolated from treated and untreated patients 51>85’191’327. it is thought that mutations at 
the rate limiting cleavage sites are more likely to occur as these sites are not 
optimised, such as the A431V 85. Other sites that cleave efficiently are less able to 
mutate, since they are already optimised and thus, any deviation in sequence will 
result in a less hydrolysable substrate.
The passage of the recombinant containing only the mutant protease derived from the 
patient 1 virus, showed no deviation in both the gag and protease from the input 
genotype. This may be because the NL4.3 gag is more T-cell adapted, therefore it 
requires less adaptation to occur as a result of the new transfection. It has also been 
shown that differences in replication capacity can exist between T-cell lines when 
infected with the same virus 324. The virus isolated from this patient was probably 
exposed to a different host cell environment, than the one that is created during in 
vitro culture. There may be some selection pressure on the gag as a function of 
adapting to a ‘new’ protease, which may require some level of variation or 
complementation as one is the substrate for the other. However, no changes were 
detected in the gag from the Ptl-Pro virus, this could be due to any adaptation being 
at a low level, probably below the limit of detection of the heterogeneous PCR 
product sequencing of the infected cell pellet. Such techniques are known to have a 
sensitivity of 35-50% 93,151 i.e. any population that exists at a percentage lower than 
35% will not be routinely detected.
Another possibility for the lack of gag adaptation seen, could be that the virus derived 
from patient 1 which contained only the protease region also had less time in tissue to 
culture to adapt, as this recombinant produced detectable CPE several days earlier 
after transfection compared to those viruses which contained the patient derived virus 
gag  region.
The changes in the recombinant virus genotypes seen over the passage period can 
only be attributed to deviations from the original, input genotype. In other RVA 
approaches, the use of heterogeneous populations means that any other sequence 
variations could have always been present and as a result could lead to the formation
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o f artificial genotypes through recombination, which are then selected for. In vivo, 
recombination and minority populations are thought to play a major role in the
'7'}^  K? _development of heterogeneity and resistance. ’ . Therefore, these systems are able
to provide valuable information on the contribution of quasispecies to appearance of a 
fitter, resistant phenotype. The advantage of this clonal system is that it provides a 
means to assess the impact of a single virus genotype on the replication phenotype.
Several caveats exist to this research.
(i) All the passage data was subject to heterogeneous analysis, which may not 
detect or underestimate the presence of minority variants.
(ii) This also provides no information on the linkage of mutations, not only in 
the same protein coding region, but also on those regions or proteins more distal.
(iii) It is also unclear how much the recombinants have evolved, given more 
time in culture further adaptations would probably occur, resulting in the appearance 
o f  fitter genotypes.
The sequence data obtained from the first passage experiment infers that without PI 
selection pressure the mutant gag would be likely to revert to a more wild-type 
sequence. To abrogate this, transfections were repeated and then transferred into 
media containing antivirals, each infection was passaged under constant selection 
pressure. The transfection in the presence of antiretrovirals would potentially allow 
for the maintenance of the resistance mutations. However, it may also result in no 
virus production as the sample chosen (patient 1 derived vims) contained highly 
mutated gag, protease and RT coding regions. Due to the lack of PI resistance 
mutations and the apparent lack of replication capacity of the gag only vims, no 
growth was detected in any of the antiviral containing infections (see section 6.2.4). 
All the infections required multiple rounds of passage before a sustainable infection 
could be attained. As demonstrated by the growth rate comparisons, the Ptl-Pro vims 
again would appear to be the least impaired of the recombinants, this is also reflected 
in the lack of sequence reversions in the Ptl-Pro vims isolate, in both the protease and 
gag  regions.
It may also be possible that Ptl-Gag+Pro vims was eventually able to grow better 
than the Ptl-Pro vims in the presence of SQV, as was demonstrated by the appearance
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o f CPE in this infection at passage three. Although the only comparative analysis that 
was carried out was by a subjective method, such as CPE scoring i.e. assigning a 
relative score to each culture, based on the level of CPE visible.
The sequence data derived from the transfection and passage of the viruses in the 
presence of antiretrovirals has shown less reversions than those from the high titre 
passaged stocks, this could be attributable to the different experimental conditions 
used. The main difference between the two methods was that the high titred stocks 
were generated to maximise virus production, which involved culturing with much 
larger numbers of cells and the cultures were maintained until full CPE was observed. 
The latter transfections were carried out primarily to maintain the genotype of the 
input recombinant, although a ‘no drug’ control was included, most of the cultures 
failed to reach the stage where extensive CPE was observed. This would imply that 
the transfections and subsequent culturing in the prensence of antivirals would result 
in a reduction in the amount of virus produced in these infections. Therefore, each 
infection would have a lower number of overall replication cycles in a given volume, 
than occurred in development of the high titre stocks.
The most reversion was again seen in the Ptl-GAG virus, however, on this occasion, 
all the MA mutations and the insertion were preserved. This data also showed that the 
CA region reverted to NL4.3 sequence, these changes may be adaptive to the MA 
insertion, as both these regions interact in the uncleaved Pr55 Gag polyprotein 29. The 
much more extensive heterogeneity seen in the latter sequence data, i.e. the mixtures 
in the sequence chromatograms also implies that reversions may have been occurring, 
as less time had been allowed for changes to take place. The same reversion pattern 
was seen in the C-terminal region of gag, in both passage experiments, from the P tl- 
GAG viruses, although with more extensive heterogeneity at the reverted sites.
The previous sequence data demonstrated less reversion occurred in the Ptl-Gag+Pro 
virus than in the gag alone, this also appears to have transpired in the second sequence 
analyses, as here, no changes were detected when the patient virus gag was cloned 
with the cognate protease. This again could be due to the lower number of virus 
replication cycles and the low detection limit of population sequencing. As already 
mentioned, the possibility of contamination exists, however, the inclusion of the
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ampicillin detection PCR to verify that the input plasmid was not contaminating the 
virus infected cell pellet amplicons, provided a control for this.
Also in agreement with the initial passage data, is the lack of reversion in the Ptl-Pro 
virus, this maintenance of the original input vector sequence, was seen across both the 
gag  and protease coding regions. However, mutations were detected in the cultures 
under antiviral selection. Both the AZT and IDV infections produced an L75R change 
in gag, which has been previously seen with APV passage experiments. This change 
also conferred replication advantages, especially when an additional p24 mutation, 
H219Q was also present107. The H219Q mutation is thought to increase replication of 
HIV in CyPA rich cells, by decreasing the amount of CyPA incorporated into progeny 
virions 106. This mutation is polymorphic, occurring in clade F and G isolates and was 
also spontaneously generated in in vitro passage of HIV NL4.3, when L75R was also 
detected 107. The appearance of the L75R mutation in the AZT infection and its more 
apparent homogeneity than in the IDV infection, as seen in the sequence 
chromatograms, could suggest that this mutation arises through an overall response to 
low viral replication and not as a result o f PI selection. The Ptl-Pro virus displayed 
high level resistance to IDV and would not be resistant to any RT inhibitors, as the 
cognate RT was missing. Thus, AZT would have a much greater inhibitory effect on 
vims replication than IDV, which would apply only minimal selection pressure, 
therefore, if the existence of the L75R is low viral replication driven, then it would be 
selected for more in the AZT containing infection, thus, explaining the homogeneity 
seen in the sequence chromatograms.
HIV like most other retroviruses, packages two unspliced copies of genomic RNA in 
each progeny virion, through the \ji, located in the 5’UTR. This region has been 
predicted to form a highly ordered secondary structure, comprising of four RNA 
stem-loops that each contribute to the overall viral RNA packaging efficiency (see 
Figure 6.7b). Encapsidation of viral genomic RNA is a highly specific process that 
must distinguish unspliced viral RNA, against a high background of cellular and 
spliced viral RNA 42,150. The NC protein is thought to be one of the determinants for 
this specificity and may also have a role in stabilisation of 'P secondary structure
42,218,303,319
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The two encapsidated RNA copies are held together in an apparent parallel 
orientation, as a non-covalent dimer at the dimer inititiation site (DIS), located in SL1 
o f VF. This contains a pallindromic, GC-rich loop, that promotes Watson-Crick base 
pairing between the two pallindromic viral RNA sequences by forming stable, 
‘kissing-hairpin loop’ dimers 82>2152l8’3,0> Incompatibilities between the pallindromic
215sequences have been shown to result in a 9-fold reduction in RNA packaging 
Although in the patient virus the DIS may be less functional through deletion of the 
pallindomic sequence, it is thought that secondary sites can also act as packaging 
sites, but function at a much lower efficiency 356. This may explain the slow growth 
initially o f both the recombinants containing the patient virus derived 'F and the 
heterogeneous changes detected in the sequence chromatograms for the Ptl-GAG 
virus in the second passage data set.
Other supporting evidence that suggests the is under selection pressure during the 
passage experiments, are the mutations in the C-terminal region of gag, in both NC 
and p2. These two proteins have been shown to be involved with viral RNA
i ca  1 f . 9 1 Q 984 9 1 Q __
dimerisation and encapsidation ’ ’ ’ ’ . The NC contains two zinc knuckle
motifs, these both bind zinc ions, in a process that facilitates the folding and 
stabilisation of the viral RNA-NC packaging complex and is also thought to be one of 
the primary events involved in the selectivity of the encapsidation process 205. Both 
the zinc knuckle motifs contained a mutation from NL4.3 sequence in the original 
study vims clone, a K403R and M423I change. After passage, reversions back to 
NL4.3 sequence occurred at both these mutated sites, the K403R change occurs at a 
codon thought make contact with the viral RNA in the SL3-NC complex 63>2445 see 
Figure 6.7.
It has been previously demonstrated that /raws-packaging, (as opposed to cis- 
packaging; encapsidation from the RNA from which the Gag was translated) of Gag 
is a major mechanism of HIV-1 RNA encapsidation and may contribute to the rescue 
o f gag  mutants by wild-type vims 232. This has also been shown to occur with 
restoration of replication after deletions in the SL1 loop and compensation by 
mutations after 18 passages in both p i and NC 180,181. Deletions in SL3 were also 
shown to be compensated for by mutations in both p2 and NC 282.
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It is unclear if the mutations in the gag p2/NC were in response to the mutations in the 
4* and may have lead to increased encapsidation or dimerisation of viral RNA. Or if 
the mutations in the 'F were as a result other mutations in gag p2/NC associated with 
compensation of PI resistant viruses. In which case this would demonstrate that Pis 
have pleiotropic effects even beyond those in gag and that they may affect packaging 
o f  viral RNA. The distal effects of PI therapy have previously been shown to 
influence the genetic variability of env and cause strong bottleneck events 229.
This chapter highlights the identification of highly mutated protease which appeared 
to grow efficiently despite the presence of a number of debilitating PI resistance 
mutations. The presence of a two amino acid insertion in the protease gene; not 
previously reported, may provide a means of compensation, through extension of the 
flap region 156 providing increased substrate recognition 161’290. it was also shown that 
cloning of the cognate gag, reduced the replication capacity of the resistant protease 
when included in the recombinant virus. This observation is not in agreement with the 
commonly held theory of gag restoration o f aberrant protease cleavage. Indeed the 
addition of mutations in gag to compensate for the deleterious effects of PI resistance 
mutations would be an elegant means of affording a small protein like protease, a 
greater potential for genetic variability, to produce a resistant and replication 
competent phenotype. However, the selection of this genotype may not have primarily 
been through a pathway that was able to select for the fittest species, it is conceivable 
that this genotype has been forced to exist as a result of fixation of certain mutations. 
This anomaly may also be explained by the level of reversion that is occurring in the 
gag, i.e. the slow replication is a result of the time taken for the clonal population to 
discard the growth deficient mutations and acquire more fit ones. Reduced replication 
o f  constructs with the patient 1 virus derived gag may also be due to the altered 
packaging signal region present in both viruses containing patient 1 virus derived gag 
region. This region was shown to mutate back to a sequence similar to that o f wild- 
type in the second passage experiment. The mutated packaging signal present in the 
original patient derived virus contained a deletion in the palindromic, ‘kissing-hairpin 
loop’ region, which others have shown causes a substantial loss in vims infectivity 
131,173,310,319 g u c k  maintenance of an unfit vims with multiple PI mutations and 
containing a two amino acid insertion at codon 35 in protease, has previously been
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reported 245. The aforementioned study demonstrated that the protease insertion when 
present in a PI sensitive background, grew as well as the wild-type control virus. 
However, virus containing the resistance mutations and the insertion, demonstrated 
much poorer growth than the analogous virus minus the insertion. The virus that was 
isolated from the study patient had been exposed to extensive therapy and although 
the gag would appear to be detrimental to the growth ability of the virus, its existence 
may be due to the enhanced PI resistance, which in some cases results in IC 5 0  shifts 
that may exceed the nadir drug levels present in the patient plasma.
The results presented here raise more questions and avenues of research which are 
discussed further in the next chapter. Some relevant points relating to this chapter are 
also discussed below.
(i) Other methods to determine the start input of the growth curve, such as p24, RNA 
viral load and RT activity could also have been used. Although cell viability gives a 
measure of infectious virus. Others have shown that p24 antigen concentration is not 
always reflective of the level of infectious virus contained in the stock 28.
(ii) Although the reversions that were seen in the virus stocks prevented any further 
continuation of the competition or dual infection study, these types of experiment are 
thought more likely to determine small fitness differences between viruses. This 
would have allowed a greater dissection of the differences between the Ptl-Gag+Pro 
and the Ptl-Gag viruses, which showed similar profiles in the comparison of growth 
rates experiment. Such an experiment would also have helped to determine if the P tl- 
Pro virus was also growth impaired compared to the wild-type stocks, NL4.3 and X- 
PSX.
(iii) The analysis of the sequence data after passage, in both experiments was carried 
out using the infected cell pellet as the source for the viral integrated DNA. This 
would represent the viral genome that has successfully completed entry, reverse 
transcription and integration. The analysis used a heterogeneous PCR product to 
determine the viral sequence, a more complete and relevant analysis would have been 
achieved if the sequence data were generated from clonal analysis, although, this 
would have required much more time to complete.
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Chapter 7 Conclusions and Future Work
7.1 Conclusions
The initial aim of this study was to develop a cloning vector that could be used to 
determine the antiviral sensitivity of recombinant viruses containing the gag, protease 
and RT coding regions derived from antiviral therapy treated individuals. This was 
initially undertaken through the use of a single cycle replication system. Due to the 
lack of infectious particles generated using the pseudotyped system, when 
recombinants containing gag derived from antiviral therapy treated individuals were 
generated, a live virus system was constructed. The chosen study patient virus sample 
was shown to contain a novel two amino acid insertion in the protease gene, which 
demonstrated high resistance to several Pis tested and was also shown to replicate 
efficiently. The recombinants containing the gag from the patient isolated virus, were 
shown to cause a reduction in growth capacity of the viruses, even when cloned with 
the cognate protease. However, the virus containing the patient virus derived gag and 
protease, demonstrated a 2-fold increase in resistance to some of the Pis tested, 
compared to the virus in which only the mutant protease was cloned. Recombinants 
which included the gag region showed multiple reversions in gag and the reversion 
pattern was shown to be dependant on whether or not the recombinant contained the 
highly resistant protease. Therefore, the data suggests the emergence and eventual 
dominance of an unfit virus, with respect to gag, under drug selection pressure. The 
gag  persists even though alone it provides no resistance and replacement of the 
patient virus derived gag region with that of wild-type, results in a virus that is more 
fit but slightly less resistant.
These observations raise the question, how does such an unfit virus come to exist as 
the majority species? The restoration of growth impairment may occur through 
recombination with other genomes present as minority species. Recombination is 
common to all retroviruses, primarily due to persistent breaks during reverse 
transcription, which can lead to template switching between the two genomic RNA
235 286strands ’ . Heterozygous virions can also be produced by cells that are co-infected
C O
by two separate proviruses .
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The role of recombination in repair of a dysfunctional genome could possibly be more 
likely to occur in gag, due to its multi-functional role within the HIV Life cycle. Gag 
performs functions either as correctly cleaved proteins or as the uncleaved polyprotein 
29,94,95. Muller et a l constructed a virus containing the GFP gene located in gag, at the 
C-terminus of MA. The GFP viruses displayed greatly reduced infectivity and 
demonstrated an accumulation of budding structures at the plasma membrane when 
visualised by EM 219. Co-transfection of the GFP virus and wild-type resulted in 
viruses displaying wild-type protein composition, morphology, and infectivity. 
However, serial passage of the co-transfected population resulted in the rapid loss of 
the modified variant. This dominant interference mechanism has been proposed for 
the inhibition of wild-type virus by HIV gag mutants by several groups 174,315 and 
rescue o f gag deletion mutants by wild-type gag has also been demonstrated .
Another possibility is the restoration of growth by the patient derived virus gag, may 
occur through pleiotropic means, this was shown with gag and Env, where virus 
replication capacity of MA mutants was restored by truncations in the envelope 
glycoprotein gp41 193. The association of p6Gag with Vpr is also another example of 
the pleiotropic effect of gag, efficient incorporation of Vpr into virions has been 
shown to require the C-terminal gag protein, p6 ’ . The transframe protein (p6*),
has also been reported to associate with Nef in progeny virions in producer cells. This 
Gag-Pol and Nef interaction may allow Nef to target HIV-1 budding to lipid rafts 50. It 
has also been shown that mutation of Nef results in a loss of infectivity in the 
molecular clone virus NL4.3, but not in a closely related virus, LAI. These clones 
share 93.2% and 96.5% sequence homology in gag and Pol respectively and only four 
amino acid changes in the Nef gene. Nonetheless, the C-terminal region of gag was 
shown to be responsible for the diversity seen in infectivity of the N ef mutants. This 
suggests that a mechanism exists by which the Gag region regulates the viral 
infectivity in combination with N ef239.
The vims genotype isolated from the study patient was selected for under HAART 
and thus, was either already adapted to this environment or was still in the process of 
adapting. This may explain the low percentage of the K20R containing protease, 
which was found in only 1 clone. This mutation has been shown to compensate for
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growth restoration of PI resistant viruses 48’213 230 and may represent a low percentage, 
emerging population isolated during a transition state to a fit species.
The addition of antivirals results in the selection of an evolutionary pathway that 
would previously not have been selected for due to the detrimental effects on virus 
growth of the resistance mutations. This pathway now allows for the selection of a 
combination of mutations that results in a species fitter than the original wild-type 
strain 23°. This mechanism is also proposed for illustrating the molecular basis for the 
emergence of the AZT resistance associated mutations, T215Y and Q151M. Dual 
infection experiments determined that the Q151M demonstrated greater replicative 
capacity than the T215Y in both the presence and absence of dideoxynucleosides. 
Both mutations require double nucleotide substitutions, yet the Q151M is found only 
in patients after long-term therapy with multiple RT inhibitors. Researchers 
demonstrated that the basis for lack of selection of the Q151M was the poor growth 
abilities of this viruses intermediates, whereas those for T215Y were fitter 164.
The vector system developed in this study is not high throughput and so would not be 
ideal for routine evaluation of clinical isolates. This is primarily due to the difficulties 
during cloning and the other difficulties a associated with vims production. However, 
the latter problem was in part due to the difficult sample selected for evaluation i.e. 
the patient 1 derived vims had extensive prior exposure to multiple antivirals and was 
thus highly mutated and resulted in low level replicating vims amounts, if the gag 
region was included in the recombinant. However, the general aim was to develop a 
vector system that could be used to evaluate the effects of the gag, protease and RT 
coding regions either separately or in combination. This has successfully been 
demonstrated, albeit with a very small number of samples.
This study demonstrates that the inclusion of gag in determining phenotypic 
sensitivity to antivirals should be routinely undertaken, as an increased resistance 
profile an be demonstrated when this region is considered. Although, p2/NC is 
included in some of the antiviral assay systems 257, these may require the addition of 
the N-terminal portion of gag to fully determine the resistance capacity of vimses in 
the presence Pis. This is also of paramount importance if fitness is also to be
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examined and this study also suggests that regions upstream of the gag initiation 
codon, which are involved in packaging of viral RNA, should also be considered.
7.2 Further Work
The study has focused primarily on the development of a vector, cloning of patient 
virus derived gag, protease and RT sequences and assessment of the contribution of 
these coding regions to virus growth capacity and resistance phenotype. The 
identification of a highly mutated genotype with multiple insertions and an apparent 
dysfunctional 'F raises other avenues of research that deserve further and more 
detailed examination, such as:
i. to facilitate the cloning using the pNL4.3X-PSX vector, a series of small 
oligonucleotide linkers were constructed, but due to time constraints this was 
not completed. These linkers would allow the pre-digested vector i.e. minus 
the gag, protease and RT regions, to be used directly, thus, negating the need 
to gel purify the vector prior to cloning and preventing uncut contamination. 
Linkers would also enable the use of a PCR screen to differentiate between 
colonies containing the region of interest and those not containing any insert.
ii. the requirement to determine titres or viral input more accurately, as these 
affect any determinations of replication capacity, although a reasonable 
number of replicates may abrogate this. Both systems used in this study to 
calculate titres were measures of live replication and or infectivity. An 
alternative would be p24. However, this is also an indirect measure and may 
be affected by Gag processing defects. Discordances between measures such 
as p24 and viral infectivity have previously been reported 8,248. Other studies 
using viral RNA level have shown that the ribonucleoside analog, ribavirin 
inhibits virus production without substantially affecting RNA synthesis 53. 
Another alternative would be the development of a single cycle system with 
the pNL4.3X-PSX vector, by first removing the Env and then pseudotyping 
with the pMDG vector, encoding the VSV-G envelope protein. This would 
produce a more accurate measure of virus production due to the limited 
number of replication cycles 272 than the live systems used in this study.
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Although, a potential drawback to this approach could be very low titres if the 
gag region is included in the recombinant, as was seen in this study.
iii. the dissection of the effects of the two amino acid insertion in protease. This 
would involve the construction of a series of site directed mutants with and 
without PI resistance mutations and gag mutations. A similar insertion to 
35QN, namely 35TN, was shown to be detrimental in the presence of PI 
resistance mutations. Although the authors suggest the affect of insertions is 
dependant on the amino acid insertion and the drug resistance mutations 
present 245.
iv. continued passing of the recombinants in the presence or absence of Pis. This 
would determine the divergence of the genotypes under antiviral selection and 
establish which mutations in gag are drug resistance associated. In the second 
passage experiment at passage three, the Ptl-Pro virus produced higher 
TCID5os/ml in the IDV and RTV infection than in the ‘no drug’ control (data 
not shown). This may represent increased replication in the presence of the 
these two Pis to which the virus had prolonged previous exposure. A virus 
containing highly mutated protease and an insertion in gag, also in helix 5 of 
MA, was shown to confer NFV-dependent replication enhancement phenotype 
on NL4-3, this phenotype only required protease and MA. Also, at passage 
three the Ptl-Gag+Pro virus produced higher TCIDso/ml than the Ptl-Pro 
virus, in the infections passaged in the absence of antivirals. This virus may 
have become more fit that the Ptl-Pro virus, due to cloning with the cognate 
protease.
v. continuation of the competition growth studies and initiation of dual infections 
between the Ptl-(GAG) only virus vs. Ptl-(Gag+Pro) virus to determine the 
effect of cloning the cognate protease on the order of replication capacity.
vi. the implications of RNA packaging restrictions due to compensatory 
mutations in gag, primarily in p2 and NC, as a result of the acquisition of PI 
resistance mutations. Although the frequency of mutations in the 'P in viruses 
from patients on Pis is not known, as this region is very rarely, if ever 
considered.
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Another aim of this study is to submit this work for publication. This work could be
divided into several areas depending on the focus of research for publication.
(i) A report primarily on the development of the vector system, this would require 
more patient samples to demonstrate the versatility of the vector system. The 
amplification conditions may also require optimisation to include more 
samples. The remaining downstream steps, such as cloning, production of the 
high titre virus stocks and drug susceptibility assays do not require any further 
improvement, other than those previously highlighted, such as an alternative to 
the Xba I  cloning site. Another alteration could be the adaptation o f this 
system to one similar to a single cycle assay, as mentioned in section 7.2 (ii). 
This would mean the analysis of replication capacity would be similar to that 
used by several diagnostic laboratories e.g. Monogram Biosciences, ViroLogic 
and Virco.
(ii) One of the most interesting aspects of the patient 1 derived virus is the 
identification of a novel two amino acid insertion in protease. Further 
evaluation of this patient derived virus would require the production of 
mutants containing combinations of the 35QN insert, with and with other PI 
mutations and also clones with and without the cognate gag. In order to 
determine which cloned viruses grow best would require more growth studies 
such as competition growth experiments and also drug sensitivity 
determinations to ascertain if growth is compromised for decreased drug 
susceptibility. The evaluation of mutant and wild-type gag cleavage by the 
35QN containing protease clones would also be worth investigating using 
western blots analysis.
(iii) Possibly the most interesting finding was the changes in the \j/, at the ‘kissing- 
hairpin loop’ region in the Ptl-GAG clone after only three passages. To 
explore this further would require examining other heavily PI and RTI treated 
patients. A control group for this study would be patient derived virus samples 
which had only been exposed to NRTIs and NNRTIs, this is because others 
have shown that insertions and deletions are associated with RTI treatment.
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The observation in this study of the mutated packaging signal is thought to be 
related primarily to PI treatment and the development of compensatory 
mutations in NC, which require changes in the \\f in order to facilitate both 
resistance and RNA genome packaging. Although this latter point has not been 
demonstrated, it could be shown by cloning the \|/ from the patient derived 
virus into the pCSGW vector and comparing it to one conating a wild-type \\f. 
The vector pCSGW was used in this report to package the HIV Gag-Pol 
region in order to produce the VSV-G pseudotyped viruses. Differences in i\f 
function could be measured using FACS analysis to measure GFP production 
in the pseudotyped viruses.
The development of antiretrovirals to several HIV protein targets, RT, protease, Env, 
integrase 172’20\  RNase H 159 and gag ,79>307, provides the future potential for a 
chemotherapeutic arsenal that could possibly force HIV into an unfavourable 
mutational pathway. However, this ” reduced fitness approach” may only be feasible 
for relatively newly acquired infections, as within untreated infected individuals there 
are virions that encode every possible single, double, and triple amino acid 
substitution 8. The use of a more targeted approach to treatment at a very early stage 
o f the infection to prevent the appearance of such highly resistant strains which are 
fully compensated could also be enhanced by fitness reductions through Muller’s 
Ratchet 8, the stochastic accumulation of deleterious mutations. This occurs under 
strong selective pressure or in populations undergoing repetitive bottlenecks. High 
mutation frequencies will result in the accumulation of deleterious mutations, which 
can become fixed, reducing overall fitness. As the population size is low 355 and
1A 71relatively homogenous ’ ’ , this reduces the chance of escape from Muller’s
Ratchet through recombination 8,353. Development of such ‘fitness targeted’ regimens 
could also be improved by selection of compounds leading to non-synergistic 
resistance pathways, such as AZT and 3TC. Also the PI, Atazanavir, which selects for 
an I50L mutation in protease, which has been shown to cause hypersusceptibility to 
other currently approved Pis 346. One caveat to this approach at present is the lack of 
viral targets for antiretrovirals. It would require more new compounds to become 
available that can be directed at different HIV proteins or regions, and also an 
increase in our understanding of resistance and fitness.
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However, the evidence would suggest that HIV is be able to correct any deleterious 
phenotypes through the myriad of compensatory mutations and mechanisms alluded 
to in this study.
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